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Abstract
At the time of commencing this study HHV-6 was a recently discovered lymphotropic
herpesvirus, cultured from the lymphocytes of adult patients with malignancy and HIV
infection and subsequently shown to be the cause of the childhood febrile illness exanthem
subitum. Whether this virus had any pathogenic role in the symptomatology of
immunosuppressed children had not been widely investigated.
The aim of this study was to examine certain aspects of the activity of HHV-6 in a cohort of
immunosuppressed paediatric oncology patients. To ascertain whether children presenting
with malignant disease had mounted a serological response to this virus, and if so to examine
whether HHV-6 played a role in infectious problems occurring in these children when on
treatment. A review of the literature was undertaken considering a number of areas relevant
to the activity of HHV-6 in immunosuppressed children. Virological data on HHV-6 was
examined, as well as the clinical manifestations of HHV-6 infection in the immunocompetent
and immunocompromised. The methods used for clinical detection of HHV-6 were also
examined and considered for development for the study. Immune deficits and the problems
caused by other herpesviruses in paediatric oncology patients were also reviewed.
The current study was designed to include a retrospective serological assessment of HHV-6
antibody responses in samples taken from children at presentation with malignancy and
sequentially during treatment. An indirect fluorescent antibody test (IFA) and an enzyme
linked immunosorbent assay (ELISA) were used to detect HHV-6 IgG, and selected samples
were tested for HHV-6 IgM by IFA. The paediatric patients, whether solid tumour or leukaemic
patients, had a similar response to HHV-6 as age matched controls and almost all (97%) had
IgG to the virus at the time of presentation. Acquisition of a response to more than one
herpesvirus increased with age in the patients and where there was a response to only one
virus it was usually HHV-6. Antibody responses to CMV and VZV were similar in patients and
controls. Sequential samples from patients during immunosuppressive treatment showed a
gradual decline over time in ELISA index for IgG to HHV-6 and no reactivations of HHV-6
were seen. IgM to HHV-6 was produced by one child with a primary CMV seroconversion but
HHV-6 reactivation could not be confirmed as the possibility of cross reactive antibody was
not excluded by a cross absorption experiment.
A prospective analysis of HHV-6 DNA in saliva and serum was undertaken on new patients
presenting between August 1992- August 1993. HHV-6 is secreted in the saliva of those
previously infected, and presence of HHV-6 in the serum implies an active viraemia. Saliva
was collected prospectively from new patients, from siblings and from volunteer healthy
controls. Serum was collected from patients during treatment. A nested PCR for HHV-6 was
developed. The sequence of DNA chosen for amplification contained a cleavage site for the
restriction endonuclease Hind III which enabled type "A " and "B" HHV-6 to be identified in
I
any PCR positive samples. HHV-6 DNA (type "B") was commonly found in the saliva of
healthy controls (74%) and patients (58%), but patients who were febrile, unwell and
neutropaenic less frequently secreted HHV-6 in the saliva supernatant (18%). Whether this
was a local effect of chemotherapy on the salivary glands was considered. HHV-6 DNA was
not detected in any serum samples, suggesting no evidence of active viraemia.
The potential role of HHV-6 as a serious pathogen in immunosuppressed patients remains to
be fully elucidated, but in this limited study of a small paediatric cohort of oncology patients
no evidence of deleterious virus activity was found.
I declare that the experimental work and composition of this thesis was undertaken entirely
by myself.
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Human Herpesvirus Virus -6 (HHV-6) infection in
Immunocompromised children
Aims of this study
The aim of this study was to examine certain aspects of the activity of human herpesvirus
virus -6 (HHV-6) in a cohort of immunosuppressed paediatric patients. To ascertain whether
children presenting with malignant disease had mounted a serological response to this virus,
and if so to examine whether HHV-6 plays a role in infectious problems suffered by children
immunosuppressed on chemotherapy for treatment of malignant disease.
Questions:
1) Have children presenting with malignancy an immune response to HHV-6, and if so
does it reflect the same pattern as that of normal children?
2) Is there evidence of HHV-6 primary infection / reinfection / or reactivation of infection
in this group of children during the course of treatment and if so does this relate to
any clinical problems?
Plan of investigation
A review of the literature concerning HHV-6 was undertaken to examine a number of areas
relevant to the question of the activity of this virus in immunosuppressed children. The basic
virological data on HHV-6 was examined, as well as the clinical manifestations of infection in
the immunocompetent and immunocompromised The methods developed for clinical
detection of HHV-6 were also examined and considered for use / adaptation for this study
The immune deficits of paediatric oncology patients and the problems caused by
herpesviruses in these patients were also considered.
With this background the current study was designed, to include a retrospective and
prospective arm. A retrospective collection of sera obtained from children at presentation
with malignant disease and sequential sera collected during treatment for malignancy were
tested for an antibody response to HHV-6.
A prospective analysis of salivary HHV-6 DNA excretion and serum HHV-6 DNA was
undertaken on new patients presenting during the period of the study (August 1992-
August 1993) HHV-6 is known to be excreted in the saliva of those previously infected,
and presence of HHV-6 in the serum implies an active viraemia. Saliva samples were collected
prospectively from patients presenting with malignancy, from siblings and from volunteer
healthy controls. Serum was collected from patients during treatment. Evidence of secretion
of the virus in these different sites was sought to assess its activity in these
immunocompromised hosts.
XIV
Methods developed for this study
Serology
To evaluate serological responses to HHV-6 two systems were developed:
Indirect fluorescent antibody test (IFA): HHV-6, type A was cultured in a lymphoblastoid cell
line and slides of infected and uninfected cells prepared for examination with sera under ultra
violet illumination.
Enzyme linked immunosorbent assay (ELISA): Antigen from HHV-6 infected and uninfected
lymphoblastoid cells was coated onto rnicrotitre plates and binding antibody detected by a
colorimetric reaction.
Where volume permitted, all sera were tested by the above methods for HHV-6 IgG, selected
samples were tested for HHV-6 IgM by IFA.
DNA Amplification
A nested PCR for HHV-6 was developed for use on saliva and serum. The sequence of DNA
chosen for amplification contained a cleavage site for a restriction endonuclease which
enabled type A and B HHV-6 to be identified. Any samples which amplified HHV-6 were
subsequently subjected to restriction enzyme digestion. Amplification products were stained
with ethidium bromide, run on electrophoretic agarose gels and visualised under ultra violet
light.
Viral culture and antigen preparation was undertaken with Dr M Ogilvie, at the Department of
Medical Microbiology, Medical School, University of Edinburgh, and all other techniques with
Dr HA Cubie at the Regional Virus Laboratory, City Hospital, Edinburgh.
XV
1) The Sixth Human Herpesvirus EGH Lyall
The sixth human herpesvirus (HHV-6)
History
Human herpesvirus-6 (HHV-6), originally named human B lymphotrophic virus (HBLV), was
discovered in 1986. It was isolated from the the peripheral blood mononuclear cells (PBMC)
of patients from the USA and Africa, some of whom were infected with human
immunodeficiency virus (HIV) and others undergoing treatment for lymphoid malignancy
[Salahuddin 1986; Downing 1987; Tedder 1987], This double stranded DNA virus
(approximately 170,000 bases pairs in length) is the sixth member of the human herpesvirus
family. HHV-6 has considerable DNA homology with human cytomegalovirus (CMV) and is
the second member of the beta subgroup of human herpesviruses [Efstathiou 1988;
Lawrence 1990; Neipel 1991], HHV-6 preferentially infects human T helper (CD4+)
lymphocytes [Becker 1988; Becker 1989 ].
Initially HHV-6 was described as a virus searching for a disease, until in 1988 it was identified
as the causative agent of the childhood fever exanthem subitum (ES), also known as roseola
infantum [Yamanishi 1988], Since then the role of HHV-6 in many other conditions affecting
immunocompetent and immunosuppressed individuals has been examined.
Many strains of this virus have now been isolated and on antigenic, genomic and cell culture
characteristics these appear to fall into two main subgroups, Types A and B [Ablashi 1991].
The prototype virus isolated from immunocompromised patients was of type A and the great
majority of strains isolated from children with exanthem subitum have been type B [Dewhurst
1992; Dewhurst 1993], Differences in the pathogenicity of these stains have been explored.
Since HHV-6 was first grown from the cells of immunocompromised patients the relationship
between the virus and the immunocompromised host has been closely examined (see
below).
Morphology
Morphologically herpesviruses cannot be distinguished. Ultrastructural studies of HHV-6
demonstrate an enveloped virion with an icosahedrai capsid of 162 capsomers. The diameter
of the enveloped particle is around 200nm. Within the capsid the viral DNA is coiled into a
cylindrical mass. Virus particles mature within the nucleus of an infected cell and here acquire
their capsids, the diameter of capsid plus core being around 100nm. Within the cell's
cytoplasm the viral particles acquire a distinct tegument of moderate electron density, with an
average thickness of 30 nm. Particles acquire their envelope prior to release by a process of
exocytosis [Nii 1990 ; Roffman 1990b]. These early ultrastructural studies did not give any
time scale to the assembly process of HHV-6 virions.
1
1) The Sixth Human Herpesvirus EGH Lyall
Culture
The first isolates of HHV-6 came from the peripheral blood mononuclear cells (PBMC's) of
immunosuppressed patients, grown in co-culture with either cord blood lymphocytes (CBL's)
or healthy donor PBMC's [Salahuddin 1986; Downing 1987 ; Tedder 1987; Becker 1988 ;
Agut 1988], The lymphocyte cultures were activated with phytohaemagiutinin (PHA) prior to
addition of the infected patients' cells and after 3-4 days a cytopathic effect could be seen.
The large, ballooned cells which appeared were mutinucleate, fragile and some contained
inclusion bodies (figure 1a,b,c). Ultrastructural examination of these cells revealed evidence
of a herpes virus which by serological and antigenic analysis was not a known member of the
human herpesvirus family. Supernatant from some cultures could be used to infect further
donor PBMC's or CBL's, but in other cultures this could only be achieved with cellular
material, implying that some strains were more cell associated than others [Salahuddin 1986 ;
Downing 1987; Tedder 1987; Becker 1988; Becker 1989], Originally, it appeared that the
cells infected with HHV-6 were of B lymphocyte lineage, but all subsequent analysis has
shown HHV-6 to preferentially infect lymphocytes of T cell lineage [Ablashi 1988b; Becker
1988; Becker 1989]. Both immature and mature T cells can be infected [Lusso 1987; Lusso
1988]. GS strain, the first strain of HHV-6 type A isolated, grew well in immature T cells from
PBMC's, CBL's, bone marrow, thymus and tonsil [Lusso 1988]. Z 29 strain, the first strain of
HHV-6 type B isolated, grew well in cord blood T cells and less productively in adult PBMC's
[Lopez 1988]. However certain CBL donor cells appeared more permissive to infection than
others [Black 1989], SF strain HHV-6 was isolated from the saliva of a person with HIV and
although a B type and genetically most close to Z 29, it grew better in adult PBMC's then
CBL's [Levy 1990b], The CD4 molecule is not the site of attatchment of HHV-6 to the
lymphocyte [Lusso 1989b].
Optimisation of culture conditions for HHV-6 is again to some extent strain specific, but it has
been demonstrated that HHV-6 replication is encouraged where donor cells are stimulated
with PHA and low concentrations of interleukin -2 (IL-2) [Black 1989; Frenkel 1990b; Frenkel
1990c].High concentrations of IL-2 are inhibitory to HHV-6 replication [Roffman 1990]. OK
strain HHV-6 was isolated from PBMC's of a patient with exanthem subitum. Polyclonal
stimulation of T cells by anti CD-3 monoclonal antibody was found to make PBMC's
permissive to infection with OK (B type) strain HHV-6 where PHA stimulation did not. Both
anti CD-3 and PHA enhanced infection of CBL's with OK strain by 5-10 and 5-6 fold
respectively [Kikuta 1989b], Centrifugal inoculation of cultures can also enhance infection of
PBMC's by up to 100 fold [Pietroboni 1989].
To facilitate culture of HHV-6 in vitro, infection of various transformed and continuous eel!
lines has been undertaken (table la & b). The most productive infections occur in T cell
lymphoblastoid lines, and this is strain specific. GS strain HHV-6, grows best in HSB-2 cells,
where by 9 days in culture 90% of cells will be infected [Ablashi 1987], Z 29 strain HHV-6,
grows best in MT- 4 cells, where 25% of cells will be infected by 7 days [Black 1989]. Strain
specific, low level infection of other tissue cell lines can be achieved, in particular:
2
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neuroblastoma; megakaryocyte; lung epithelium; and bowel (table 1a & b). Similarly with
CMV, fibroblasts on coverslip cultures can also be infected by HHV-6 and early viral antigen
produced can be detected using monoclonal antibodies [Luka 1990], Although HHV-6 was
originally thought to be a B cell tropic virus only low level infection of B cell lines occurs.
Where B cells also carry EBV genome they are more permissive to infection with HHV-6, in
some way the presence of EBV may increase receptors for HHV-6. In one study it was shown
that infection of EBV-positive cell lines occurs with A type HHV-6 but not B type [Cuomo
1995], Infection of these EBV-positive cell lines was associated with activation of certain EBV
promoter genes indicating possible further interactions between these two herpesviruses.
Legend to figure1a,b,c: Cytospin preparations of HHV-6 infected and uninfected cells,
all at x 500 magnification.
1a Cytospin preparation of uninfected lymphoblastoid cells, JJhan strain.
Note large nuclei with multiple nucleoli. Geimsa stained.
1 b Cytospin preparation of HHV-6 infected lymphoblastoid cells, JJhan strain.
Note large ballooned cells,intranuclear and intra-cytoplasmic inclusions and
multinucleate syncitia. Geimsa stained.
1 c Cytospin preparation of HHV-6 infected lymphoblastoid cells stained with a
fluorescent conjugated monoclonal antibody (HA5) to HHV-6 (see below). Note
large ballooned cells and multinucleate syncitia with intranuclear and intracytoplasmic
fluorescence due to expression HHV-6 antigen.
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figure 1 b: Cytospin of HHV-6 infected lymphoblastoid cells.
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figure 1 c: Cytospin of HHV-6 infected lymphoblastoid cells stained with a
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HHV-6 effects on infected cells
Lymphocyte surface markers
Blood samples from infants with exanthem subitum have shown that between 1/-|o^ -1/10®
PBMC's are infected with HHV-6 during primary infection [Takahashi 1989], Using
monoclonal antibodies to lymphocyte surface markers, flow cytometry and cell sorting
techniques, HHV-6 infected cells have been identified as mature T cells with helper cell
surface markers (CD4+ CD8-, CD3+ CD4+). No HHV-6 was isolated from cells with non T cell,
immature T cell or cytotoxic cell markers (CD3-, CD4- CD8-, CD4- CD8+). When the same
strain of HHV-6 (HST, B type) was used to infect CBL's in culture the virus was predominantly
isolated from cells with similar phenotypes (CD4+ CD8-, CD3+ CD4+, CD4+ CD8+), rarely it
was also cultured from CD4- CD8+ cells. Thus it appears in vivo and in vitro that the
predominant tropism of HHV-6 is for CD4+, mature T lymphocytes.
This finding was different from that originally reported by Lusso et al who were using the GS
strain (A type) of HHV-6 on cells in vitro. They found that HHV-6 infected cells lacked the
surface membrane CD3-T cell receptor (TCR) complex and IL-2 receptor and partially co-
expressed CD4 and CD8, demonstrating an immature rather than mature T cell phenotype
[Lusso 1987; Lusso 1988], These apparent differences in tropism could be related to the
different strains of HHV-6, different conditions of the cultures or other factors. However, in
later work Lusso also confirmed that HHV-6 infects T cell of mature phenotype (CD3+ CD4+
CD8-, CD3+ CD4-CD8+) [Lusso 1991a], Down regulation of CD3-TCR in cells in culture was
further examined and shown to be due to virus specific down regulation of transcription of
host proteins. Removal of CD3 prevents the T cell from responding to antigens presented
and therefore HHV-6 infection may lead to functionally inactive T cells. This effect would
obviously be more important in persistent than lytic infection and needs further investigation.
It also appears to be specific to HHV-6 in the herpesvirus family [Lusso 1991 a].
Infection with HHV-6 has also been shown to up regulate expression of CD4 on the ceil
surface [Lusso 1991a; Lusso 1991b]. This may have important consequences for the
susceptibility of cells to HIV infection. Although HHV-6 preferentially infects CD4+ cells, this
is not a receptor for HHV-6 as it is for HIV. Blocking of CD4 by monoclonal antibody prevents
infection of cells with HIV but not HHV-6, and the T cell line, GEM, which is chronically
infected with HIV with down regulated surface expression of CD4 is still susceptible to
infection with HHV-6 [Lusso 1989a],
The possibility that different host cellular changes might be related to the infecting strain of
HHV-6 has been examined [Furukawa 1994], When strains U1102 (A type) and Z 29 (B type)
were added to CD4+ T cells in culture, CD3 expression was markedly decreased with A type
infection and only slightly decreased with B type. Cytotoxic activity of virus specific CD4+ T
cell clones was decreased only after A type infection and could not be restored in the
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presence of lectins, implying that HHV-6 infection may have affected production of cytolytic
mediators. These in vitro differences in strain infections imply that HHV-6 type A infections
may be more immunosuppressive than type B infections and this seems to correlate with the
in vivo finding of type A infections occurring more frequently in immunosuppressed patients.
Cytokines
Interferons are natural proteins with anti-viral and anti-neoplastic activities. They are
considered to be important for the control and limitation of viral infections. HHV-6 infection of
PBMC's from seropositive adults is associated with production of interferon-a (IFN-a) [Kikuta
1990], Production of this cytokine in vitro can be detected as soon as 12 hours after
infection, rises to a peak at 3-5 days and then declines. IFN-a will also be produced when
cells are exposed to UV treated HHV-6, so the effect does not depend on infection of the T
cells, and addition of exogenous IFN-a will prevent HHV-6 replication. The IFN-a response
of infected CBL's was lower than that of the healthy seropositive adults and this may
represent some kind of memory in the previously infected. IFN-a was not produced by the
HHV-6 infected cells but by other non T cell PBMC's in the culture [Kikuta 1990],
In vitro cultures of HHV-6 have also been shown to produce the monocyte-derived
cytokines, interleukin -1 (IL-1) and tumour necrosis factor (TNF-a) [Flammand 1991],
Production of these cytokines depends on interaction of a viral protein with the infected cell,
but does not require viral replication. The IL-1, TNF-a cytokine response to HHV-6 infection
in vitro was confirmed in another study where the responses to infection with HHV-6, EBV
and HSV were compared [Gosselin 1992], HSV is only a weak enhancer of cytokines and
EBV infection increased IL-6 levels where these are not affected by HHV-6. In fact the
inhibitory effects of HHV-6 on IL-6 and EBV on TNF-a were dominant to the stimulatory
effects. This observation that herpesviruses can selectively affect the regulation of cytokine
synthesis is one method by which they may evade or exploit the host immune response. The
effect of interferon - y (INF - y) on monocytes infected with HHV-6 has also been examined,
this cytokine appears to regulate production of interleukin -10 (IL -10) and interleukin -12 (IL-
12) by these cells [Li 1997], IL-12 concentrations are increased and IL -10 concentrations are
suppressed. In another in vitro study, INF - y was found have an effect on secretion of TNF-a,
IL-1, and IL-6 by HHV-6 infected monocytes and PBMC's [Arena 1996].
The genes for three interesting HHV-6 glycoproteins have been identified, one which
encodes a basic chemokine with a dicysteine "CC" motif (CC-28X-C-15X-C like the
chemokines CC-23X-C-13X-C) and another two which encode proteins closely related to
chemokine receptors [Gomples 1995b], How these might interact with the host has not yet
been identified. Receptors for some such chemokines are known to serve as co-receptors
for HIV infection of CD4+ cells with NSI type HIV strains [Dragic 1996; Wu 1997], Individuals
who are deficient in these receptor molecules are resistant to HIV infection with these strains
[Paxton 1996],
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HHV-6 inhibition of host immune cell function
In vitro, when the sonicated product of HHV-6 infected cells was added to cultures of PBMC's
from HHV-6 seropositive healthy adults there was inhibition of lymphoproliferative responses
to mitogens and antigens (PHA, II-2, Purified Protein Derivative, Mumps) [Hovart 1993], This
inhibition occurred in a dose dependent manner, was not due to cell lysis as cell death was
not observed and could be inhibited by addition of rabbit anti-HHV-6 serum. Inhibition of
lymphoproliferation was most likely caused by either viral products or viral induced host
products rather than a nonspecific effect, but the mechanism by which this occurs is not
known. In another study infection of PBMC's with HHV-6 also resulted in suppression of T
cell function [Flamand 1995 ]. There was reduced synthesis of IL-2 and reduced cellular
proliferation in the cultures. This inhibitory effect could be achieved with non-infectious UV
treated virus. This finding is of interest, as it has been shown that only low levels of IL-2 permit
in vitro culture of HHV-6, and higher levels inhibit viral replication [Roffman 1990a], It appears
as if the virus may be modulating the host immune response to allow self replication, but this
may also have an inhibitory effect on host immune activity. Infection of CD4+ T cells in culture
with both sub types of HHV-6 has been shown to produced apoptosis or programmed cell
death [Inoue 1997], This effect appears to be produced in cells which are themselves
uninfected with HHV-6 and is augmented by TNF - a.
Cells rarely infected with HHV-6
Although HHV-6 infection of CD8+ T cells appears to be rare in vivo and in vitro, with high
concentrations of HHV-6 it is possible to productively infect CD 8+ cells from PBMC's and
transformed T cell lines [Lussob 1991], Infection of these cells leads to up regulation of CD4
and down regulation of CD3. It is speculated that this could subsequently render them
susceptible to HIV infection. Monocytes have also been shown to be rarely infected with
HHV-6 in vivo and in vitro [Levy 1990b; Kondo 1991], It has been suggested that HHV-6 may
be found in a latent state in circulating monocytes [Kondo 1991; Luppi 1993b], In an
innovative study of HHV-6 infected monocytes the respiratory burst capacity of the cells was
greatly decreased, and this could be of particular importance in persistently infected patients
[Burd 1993b]. Natural killer (NK) cells are a subset of non- T non -B lymphocytes with an
important primary defence activity against virally infected and malignant cells, and patients
deficient in NK cells can suffer severe herpesvirus infections [Biron 1989]. NK cells can be
infected with HHV-6, at high concentrations, but only after long term culture in vitro when the
cells have been shown to loose their natural cytolytic activity against the virus. If such
infection is possible in vivo then this might be a mechanism where HHV-6 could avoid the
host immune system. As a result of HHV-6 infection there is de novo expression of CD4 on
the surface of the NK cells before cytolysis. Again it can be speculated that this could render
them susceptible to HIV infection [Lusso 1993],
It has now been shown that HHV-6 infection of PBMC's leads to up-regulation of NK cell
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cytotoxicity. This is mediated by a newly discovered cytokine IL-15 which acts on NK cells and
monocytes, and addition of this cytokine to PBMC cultures of HHV-6 severely diminishes
expression of the virus [Flamand 1996b], The exact mechanism whereby NK cells recognise
virus infected cells is not completely understood but in vitro without pre-activation a
proportion of NK clones will lyse autologous cells infected with HHV-6 [Malnati 1993], The
restriction of NK cell lysis to certain clones appears to depend not only on the NK cells but
also on elements of the target cells. The role of possible viral evasion here has still to be
elucidated.
y/8 T cells are a subset of T cells with activity against certain intracellular infections. Cytolytic
activity of y/8 T cells to autologous and heterologous HHV-6 infected cells can be
demonstrated. In vitro y/8 T cells have also been infected with HHV-6 when present in high
concentrations, and as for NK cells this induces expression of CD4 at the cell surface [Lusso
1995b], Whether these cells can be infected with HHV-6 in vivo is not known, nor whether
such infection is sufficient to impare host immunity.
Genome of HHV-6
Cross hybridisation of the original probes developed from the prototype GS strain of HHV-6
did not not occur with any of the other five herpesviruses known at that time, which was
important evidence that HHV-6 was a new herpesvirus [Josephs 1986; Josephs 1988b;
Lopez 1988]. Subsequently, some cross hybridisation with the genome of the more recently
discovered HHV-7 has been shown [Frenkel 1990], Although this did not occur in all
fragments examined, it does demonstrate the close genetic relationship of HHV-6 and HHV-
7. The complete genomic linkage map for the A type strain of HHV-6, has been derived
[Martin 1991b; Gomples 1995b; Nicholas 1996], The genome is 159,321 base pairs (bp) in
length, with a unique long central portion (UL) (143,147 bp) bound at each end by direct
repeats (DR Right & DR Left) (8000 bp, approx). The overall base composition of the
genome is 43% guanosine & cytosine (G+C), with 41% in the unique region and 58% in the
terminal repeats. This simple herpesvirus genome pattern is similar to that of the channel
catfish virus and equine CMV, where other human herpesviruses have more complex
reiterations and inversions of their genomes [Thomson 1991b], The genome of over 95% of
a B subtype strain of HHV-6 (Z29) has also been mapped and it is closely colinnear with the
previously mapped A subtype [Lindquester 1996].
Direct Terminal Repeats
Different overall estimates of the length of HHV-6 relate mostly to variation in the length of the
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terminal repeats, with relative stability of the length of the unique central region [Lindquister
1991; Neipel 1991], The terminal repeats contain simple repeats, unique sequences and
regions involved in DNA packaging [Thomson 1994a], Bounding each direct terminal repeat
are arrays of simple repeats similar to human chromosomal telomeric sequences [Martin
1991b; Thomson 1994a; Gomples 1995a], The function of these telomeric repeats is not
certain but it has been suggested that they could in some way protect the viral genome from
exonuleases or ligases and that host telomerase could assist in reassembly of viral genome.
They might also have some role in maintaining the viral chromosomal structure as they do in
host chromosomes, or they may have a role in cleavage and packaging of replicating viral
genome [Thomson 1994a; Gomples 1995b], The replication of HHV-6 occurs by a rolling
circle mechanism, where head to tail concatemers are produced and cleaved to unit length
genomes as they are packaged into the protein capsid [Martin 1991 b].
There are also three short areas of repeats towards the right hand end of the unique long
region of the genome, but delineation of these is not precise as they are degenerate [Martin
1991a; Martin 1991b; Thomson 1992; Nicholas 1994a],
Unique Long Region
Although CMV has a larger genome than HHV-6 (230Kbp, compared to 160Kbp), both are
densely packed genomes with minimal splicing and the central unique portion of the HHV-6
genome is colinear with that of CMV [Efstathiou 1988; Lawrence 1990], The degree of
relatedness between HHV-6 and CMV is similar to that between VZV and HSV-1, but the
CMV genome is considerably longer than that of HHV-6 and has more genes. There is
divergence of the genome colinearity with CMV at either end of the HHV-6 genome.
Although HHV-6 and CMV share little nucleotide sequence similarity they have a similar gene
organisation of "conserved genes" which encode homologous protein products [Littler
1990; Neipel 1991; Teo 1991; Martin 1991a; Gomples 1992; Chou 1992; Efstathiou 1992;
Thomson 1992; Nicholas 1994a; Nicholas 1994b], The homology of HHV-6 proteins with
CMV is 67% compared to 21 % for the herpesvirus group as a whole [Gomples 1995b],
The genome of HHV-6 contains 119 open reading frames, 8 of which are duplicated in the
repeats, 6 span repetitive elements and three are spliced, therefore the genome can encode
a possible 102 proteins. The list of all these genes, their known encoded proteins and CMV
homologues has been defined [Gomples 1995b], There is a common core of genes
conserved in all herpes viruses essential for viral replication, for HHV-6 this core extends for
86Kbp's in the centre of the unique long (UL) region, and it is the most compact of all the
herpesviruses examined [Gomples 1995b], This core group of genes consists of seven
gene blocks (I - VII), and in the p herpesviruses CMV and HHV-6 these are arranged in
ascending numerical order. The gene group order for the y and a herpesvirus is different
but group specific. The HHV-6 genome contains at least one origin for DNA replication within
the UL region between gene blocks II and III. Interestingly this important area of the
genome shows more sequence similarity with that of the a herpesvirus HSV-1 than with that
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of CMV [Lawrence 1995], It has been suggested that HHV-6 may be nearer to a progenitor
human herpesvirus, in view of its compact core and more simple origin for DNA replication
and that diversion from this pattern has led to evolution of the different subgroups of human
herpesvirus [Karlin 1994].
Gene families appear to be a feature of the p herpesviruses and are extensive in CMV, they
also exist to a lesser extent in the genome of HHV-6. The largest gene family is the CMV
US22 collection of genes which is involved with transformation and transactivation of the
genome and has a corresponding family in HHV-6 [ Efstathiou 1992; Thomson 1992;
Nicholas 1994a; Nicholas 1994b] . Other families include the G-protein coupled receptor and
immunoglobulin gene families. These families may have come about by duplications and
alterations of tandem genes. There are also HHV-6 genes which do not have detectable
herpesvirus homologues and most of these are at the ends of the viral genome. These
include genes in the direct terminal repeats (right & left), certain glycoprotein genes, the
parvovirus rep homologue [Thomson 1994b], some of the immediate early proteins and
others [Gomples 1995b],
Genes for immediate early proteins & transactivation of HHV-6
Immediate early (IE) proteins control the cascade of gene expression of the viral genome and
thus are important in lytic and latent infection. They are the first genes to be transcribed and
are essential for the coordinated expression of delayed early and late herpesvirus genes. IE
proteins can transactivate a variety of host and viral promoters. Several HHV-6 IE genes have
been described which can act as transcriptional activators in vitro (see below, HHV-6 and HIV)
[Martin 1991a; Geng 1992; Nicholas 1994a; Thomson 1994b; Thomson 1992; Zhou 1994],
Transcription of at least one gene can occur without production of a corresponding protein
[Schiewe 1994]. As regulation of IE gene activation controls viral expression in cells and is
therefore crucial to the outcome of infection, understanding the control of activation of IE
genes is important. The area of genome to the right of the IE genes contains a complex set
of tandem repeats each containing binding sites for cellular transcription factors such as NF-
kB and AP2. This IE gene enhancer region is similar to that found in CMV and activation of
this region will set in train viral replication [Thomson 1992], Although major HHV-6 IE genes
are homologous and colinear with CMV IE genes, within these groups of genes there are
unique genes which occur only in HHV-6 or CMV [Nicholas 1994a; Nicholas 1994b; Gomples
1995b]. These unique genes must contribute to specific biological characteristics of each
virus, and may be important elements in the maintenance or interruption of latency in for each
virus.
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Proteins of HHV-6
Glycoproteins of HHV-6
All human herpesviruses express glycoproteins on their envelope surfaces and on the
surfaces of infected cells. Certain of the glycoproteins have homologues throughout the
herpesvirus family and others are specific to a sub family or to the individual viruses.
Herpesvirus glycoproteins are an important expression of viral pathogenicity. They are
required for attachment of virus to cells and thus influence the cell tropism of the virus. They
mediate entry of virus to cells by fusion and also spread of virus from cell to cell. In view of
their surface expression they are also targets for the host immune response. The
glycoproteins gB and gH are conserved throughout the human herpesviruses and
neutralising antibody is often produced against them [Manservigi 1991].
The gH glycoprotein is a highly glycosilated protein important in viral-cell fusion, the gene for
HHV-6 gH has been identified and lies within the area of highly conserved genes for all
herpesviruses [Josephs 1991a]. The organisation of the conserved genes in this area is
identical for HHV-6 and CMV, to which the HHV-6 gene is most closely related. In this area the
thymidine kinase gene is present in HSV, VZV and EBV, but absent in HHV-6 and CMV
[Gomples 1992]. Where gH of a type A and type B strain were examined the overall
nucleotide difference was only 0.5%. Expression of HHV-6 type A gH gene in a bacterial
fusion protein system demonstrated this to be an immunogenic protein and rabbit antisera
produced against the protein could block the infectivity of both types of HHV-6 [Foa-Tomasi
1991; Qian 1993],
In herpesviruses it has been shown that gH combines with another glycoprotein gl to form a
stable heterodimer, and this is also the case for HHV-6 [Liu 1993a]. Again the gL of HHV-6 is
most closely related to that of CMV. Expression of the HHV-6 gH-gL heterodimer in T
lymphoblasts and fibroblasts demonstrated this to be an immunogenic protein which was
recognised by HHV-6 immune, CMV negative sera. Monoclonal antibodies have been
generated to gH, gL and the gH-gL heterodimer [Liu 1993b]. The monoclonal antibodies to
gH, and the gH-gL heterodimer neutralised viral infectivity but that to gL alone did not. The N
-terminus of gH has a 230 amino acid domain where interaction with gL occurs, this domain
has residues specific for the p herpesviruses and the CMV gH and gL molecules can
functionally substitute for the HHV-6 molecules in this complex. Without gL the complex is
not expressed at the cell surface. The C- terminal cysteine domain is conserved in all the
herpesviruses and is probably important for cell fusion and infectivity [Anderson 1996].
Glycoprotein gB is essential for infectivity and important in attachment and penetration of the
host cell membrane and is a prime target for neutralising antibodies, it is the major envelope
component with homologues in all known herpesviruses. The HHV-6 gene for gB has been
identified and the protein is again most closely related to that of CMV, there is also minimal
difference between the A type and B type HHV-6 gB [Chou 1992; Ellinger 1993], The
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degree of similarity between HHV-6 and CMV gB is greatest in the N-terminal portion. This
area contains confirmation epitopes recognised by CMV neutralising antibodies from
immune human sera and cross reactivity with HHV-6 could well occur (see
below).Glycoproteins B and HL are not detected on the plasma membranes of infected cells
[Cirone 1994].
The U100 HHV-6 gene encodes part of a glycoprotein complex, gp82-gp105, which is
unique to HHV-6. This glycoprotein complex is made up from a multispliced mRNA and the
encoding genes can be found at the right end of the unique long region, and in the left and
right direct repeats. This is the first example of a human herpesvirus envelope glycoprotein
encoded in this way [Pfeiffer 1995; Pfeiffer 1993], Monoclonal antibodies to this complex
neutralise HHV-6 infectivity and the neutralising epitope has been identified. An HHV-6
glycoprotein, gM, has also been identified, this glycoprotein is also conserved within the
herpesvirus family but its function remains to be determined. The HHV-6 gM has a high
degree of homology with that of CMV [Lawrence 1995].
There are several other less well defined HHV-6 glycoproteins, some which have CMV
homologues and some which are unique to HHV-6 [Gomples 1995b], Some of these have
similarities to cellular counterparts which are members of the Immunoglobulin super gene
family. Some are similar to G-protein-coupled receptors and only found in the [3 and y
herpesviruses.
Immediate Early Proteins
Immediate early proteins are expressed by host cell transcription and translation systems
without prior viral protein synthesis (see above). They are very important and act as
controllers of the "Temporal Cascade" of viral reproduction. It has been demonstrated that
within three hours after infection of host cells with HHV-6 nuclear antigens are expressed
which are most probably immediate early proteins [Eizuru 1992]. These proteins only appear
to elicit a weak host antibody response in certain cases where there is a generally high titre
antibody response to HHV-6. The exact function of these proteins has not yet been
demonstrated. When considered from genomic examination there is, not surprisingly,
homogeneity of HHV-6 genes to those of CMV known to encode immediate early proteins
[Gomples 1995b], The location of these immediate early genes, IE - A and IE - B, lie in two
areas on the unique long region of the genome, one at each end of the block of herpes virus
conserved genes. Several HHV-6 genes have been described which can act as
transcriptional activators and thus turn on the cascade of host protein synthesis under viral
control [Martin 1991a; Geng 1992; Nicholas 1994a; Thomson 1994b; Zhou 1994],
DNA Replication Proteins
A series of proteins are required by herpesviruses for viral DNA replication and the majority of
these are produced by HHV-6. The first such HHV-6 proteins identified were the DNA
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polymerase and DNAase [Bapat 1989; Williams 1989], The DNA polymerase maps to the
HHV-6 genome within block II of the Herpesvirus conserved gene blocks. The HHV-6 DNA
polymerase is the smallest of the herpesvirus DNA polymerases and although colinear with
CMV it has closer amino acid identity to EBV [Teo 1991; Tsai 1990], The following HHV-6
DNA replication proteins also have CMV homologues: DNA polymerase processivity factor;
single stranded DNA binding protein; and the helicase / primase complex. The HHV-6 origin
binding protein does not have a CMV homologue [Gomples 1995b], HHV-6 produces a
homologue to the parvovirus rep protein, a multifunctional protein with a role in priming DNA
replication [Thomson 1991a; Agulnick 1994]]. Herpesviruses also produce proteins for DNA
repair and nucleotide metabolism, importantly neither CMV nor HHV-6 produce a thymidine
kinase which renders them relatively resistant to aciclovir [Williams 1989; Gomples 1995b],
There are also a number of proteins which play a role in the assembly and packaging of newly
formed viral DNA and again the HHV-6 proteins have close CMV homologues [Gomples
1995b; Tigue 1996],
Virion Structural Proteins
There are herpesvirus conserved genes for structural proteins of the tegument and capsid
and these are also found in HHV-6 [Shiraki 1989 ; Yamamoto 1990], The HHV-6 major capsid
protein is most closely related to that of CMV [Littler, 1990 #199], The HHV-6 tegument
proteins also have significant sequence similarity with this other beta herpesvirus [Josephs
1991a; Neipei 1992],
Antigenic Proteins
The nature and host significance of viral proteins can also be examined by looking at
serological responses to these proteins in the natural host and other animals [Josephs
1988b; Saxinger 1988; Balachandran 1989b; Yoshida 1989b; Yamamoto 1990;
Balachandran 1991; Chang 1991], In this way proteins can be identified which are antigenic
to the host and might be important in a protective response against the virus. Usually, for
such experiments virus is cultured in cells and then the lysate examined for a response after
electrophoresis with reactive serum. Not all immunoreactive proteins are necessarily virion
derived, some originate from virus directed alterations of cellular metabolism [Black 1991],
Human sera have been shown to immunoprecipitate with both polypeptides and
glycoproteins of HHV-6, however the viral glycoproteins have usually been most
immunoreactive [Balachandran 1989b; Yamamoto 1990; Okuno 1990b; Balachandran 1991;
Okuno 1992]. The glycoprotein complex of HHV-6 gH and gL appears to be a major
immunogen for reactive human sera [Liu 1993a], Monoclonal antibodies to this glycoprotein
neutralise HHV-6 and prevent virus induced cell fusion [Liu 1993b], Human sera containing
antibodies to HHV-6 also react strongly with a protein p101 / p100, the homologue of CMV
pp150 [Yamamoto 1990; Neipei 1992; Pellet 1993], In contrast to HSV-1 and similar to CMV
the HHV-6 major capsid protein appears only weakly immunoreactive with human sera
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[Balachandran 1989b; Yamamoto 1990].
Monoclonals antibodies to early and late HHV-6 proteins have been developed and these
have been used to discriminate between ongoing virus activity with continued antibody
production to early antigens compared to past infection with development of antibody
responses to late antigens, a pattern similar to that seen with EBV [Iyengar 1991 ].
Strain variation
Two subtypes of HHV-6,"A" and "B", have been described [Ablashi 1993], Although closely
related, they can be distinguished at all levels from the genomic to the serological response.
The overall level of genomic similarity between subtypes at most loci examined has been
around 94-96%, whereas within subtypes it is 97-100%. At the amino acid level the degree
of variability between subtypes is slightly more, 92-96%. [Aubin 1993 ; Gomples 1993],
There is closer subtype similarity in the centre of the genome and more divergence at the
ends [Gomples 1995b], The subtypes of HHV-6 are more closely related than the subtypes
of EBV or CMV. Restriction enzyme "finger-printing" of total viral DNA from different isolates
has demonstrated polymorphisms which can discriminate between the two subtypes [Kikuta
1989a; Pellet 1990; Ablashi 1991; Aubin 1991; Schirmer 1991].
Amplification of the DNA sequence of the large tegument protein produces a 830 base pair
(bp) amplimer for both subtypes of HHV-6 [Aubin 1991; Aubin 1992a], Digestion of this
amplimer with the restriction-endonuclease (RE) Hind III, will produce two fragments for
type B strains, but does not digest type A strains. A similar discrimination of the two subtypes
can be shown by Hae II digestion of a 380bp amplimer from the major capsid protein [Aubin
1993]. These RE digestion sites have been exploited to differentiate between the subtypes
of HHV-6 in clinical samples [Aubin 1994] (see methodology below).Cell culture tropism can
also be found between the two subtypes, for example, A type strains grow better in the T-cell
line HSB-2 and B type strains grow better in Molt-3 [Wyatt 1990; Ablashi 1991] (table 1).
Panels of monoclonal antibodies raised to the two prototype strains of HHV-6 (GS, type "A"
and Z29, type "B") have reproducibly demonstrated that some antibodies react with both
strains and that others are strain specific [Wyatt 1990; Ablashi 1991; Chandran 1992; Aubin
1993; Campadelli-fiume 1993; Takeda 1996; Takeda 1997], An HHV-6 subtype A specific
neutralising epitope on glycoprotein B has been identified with monoclonal antibody 87-y-13
[Takeda 1996], An HHV-6 subtype B specific neutralising epitope on glycoprotein H has
been identified with monoclonal antibody OHV3 [Takeda 1997],
Reaction of human sera to different strains has demonstrated that most show a similar titre of
antibody to both subtypes, but a minority can show a 2-4 fold difference in titre. This would
imply that it is possible to have serological response to both strains [Chandran 1992],
On a clinical level, the overwhelming majority of isolates from children with ES have been B
type viruses [Schirmer 1991; Aubin 1991; Ablashi 1991; Dewhurst 1992; Diluca 1992;
Aubin 1993], Immunocompromised patients and those with malignancy have been found to
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both subtypes and sometimes both together [Ablashi 1991; Aubin 1993; Gomples 1993;
Luppi 1993a], The clinical significance of infection with either subtype is not yet elucidated.
Latency and dissemination of HHV-6
In common with all the herpesviruses after primary infection HHV-6 persists in the host in a
latent state. Latency allows competent viral genome to remain within a particular cell type, in a
nonreplicative state, without generation of antigenic proteins. Recognised RNA transcripts
have been found in cells latently infected with herpesviruses and these may play a role in
preventing initiation of lytic cycles of replication [Stevens 1989], At certain stimuli, viral
replication will be reinitiated and reactivation of infection can occur. Reactivation from latency
may be at an asymptomatic level and fail to progress in the presence of an active immune
response. In the immunocompromised host by contrast, reactivation from latency can lead to
severe symptomatic infections with a number of the herpesviruses (e.g. varicella zoster, and
Epstein Barr virus).
HHV-6, known to be a lymphotrophic virus in primary infection, appears to establish latent
infection in a proportion of circulating mononuclear cells. HHV-6 DNA can be found in the
blood lymphocytes and monocytes of healthy adults [Kondo 1991; Sandhoff 1991; Cone
1993a; Luppi 1993a; Aubin 1994; Cuende 1994; Di Luca 1994], The proportion of persons
with detectable HHV-6 genome and the proportion of infected cells has varied in different
studies, perhaps relating to use of different amplification techniques. HHV-6 genome has
been detected in PBMC's from 5% - 90% of healthy adults [Aubin 1994; Cone 1993a] . In
one study, 10 - 4,000 HHV-6 genomes were detected per 10® PBMC's examined, implying
that between 1/105 to 1/103 cells could be HHV-6 infected [Cone 1993a], In a study of
previously infected children, a median of 1606 HHV-6 genomes per 10® PBMC's were
detected [Clark 1997], Other workers have suggested that HHV-6 positive cells are less
frequent (< 1/10® PBMC's) [Jarrett 1990; Sandhoff 1991; Cuende 1994 ; Rajcani 1994],
Non-diseased lymph nodes from patients with carcinoma of the head and neck have also
been shown to contain HHV-6 DNA. The quantity of DNA present ranged from the detection
limit of the test, 10 viral genomes / pg of DNA to 103 viral genomes / pg of DNA. This was not
found to be increased in nodes examined from patients with AIDS or Hodgkin's disease
[Secchiero 1995b],
HHV-6 can frequently be found in the saliva of healthy adults and children, and this may be
the mode of transmission of the virus [Levy 1990a], HHV-6 genome can also be found in
salivary and bronchial glands which may serve as another site of latency for the virus [Fox
1990a; Krueger 1990; Di Luca 1995]. HHV-7 also appears to persist in the salivary glands
and is secreted in saliva [Sada 1996],
In vitro models have been developed to study reactivation of HHV-6 from latency [Kondo
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1991; Katsafanas 1996], HHV-6 could be reactivated from monocyte culture after treatment
with phorbol ester [Kondo 1991], Lymphocyte cultures activated with T cells first reactivated
HHV-7 and after HHV-6. It was suggested that the HHV-7 may have some transacting
functions in the reactivation of HHV-6 [Katsafanas 1996]. A cell line derived from a Burkitt's
lymphoma containing latent HHV-6 DNA sequences and no EBV has been established
[Bandobashi 1997], It will be possible also to use this cell line to study the mechanisms of
HHV-6 latency and reactivation.
HHV-6 has been found in a number of other tissues in the body, in addition to those already
mentioned, including the central nervous system, the bone marrow, and the kidneys.
Whether the virus can reactivate from these sites and cause later symptoms has been
disputed.
Natural transmission of HHV-6
The sero-epidemiology of HHV-6 implies that most infants are infected with this virus within
the first two years of life (see chapter 2). Although HHV-6 DNA can be found in peripheral
blood mononuclear cells of most seropositive persons direct viral transmission via blood is
unlikely to be a common route of infection. HHV-6 is often secreted asymptomatically in the
saliva of the seropositive and this would seem to be a plausible mode of transmission.
[Pietroboni 1988a; Gopal 1990; Harnett 1990; Jarrett 1990; Levy 1990a; Cone 1993a; Di
Luca 1995a; Aberle 1996; Hall 1998], This corresponds with the finding of persistence of
HHV-6 genome in the salivary glands [Fox 1990a; Krueger 1990; Di Luca 1995a]. Viral DNA
has been detected in saliva as well as the virus cultured from saliva, and the virus has been
found to be both cell free and cell associated. In longitudinal surveys of healthy individuals
persistent shedding of HHV-6 in saliva has been demonstrated [Cone 1993a; Hall 1998],
Presence of virus in saliva did not correlate with serum antibody levels. Quantification of HHV-
6 DNA has revealed that in some persons up to 2 x 105 HHV-6 particles per ml of saliva are
secreted. In one small study of infants with primary HHV-6 infection and their mothers, one of
the three mothers was found to be persistently secreting HHV-6 DNA in the saliva, and all
three mothers had HHV-6 DNA in peripheral blood lymphocytes [Suga1995]. Direct
sequence analysis of PGR amplified HHV-6 DNA from 4 mother-infant pairs where the infant
was found to have primary HHV-6 infection revealed possible mother to infant transmission in
3 cases [van Loon 1995]. The maternal and infant PBMC strains of HHV-6 were identical, but
interestingly, in one case the maternal saliva strain of HHV-6 was different from her PBMC
strain and the PBMC strain was found in the infant. A further study also demonstrated close
similaritly between HHV-6 strains identified within families compared to other family groups
[Mukai 1994],
In a series of 52 electively aborted foetuses from mothers with HIV one case of a congenital
infection with HHV-6 in a 26 week gestation foetus was found, the foetus was clinically normal
but, virus was amplified from all the major organs [Aubin 1992a], A possible link with
spontaneous abortions and HHV-6 infection has also been suggested [Ando 1992].
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Serological evidence for possible intrauterine transmission of HHV-6, with IgM in cord blood
samples has been demonstrated in one study, where 2 / 799 (0.28%) samples were IgM
antibody positive [Dunne 1992]. HHV-6 DNA could not be amplified from these samples, and
no clinical data on the infants was given. Thus far, no clinical syndrome associated with
congenital HHV-6 infection has been demonstrated, as is well known for the closely related
virus, CMV. As several of the human herpesviruses (HSV 1 & 2, CMV, EBV) are known to
replicate in the female reproductive tract, evidence of HHV-6 in the birth canal has also been
sought. In one study, HHV-6 DNA could be amplified from 19% (14/72) of cervical swabs from
women in late pregnancy, and all were subtype B [Okuno 1995]. PCR amplification of vaginal
secretions from non-pregnant women demonstrated HHV-6 DNA in 10% (3 / 29) [Leach
1994]. In another study the virus could not be cultured from 50 endocervical swabs or 30
male urethral swabs, but these samples had been stored in liquid nitrogen and were not
cultured fresh [Harnett 1990]. In a study of vertical transmission of HHV-6, virus could be
amplified from vaginal swabs taken during the first trimester in 25% of 110 pregnant
Japanese women [Maeda 1997]. No saliva and PBMC's collected from their infants at birth
and one month of age amplified HHV-6, implying no evidence of vertical transmission,
although the maternal samples were collected very eariy in pregnancy and might not
represent the birth canal at delivery. As regards postnatal infection, examination of 120
randomly selected, breast milk samples for HHV-6 by PCR did not demonstrate any HHV-6
DNA [Dunne 1993], There is no difference in the seroprevalence of antibodies to HHV-6 in
breasted or bottle fed babies at 12 -23 months of age, again implying that breast milk is
unlikely to be a significant source of this infection [Kusuhara 1997],
Interaction between HHV-6 and other viruses
HHV-6 and other Herpesviruses
Attempts have been made to understand the nature of interactions between HHV-6 and
other herpesviruses in vitro and in vivo. In most studies it has been difficult to tease out not
only the roles of the different viruses but also that of the host immune response. As
mentioned above secretion of certain cytokines after infection with one of the herpesvirus
family may alter the cellular environment in a negative or positive way for other herpesviruses.
HHV-6 and the other (3 herpesviruses, HHV-7 & CMV
In terms of genome, HHV-6 is most closely related to these two viruses and all three infect
lymphocytes. Interactions between these viruses at a genomic or transcriptional level can
therefore be implied, but there is little current evidence. In vitro infection of cells with HHV-6
and HHV-7 can be achieved and both have different effects on expression of cell surface
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markers [Furukawa 1994], Such experiments with CMV have not been undertaken. Further
study on the cellular effects of combined infection could be undertaken. As far as the host
response is concerned, there are cross over epitopes between HHV-6 and HHV-7 and
between HHV-6 and CMV for antibody production [Adler 1993 ; Wyatt 1991; Wyatt 1992 ;
Foa-Tomasi 1994; Nakagawa 1997], There are also cross over epitopes between the three
viruses for cytotoxic responses [Yasukawa 1993] . In the clinical situation, primary infection
with HHV-6 usually occurs first followed by HHV-7 and then CMV. Therefore, in most infants
any cross reaction with other herpesviruses is not seen with primary HHV-6 infection [Asano
1990a], An anemnestic serological response to HHV-6 can be found with primary CMV
infection, as well as evidence of virus reactivation [Chou 1990; Irving 1990a; Linde 1990:
Ward 1991], In one study of liver transplant patients, seroconversion to HHV-6 post
transplant was associated with an increased risk of later CMV disease [Dockrel 1997].
Whether this was simply a serological phenomenon or a result of direct viral interaction
remains to be fully elucidated. Primary HHV-7 infection may reactivate HHV-6, and both
viruses can be found in blood and saliva [Asano 1995]. The viral or host interactions which
allow these responses to occur are not well understood. In the immunocompromised host,
reactivation of more than one herpesvirus infection can occur symptomatically or
asymptomaticaliy. In this situation the inadequacy of the normal host immune response to the
virus enables reactivation to occur, but whether there are viral interactions which also affect
this is not well understood. (See different Host sections for particular immunocompromised
groups).
HHV-6 and the y herpesviruses: EBV & HHV-8
The natural target cell for EBV infection is the CD21+ B lymphocyte, not usually permissive to
HHV-6 infection. However, in vitro T cell lines which have been infected with HHV-6 can
express CD21 and could therefore be susceptible to EBV infection [Schonnebeck 1991], B
cell lines which have been EBV transformed can become infected with HHV-6 with variable
efficiency [Ablashi 1988a], Such EBV genome-positive cell lines, when infected with HHV-6
can demonstrate EBV reactivation, with evidence of production of both early and late
structural EBV proteins [Flamand 1993]. This effect of HHV-6 on latent EBV could not be
produced by UV light - irradiated or heat inactivated HHV-6, implying that infectious virus
particles are required. The mechanism by which HHV-6 activates the EBV lytic cycle has been
investigated [Flamand 1996a], Activation of EBV from latent to lytic cycle follows expression
of the immediate - early EBV Zebra gene, and HHV-6 can up regulate Zebra gene
transcription through a cyclic AMP- responsive element located within the Zebra gene
promoter. This effect of HHV-6 has been found to be due to subtype A [Cuomo 1995],
In clinical terms these findings imply that HHV-6 activation can lead to increased production of
EBV. This is of most importance in the immunocompromised who are at risk of EBV
polyclonal activation with subsequent clonal activation and lymphoproliferative malignancy.
Thus although HHV-6 activation may not be significant to the host its effects on EBV activity
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could very well be. The interactions between these two viruses in the host deserves further
investigation.
Interactions between HHV-6 and HHV-8 are only beginning to be investigated, HHV-8 can be
cultured in transformed lymphoblastoid cell lines [Renne 1996], HHV-8 infection is most
prevalent in Africa. In one study of infants in Zambia presenting with first fever, infection with
HHV-6 and HHV-8 was sought [Kasolo 1997], Levels of viral DNA concordant with primary
infection were detected in 30% of infants for HHV-6 and in 8% for HHV-8. HHV-6 subtype A
was found in 44% of these African infant samples, very different from almost universal
subtype B infection in studies of first fevers from Japan, Europe and the USA. Whether there
might be an interaction between HHV-6 and HHV-8 which predisposes to development of
later Kaposi's sarcoma is under investigation. It is also of interest to note that EBV associated
Burkitts lymphoma is also prevalent in sub-Saharan Africa. Perhaps there could there be an
interesting link here with the increased prevalence of HHV-6 sub type A in children and
activation of EBV.
HHV-6 and the a herpesviruses: HSV 1&2 and VZV
The main target cells for infection of the a herpesviruses are epithelium and neurones.
Although HHV-6 appears to be tropic for the central nervous system, major interactions
between these groups of viruses have not so far been demonstrated. However in vitro, HHV-
6 encodes a transactivator region which can activate heterologous promoter-
chloramphenicol acetyltransferase (CAT) constructs of HSV-1 and HIV [Campbell 1991].
Therefore it is possible that there could be interaction of activity of these two viruses.
HHV-6 and other viruses
HHV-6 and HIV
Since some of the first isolates of HHV-6 came from patients with HIV and as HIV and HHV-6
preferentially infect the same host cells, the relationship between these two viruses has
been closely examined. The main question being, whether the ubiquitous virus, HHV-6, acts
as a possible co-factor up regulating replication of HIV and thus progression of
immunodeficiency [Ablashi 1995], In early culture studies it appeared that replication of HHV-
6 was so quickly cytopathic to host cells that it tended to suppress growth of HIV [Pietroboni
1988a; Agut 1989a]. Using different strains of HHV-6 at lower concentrations and PBMC's
rather than transformed T cell lines it has conversely been shown that HHV-6 can suppress
HIV replication and prolonged survival of CD4+ cells can be maintained [Levy 1990a; Carrigan
1990],
Subsequently it was demonstrated that dual infection could lead to up regulation of HIV
replication and transactivation of the HIV promoter region by HHV-6 [Lusso 1989a; Ensoli
1989; Horvat 1989], In most of the experimental systems described the T cell lines
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investigated were transfected with plasmids containing the HIV Long terminal repeat (LTR)
region ligated upstream to the indicator gene chloramphenicol acetyl transferase (CAT).
Evidence of activation and production of the CAT gene product could then be sought by
measurement of acetylated chloramphenicol in a biochemical system [Horvat 1989]. Several
groups of investigators have examined the relationship of HHV-6 to the HIV promoter region.
A fragment of the HHV-6 clone pZVB70, can act via an NF-KB site to activate the HIV
promoter [Horvat 1991; Geng 1992], This protein had homology to the CMV early US22
gene family and may be an early regulatory protein of HHV-6. Another HHV-6 transactivating
protein described by Zhou et al also makes use of an NF -KB site [Zhou 1994], This protein
P41, is conserved among all the HHV-6 strains examined and the amino acid sequence
shows homology with the CMV UL44 gene product coding for the ICP36 family of early-late
class phosphoproteins. Another HHV-6 protein has been identified which acts by attachment
to a different transactivation response element, Sp1[Wang 1994], This protein B115 (115
amino acids) comes from the HHV-6 gene segment ZHV14 which is capable of neoplastically
transforming NIH 3T3 cells [Razzaque 1990], Another protein from a Sal1-L fragment of HHV-
6 also appeared to have HIV transactivating properties but does not require an Sp1 site
[Kashanchi 1994], In one study it was demonstrated that subtype A HHV-6 strain may have
more up regulatory effects on HIV [Knox 1996].
The interaction between HHV-6 and HIV is not necessarily going to be one way, it has also
been shown that the HIV retroviral transactivator protein (tat) can act synergistically with HHV-
6 to increase transactivation of HIV, but that tat has an inhibitory effect on HHV-6 replication
[Di Luca 1991], Another group has found that the HIV tat gene activates HHV-6 expression
and enhances replication of HHV-6 [Sieczkowski 1995], An HHV-6 functional transformation
suppression gene has also been described which suppresses HIV LTR expression [Araujo
1995]. This gene has homology with the adeno- associated virus type 2 Rep 68/78 gene.
All of these experimental systems are far from the physiological situation in terms of the cells,
the viruses and the many factors which can affect the interactions which occur in vivo. It is
likely that a balance of positive and negative effects on activation of HHV-6 and HIV is
constantly swinging, and in different situations the effect of one virus or another will be
ascendant. Within this it is important to remember that in the host the daily rate of turn over of
CD4+ cells infected with HIV is extremely high and the number of cells co-infected with HHV-
6 is not actually known [Ho 1995; Wei 1995], A more complete understanding of these CD4+
dynamics in vivo would help to better elucidate the relationship of HHV-6 and HIV. Double
infection with HIV and HHV-6 can also occur in monocytes in vivo and in vitro, the importance
of the interactions of the viruses within these cells also requires further study [Kempf 1997].
Human T Lymphotrophic Virus-1 (HTLV-1)
This is another virus which has a tropism for CD4+ lymphocytes. HTLV-1 can cause
transformation of these cells and is associated with the development of adult T cell
leukaemia. HTLV-1 transformed T cell lines (CD4+ and CD8+) can be infected with HHV-6 in
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vitro and both viruses can simultaneously replicate [Ablashi 1992]. HHV-6 encodes a
transactivator region which can activate heterologous promoter-CAT constructs of HTLV-1
and HIV [Martin 1991a; Campbell 1991], Interactions of these two viruses at a clinical level
have not been described.
Adenovirus
HHV-6 has acquired an adeno-associated virus type-2 (AAV-2) rep gene [Thomson 1991a].
This gene has an essential role in AAV-2 DNA replication. It can regulate homologous and
heterologous gene expression and inhibits cell transformation. In vitro HHV-6 and AAV-2 can
both infect CD4+ T cells so exchange of genetic material between these viruses is
conceivable [Thomson 1994b], The acquisition of this gene by HHV-6 may have important
effects on the host cell and the HHV-6 life cycle, although these have not yet been
demonstrated in vivo.
Measles virus
It has been reported from Japan that concurrent measles and HHV-6 infection can occur in
infancy [Suga 1990a], In a further prospective study of 50 infants with acute measles
infection, all but 5 of whom had a prior antibody response to HHV-6, it was found that the
measles infection led to rising titres of antibody to HHV-6 in 40% of cases [Suga,1992a]. In
three cases HHV-6 was also cultured from the blood. Measles infection is well know to be
strongly suppressive to the cell mediated arm of the host immune response, whether this is
why reactivation of HHV-6 can occur, or whether there is a more direct interaction between
the viruses which can both infect lymphocytes is not known.
HHV-6 and other hosts
Antibodies to HHV-6 have been detected in serum from eight species of monkeys [Higashi
1989], It is also possible to experimentally infect monkeys (Cynomolgus and African Green)
with HHV-6. In most cases the infection is asymptomatic but a rash has been described
[Yalcin 1992], In vitro, chimpanzee T lymphocytes have been productively infected with both
HIV-1 and HHV-6 [Lusso 1990],
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The Host and HHV-6
The Serological Response to HHV-6
Methods used to assess the antibody response to HHV-6
The first method used to test sera for an antibody response to HHV-6 was the indirect
immunofluorescence assay (IFA) [Salahuddin 1986], This was adapted from the assay first
designed to study EBV antibody responses [Henle 1966], Results of IFA for HHV-6 from
different groups have not always been concordant, this may be for a variety of different
methodological reasons, as it is difficult to standardise the nature of antigen presentation by
infected cells. Thus the use of different cell lines, different strains of virus and different ages
of cultures may affect results. The dilution of human serum tested is also very important and
studies where a dilution of 1: 10 has been used have given a much higher seroprevalence
than those using more dilute sera (table 1). The IFA test can be adapted to assess for avidity
of IgG produced to HHV-6 [Ward 1993a], Low avidity IgG antibody is produced after primary
infection and this evolves to high avidity antibody after six months or so. In this way primary
infection can be distinguished from reactivation [Ward 1993b],
Other serological methods have been used to examine sera for an antibody response to
HHV-6, including a neutralising antibody test (NT) [Yoshikawa 1990], anticomplimentary
antibody test (ACIF) [Robert 1990], circular-immunoassay (CIA) [Coyle 1992 ], and radio¬
immunoassay (RIA) [Coyie 1992], The most sensitive test of antibody have been the enzyme
linked immunosorbent tests (ELISA) and neutralising antibody tests (NT) (table 1,2). (For
further description of these techniques, chapter 5 - Methods for Clinical Detection of HHV-
6).
Seroprevalence of antibodies to HHV-6
Many seroprevalence studies of IgG antibodies to HHV-6 have now been reported from
countries all around the world [Tedder 1987; Krueger 1987b; Ablashi 1988: Andre 1988:
Briggs 1988; Brown 1988a; Krueger 1988a; Linde 1988 ; Pietroboni 1988a; Saxinger 1988;
Balachandra 1989; Okuno 1989; Yoshikawa 1989; Asano 1990a; Dahl 1990; Enders 1990;
Farr 1990; Fox 1990 ; Levy 1990a; Robert 1990; Yanagi 1990; Yoshikawa 1990; Soriano
1991: Ranger 1991; Wahren 1991; Yadav 1991; Coyle 1992; Levine 19S2a; Huang 1993;
Parker 1993; Ward 1993a; Kangro 1994; Wilborn 1994a; Cleghorn 1995] (table 2, 3). In early
studies using IFA the test reported a wide range of seroprevalence in different populations,
however where more sensitive tests, such as the ELISA, have been used over 90% of
children and adults have been found to be HHV-6 antibody positive. Most studies have been
carried out in the USA, Europe and Japan, and in all these areas similar high seroprevalence
rates have been found. There are some more isolated populations which show a lower
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prevalence of seropositivity to HHV-6 [Ranger 1991 ; Yadav 1991], In some cohorts the titres
of antibody detected have been higher in women than men [Levine 1992b],Some studies
have demonstrated that seropositivity can wain with advancing age in adulthood [Andre
1988; Brown 1988a; Levy 1990a; Yanagi 1990; Parker 1993], All these seroprevalence
studies have been undertaken using either responses to fixed HHV-6 infected cells or crude
lysates of HHV-6 infected cells, and different strains of A and B type virus have been used,
no apparent differences in response to the different strains have been demonstrated (table
2). In general, it would appear that a serological response to HHV-6 is widespread in the
human population and implies that this is a ubiquitous infection.
Acquisition of antibodies to HHV-6
There is positive placental transfer of IgG antibody to HHV-6 to the newborn and higher titres
of antibody have been found in the cord blood than maternal serum [Yoshikawa 1989;
Yoshikawa 1990], Seroprevalence wanes during the first months of life to low levels and the
majority of children then acquire antibody within the first 2 years of life [Okuno 1989;
Yoshikawa 1989; Farr 1990; Yanagi 1990; Yoshikawa 1990; Huang 1992a; Huang 1993;
Ward 1993a], The highest geometric means titres of IgG antibody to HHV-6 are found in this
young age group [Yoshikawa 1989; Yanagi 1990; Yoshikawa 1990; Ward 1993a] .
Neutralising antibody to HHV-6 is produced within 3-5 days of presentation with fever and
persists long term, the appearance of neutralising antibody is associated with disappearance
of the virus from the blood [Asano 1989a], In children with primary infection, HHV-6
neutralising antibody appears earlier and to a higher titre than IgG antibody detected by IFA ,
although both IgG and IgM will be detected by this technique [Suga 1990bj. There is no
difference in the seroprevalence of antibodies to HHV-6 in breast fed or bottle fed babies at
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Cross reactivity of the serological response to HHV-6
When infants have their primary infection with HHV-6 there does not appear to be any cross
reactivity of their antibody response to the other herpes viruses, including EBV, CMV, VZV,
and HSV [Okuno 1989; Asano 1990a], Where the IgG antibody responses of healthy blood
donors to HHV-6 have been examined this has also been found to be the case [Salahuddin
1986; Downing 1987; Tedder 1987; Briggs 1988; Lopez 1988; Saxinger 1988; Buchbinder
1989; Fox, 1990],
Older patients experiencing primary CMV infection have usually already been infected with
HHV-6, and rises in the IgG and IgM antibody titre to HHV-6 commonly occur simultaneously
with the response to CMV. This has been shown in immunocompetent and
immunosuppressed individuals [Irving 1988; Larcher 1988; Linde 1988; Morris 1988: Chou
1990; Enders 1990; Fox 1990; Irving 1990a; Irving 1990b; Sutherland 1991; Ward 1991 ;
Adler 1993], Similar IgG HHV-6 antibody responses have rarely been seen with EBV and
VZV infection [Morris 1988; Linde 1988],
This HHV-6 antibody response to infection by CMV, the most closely genetically related
herpesvirus, could demonstrate either, reactivation of latent HHV-6 infection consequent to
CMV infection, production of cross reactive antibody, polyclonal activation of antibody, or a
combination of the above. Using selective absorption of sera with cells Infected with CMV or
HHV-6 some groups did not find antibody cross reactivity and concluded that genuine dual
viral activation / reactivation was occurring [Irving 1990a; Ward 1991 ]. Other groups have
been able to demonstrate depletion of cross reactive antibodies by absorption
studies[Sutherland 1991; Adler 1993], These divergent results may be due to the
complexities of absorption studies, but also to the possibility that in different circumstances
different responses or combinations of responses may be occurring.
The most detailed study of Adler et al confirmed that children with primary HHV-6 infection do
not make a serological response to CMV [Adler 1993], They were also able to study primary
CMV infection and a live CMV vaccination response in adult women. In both groups a more
than fourfold rise in antibody titre to HHV-6 occurred. Absorption of the sera with CMV
antigens reduced the HHV-6 titres two-fourfold, but did not abolish them. Immunoblotting
was undertaken to identify HHV-6 proteins which reacted with CMV antibodies. In some
hosts antibodies which reacted with CMV glycoprotein B also reacted with a 116-KDa protein
of HHV-6, which is the likely HHV-6 homologue of glycoprotein B. The immunoblotting
provides additional evidence that cross-reactive antibody is produced but does not
completely exclude the possibility that reactivation can occur. However, the brisk rate of the
antibody response might be more in favour of cross reaction than viral reactivation. Further
elucidation of this relationship would require quantitative assessment of HHV-6 and CMV
viraemia during the infection.
In conclusion it is important when considering antibody responses to HHV-6 to be aware of
the CMV serostatus of any individual.
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The Cytotoxic response to HHV-6
T cells of healthy adults seropositive to HHV-6 will proliferate when exposed to HHV-6
antigens in PBMC cultures, in contrast to a lack of response from cord blood lymphocytes
[Yakushijin 1991], HHV-6 specific CD4+ clones were identified which proliferated in
response to HHV-6 antigens, but not HSV. Thus it appears that a T cell cytotoxic immune
response to HHV-6 is generally present in the healthy adult population. In a further study the
nature of this T cell response was examined [Yakushijin 1992], The HHV-6 active T cell
clones were shown to respond to both types of HHV-6 ( B type - strain HST, A type - strain
GS). The cytotoxic activity of some clones was inhibited by addition of monoclonal antibodies
to HLA-Dr, implying that the response was HLA class II restricted. Other clones which were
not inhibited by antibodies to HLA-Dr could lyse autologous and heterologously infected
cells as well as the NK sensitive cell line K562. The third group of clones did not have
cytotoxic activity. All three groups produced INF-yand the first two groups expressed the
cytotoxic protein perforin. It therefore appears that CD4+ T cell response of the healthy host
produces a range of effector activities against HHV-6 and is not just a helper response for
production of antibody by B cells. Loss of such effector CD4 cells in HIV infection might
contribute to the widespread infection with HHV-6 which has been shown in some such
patients, (see section, "patients with abnormal immunity and HHV-6").
The cytotoxic T cell response to HHV-6 appears to be strain specific in some individuals. In a
large study the majority of T cell clones generated produced a proliferative response to both
A and B type HHV-6, but a small percentage were strain specific [Yasukawa 1993], In this
group of healthy adults some had a memory response to B type virus, some to A type and
some to both types, but the numbers were too small to make any epidemiological
conclusions. Conversely, a small number of clones produced proliferative responses to HHV-
6 and HHV-7 and a very small number to HHV-6, HHV-7 and CMV, indicating cross reactive
epitopes between these three related viruses which are recognised by host CD4 cells.
The cytotoxic responses of children or immunosuppressed patients to HHV-6 have not yet
been investigated.
Clinical Infection with HHV-6
Primary HHV-6 infection - often the "First Febrile Illness".
The clinical syndrome of exanthem subitum (ES), also known as roseola infantum, was first
described in 1913 and in greater detail in the 1950's when an association with an infectious
pathogen was suggested by the fact that the infection could be passed from one infant to an
other [Zahorsky 1913; Kempe 1950; Hellstrom 1951], ES was noted to be a condition of
infants, in whom several days of high fever and malaise were followed by defervescence of
the fever and appearance of a rash. The rash was erythematous, maculo-papular, usually over
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the head and trunk and could last for a few hours to several days. These observant clinicians
also documented that this condition was associated with febrile convulsions.
In 1988 Yamanishi et al, identified HHV-6 as the cause of ES [Yamanishi 1988], In a series of
infants primary infection was demonstrated: by seroconversion with production of IgM and
IgG antibody to HHV-6; by culture of virus from peripheral blood lymphocytes; and later by
using PCR, HHV-6 genome was amplified from the PBMC's. Subsequent studies confirmed
Yamanishi's findings [ Knowles 1988; Ueda 1989; Yoshida 1989a; Irving 1990c; Yoshiyama
1990; Okuno 1991; Segondy 1992; Kanegane 1993; Okada 1993], A relationship between
the blood viral load of HHV-6 and the severity of the infection in terms of days of fever and
malaise has been shown [Asano 1991a], It was also found that primary HHV-6 infection could
produce fever without rash, or rash without fever [Suga 1989; Asano 1989b]. More recently
quantitative PCR assays for HHV-6 have been developed and HHV-6 can be amplified from
plasma as well as cells [Huang 1992a; Secchiero 1995a; Clark 1996], Seccherio et al
amplified HHV-6 DNA from the plasma of 6 / 7 children with acute ES and suggested this
method could be used to detect acute infection [Secchiero 1995a]. In this study, the infants
had from 6 x 102 - 6 x 103 genome copies / ml of plasma. A quantitative examination of the
PBMC load of virus, demonstrated that children with primary HHV-6 infection had a median
24,213 HHV-6 genomes per 10® PBMC's compared to 1,606 in children who have been
previously infected [Clark 1997], In this study, in half the children with primary infection, HHV-
6 was also amplified acutely from the serum.
After the discovery of HHV-6 as the cause of ES many sero-epidemioiogical studies soon
confirmed that an IgG response to HHV-6 was found in up to 100% of children tested, and
the peak period for seroconversion occurred in the second half of the first year of life (table
2,3). HHV-7 can also cause the classical syndrome of ES [Hidaka 1994; Tanaka 1994;
Torigoe 1995; Tanaka-Taya 1996], This virus, like HHV-6, is secreted in the saliva [Frenkel
1990a], Most children also have a serological response to HHV-7, although it appears to
develop slightly later than that to HHV-6 [Clark 1993; Yoshikawa 1993; Cermelli 1996; Huang
1997],
Clinical Features of Primary HHV-6 infection
The largest Japanese study of the clinical features of primary HHV-6 infection, where
infection was diagnosed in 176 out of 688 children presenting to hospital with fever, rash or
both, tended to confirm the classical syndrome of ES [Asano 1994], This study found 94% of
infants were infected by one year of age with the mean age of infection being 7.3 months (3
weeks-18 months) and for the majority of infants this was their first febrile illness. Virtually all
children (98%) had high fever to a maximum of 39.4°c, lasting a mean of 4.1 days. A maculo-
papular rash appeared on the face and trunk in 98% of cases, most commonly at the
resolution of the fever. The rash lasted a mean of 3.8 days and there was no desquamation.
Mild diarrhoea occurred in 68% of cases and erythematous papules were seen in the pharynx
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in 65%, Cervical lymphadenopathy was seen in 31% of cases and 50% had a cough. A
bulging anterior fontanelle was present in 26% of the children and convulsions occurred in
8% (14/176). The convulsions were all of short duration and occurred during the febrile
stage of the illness, before the rash had developed. The mean age of infants having
convulsions was 10.9 months (range 5-17 months).
The most exhaustive studies of primary HHV-6 in children however, have been carried out in
the USA. The first of two very large studies, examined 243 children under 2 years of age
presenting consecutively to hospital with fever (> 38°c) for evidence of HHV-6 infection by
culture, PCR and antibody response [Pruksananonda 1992]. Primary HHV-6 infection was
identified in 34 cases (14%), with a mean age of 9.5 months. Features of this group
included, high fever (mean 39.7°c) and inflamed tympanic membranes. Three cases had a
rash after the fever defervesced and 3 had a rash with the fever. One child had a febrile fit.
The mean white blood count on presentation was 8.9 x 109/l_ with 39% lymphocytes and
51% neutrophils. All but one of the strains of HHV-6 cultured were sub-type B and the other
culture included subtypes A and B [Dewhurst 1993],
A further much larger study examined 2587 children presenting under three years of age for
adverse effects of HHV-6 primary infection [Hall 1994], There were 586 infants with acute
non febrile illness and 356 healthy controls, none of them had HHV-6 primary infection. Of
1653 infants with acute febrile illness, 160 had HHV-6 primary infection (9.7%). The mean
age of this group was 9.4 months (range 2 weeks - 25 months). Importantly .where only
infants aged 6-12 months were considered then 21% (75 / 365) of febrile illnesses were
caused by HHV-6.
In only 17% of the 160 cases was the correct clinical diagnosis made, 30% were diagnosed
as fever due to otitis media and 29% as fever of uncertain cause. The incidence of infection
did not vary with the season. The majority had high fever( > 39°c), and 15% remained febrile
for more than six days. Only 11 % had a rash at defervescence and 6% had a rash at
presentation. Seizures occurred in 13% (21/160), compared with a 9% seizure rate in the
1394 febrile children without HHV-6 infection (p = 0.18). HHV-6 primary infection accounted
for a third of first febrile seizures, median age 14 months. Where primary infection with HHV-6
occurred, in the second year of life, this was associated with febrile seizures in 30% of cases.
Some fits were prolonged or recurrent. Cerebro-spinal fluid (CSF) collected from 29 children
with primary HHV-6 infection, including 7 with convulsions, was examined. The cell count,
protein and glucose concentrations were normal in all specimens and no HHV-6 could be
cultured. HHV-6 genome was amplified from CSF by PCR in 7 cases, including 2 with
convulsions.
In an Italian study of 56 infants presenting to hospital with fever, a viral infection was
confirmed in 61%, and 40% were due to HHV-6 [Portolani 1993], In two thirds of cases the
HHV-6 was a primary infection and in one third was considered to be reactivation. In the UK,
Ward et al examined a retrospective collection of sera, submitted for viral diagnosis, from 248
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children for anti-HHV-6 IgG antibody avidity, where low avidity antibody implies recent
infection [Ward 1994]. Within this study, a group of 25 children had presented with febrile
seizures and in one case clinical ES was diagnosed at the time. Five of this group had low
avidity anti-HHV-6 IgG implying primary infection, whereas 9 were seronegative on acute
phase serum and no convalescent sample was obtained. The remaining 11 children had high
avidity antibodies to HHV-6, almost certainly excluding primary HHV-6 as a cause of the
infection and seizures. This study would also tend to support the possibility that primary HHV-
6 can be a cause for febrile seizures. Again, in the majority of the cases primary HHV-6
infection was not considered in the differential diagnosis. In a study of 25 children from
Finland where a clinical diagnosis of ES was made, this was due to HHV-6 in all but 2 cases,
implying that when the diagnosis is considered it is usually correct [Linnavuori 1992], In this
cohort a third of the cases also had convulsions.
In the only PCR study of infants presenting in Africa with first fever, infection with HHV-6 was
found in 30% [Kasolo 1997], Levels of viral DNA appropriate to primary infection were
detected, but unlike the almost universal subtype B infections detected in studies of first
fevers from Japan, Europe and the USA, HHV-6 subtype A was found in 44% of these
African infant samples. As mentioned previously, the significance of this finding deserves
further investigation.
In addition to the fact that the non-specific findings make clinical diagnosis of ES difficult, the
virological diagnosis is also not straightforward for most clinicians. Culture of HHV-6 from
PBMC's is a specialised technique, not universally available. A few laboratories offer HHV-6
PCR of CSF and plasma, again as special tests. Serology, although an indirect method of
diagnosis, is a little more widely available and primary infection can be diagnosed in paired
samples by seroconversion, presence of IgM, or low avidity early IgG antibodies. Paired
serum and CSF antibody levels could also be used to diagnose CNS infection. However, in
the majority of straightforward cases with brisk recovery, convalescent serum samples are
never obtained.
It remains the case that children with this infection are still most often diagnosed as having
otitis media or a 'Virus" with fever. They may or may not get a rash, and if they do. they have
probably left hospital or the GP's surgery by that time. Indeed, it is possible that many of
these infants are unneccesarily prescribed antibiotics and then if the rash appears are
erroneously described as "allergic to penicillin". Despite widespread use of MMR vaccine,
many children with ES are still clinically diagnosed as having measles or rubella [Black 1996;
Tait 1996].
UnusuaH features possibly associated with primary HHV-6
infection
All the possible associations with primary HHV-6 infection described below are case reports,
or series of small numbers, but they demonstrate that HHV-6 may have serious effects on the
skin, the bone marrow, the gut and the immune system.
32
2) The host and HHV-6 EGH Lyall
A case of vesicular rash with ES, where HHV-6 was amplified from the skin lesions and the
throat and seroconversion to HHV-6 occurred has been reported [Yoshida 1995], There was
no evidence of HSV or VZV infection in this child. A case of Gianotti-Crosti syndrome with a
papular rash has also been described in an eight month old girl with primary HHV-6 infection
[Yasumoto 1996],
As with other members of the herpesvirus family, cases of haemophagocytic syndrome in
association with primary HHV-6 have also been reported [Huang 1990; Chen 1995; Portolani
1997], In two cases of transient erythroblastopaenia of childhood, a rare condition where
there are decreased red cell precursors in the marrow, HHV-6 DNA was amplified from the
bone marrow [Penchansky 1997], HHV-6 has been demonstrated in vitro to suppress
erythroid and granulocyte- macrophage colony forming units [Burd 1993a],
A case of progressive immunodeficiency with fatal pneumonitis has been described, where
the authors suggest that HHV-6 infection was the cause of T cell depletion and consequent
immunosuppression, as well as the cause of the pneumonitis [Knox 1995a], In this case the
infant was found to be infected with A type HHV-6.
Several cases of intussusception in association with primary HHV-6 infection have been
reported [Asano 1991b], Whether this is just coincidental or whether the virus infection leads
to lymphoid swelling in the gut and an increased risk of intussusception needs further study.
Langerhans cell histiocytosis (LCH) is a rare disease characterised by Langerhans cell
infiltration of skin, bone and in the severe form other organs. In one study tissue from 47% (
14 /30 ) of lesions examined by PCR amplified HHV-6. Negative controls in the study
included: tissue from other lymphocytic and histiocytic benign and malignant conditions
[Leahy 1993], In another study of LCH no evidence of HHV-6 was found by hybridisation
[McClain 1994], Further investigation is warranted.
There is no good evidence to link primary HHV-6 infection with Kawasaki disease [Okano
1989; Hagiwara 1992; Hagiwara 1993], No evidence of HHV-6 activity was found in a
pathological study of sudden infant death syndrome cases [Coumbe 1990],
HHV-6 and the Central Nervous System (CNS)
Early clinical evidence described a relationship between ES and febrile seizures and this has
been confirmed by the above mentioned large studies and others [Yamanishi 1992; Barone
1995; Bertolani 1996], Although HHV-6 genome can be identified in the CSF. the lack of
inflammatory cellular changes makes it difficult to understand the mechanism by which this
virus might affect the CNS. In an extension of the large American study of primary HHV-6
infection, CSF and PBMC's from children who had experienced primary HHV-6 infection were
examined for persistence of HHV-6 DNA. HHV-6 was shown to persist in the CSF and
PBMC's after acute infection and in some patients was detected only in CSF [Caserta 1993;
Caserta 1994]. In a follow up study it was demonstrated that although more than 98% of HHV-
6 amplified from PBMC's in these children was type B, of the HHV-6 found in CSF 14% of
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samples were typeA [Hall 1998], Whether this is of pathogenic significance is not known. It
has also been suggested that children with recurrent febrile convulsions may be having
reactivation of HHV-6 in the central nervous system [Kondo 1993], HHV-7 infection has also
been demonstrated to cause febrile seizures [Torigoe 1996],
Since the discovery of HHV-6, there have been several case reports of more serious CNS
complications including fatal encephalitis with primary HHV-6 infection [Ishiguro 1990; Huang
1991; Asano 1992; Yoshikawa 1992a; Jones 1994; McCullers 1995; Yanagihara 1995;
Webb 1997; Kamei 1997; Koshiniemi 1997], HHV-6 genome and antibodies to HHV-6 have
both been found in the CSF in these cases; inflammatory changes have been seen on CT
and SPECT scans; and abnormal EEG's have been reported. In only one of these cases was
brain tissue examined for evidence of HHV-6 infection, and in that case a needle biopsy of
brain was negative for HHV-6 antigens at a late stage, 21 days after presentation [Asano
1992], In a fatal case of dual infection with HHV-6 and VZV, evidence of dissemination of
both viruses to the brain tissue as well as other tissues was seen at post mortem [Ueda
1996],
In a small study of autopsy brain specimens, HHV-6 DNA was found in frontal cortex and / or
basal ganglia of immunocompetent adults [Luppi 1994], The authors suggest that the high
frequency of HHV-6 DNA in the CNS implies that HHV-6 can invade the brain and remain
latent with the possibility of subsequent reactivation. This finding has been confirmed by
other groups, who have found not only HHV-6, but also HSV, VZV, CMV and EBV in the
brain tissue of "control" patients [Luppi 1995; Challoner 1995; Sanders 1996; Merelli 1997],
It has also been demonstrated in vitro, that HHV-6 can infect human foetal astrocytes as well
as glial cells (derived from the monocytic lineage) [Ablashi 1988a; He 1996], Thus it appears
that HHV-6 genome may frequently be found in the brain, and whether the virus reactivates
from this site or not remains controversial.
HHV-6 infection, whether primary or reactivation has been associated with some cases of
acute demyelination in the CNS. Whether this is as a direct result of viral activity or as a result
of an auto-destructive host immune response is not known. Fulminating demyelination has
been described in the apparently immunocompetent as well as the immunosuppressed
[Knox 1995b; Mackenzie 1995; Carrigan 1996; Novoa 1997].
Multiple sclerosis (MS) is a chronic condition characterised by plaques of demyelination and
an association with HHV-6 in the CNS has been suggested, but remains unconfirmed. HHV-6
antigens and DNA have been demonstrated in nuclei of oligodendrocytes (myelin producing
cells) and in particular in those close to the myelin destructive plaques, the pathological
lesions of MS [Challoner 1995], In a subsequent large postmortem PCR study of neural
tissue from MS patients and controls HSV (MS:ControIs 37% : 28%), HHV-6 (MS:Controfs
57% : 43%) , VZV (MS:Controls 43% : 32%), EBV (MS:Controls 27% : 38%), and CMV
(MS:Controls 16% : 22%) were all found in normal and plaque tissue, making explanation of
an association only with HHV-6 more difficult [Sanders 1996], Higher levels of serum anti-
HHV-6 antibodies have been found in MS patients than controls [Sola 1993; Wilborn 1994b],
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In one study IgM to an HHV-6 early antigen (p41/38) was more commonly found in patients
with relapsing-remitting MS compared to those with chronic progressive MS, patients with
other neurological diseases, or healthy controls [Soldan 1997], In that study HHV-6 DNA was
also found in the serum of 43% of MS patients and none of the other groups. HHV-6 DNA
has also been found in the CSF of a number of MS patients [Wilborn 1994b ]. However, other
groups have not been able to confirm either the serological or CSF findings in MS patients
[Martin 1997; Nielsen 1997], There is an abnormal, auto destructive immune response in MS,
and whether this is auto-reactive secondary to a viral infection such as HHV-6 still remains to
be proved. It has been suggested that an immune response in a host of a particular genetic
make up to a viral antigen which mimics a host myelin protein could trigger later T cell
activation against the host protein. As a number of the human herpesviruses can be found in
the CNS perhaps more than just HHV-6 could be implicated in this possible pathophysiology
[Steinman 1997].
HHV-6 in the CNS of the immunosuppressed
Whether HHV-6 is a significant CNS pathogen for children or adults immunosuppressed
iatrogenically, congenitally or by infection is unknown. In a preliminary study of 5 adult
patients dying with AIDS, HHV-6 was demonstrated by PCR in different areas of the brains of
all patients but in no brain tissue from 2 patients with accidental deaths [Corbellino 1993], A
case of fulminant HHV-6 encephalitis has also been reported in an infant with HIV infection
[Knox 1995c]. CNS demylination associated with HHV-6 infection has also been reported in
adults with AIDS [Knox 1995b], This was associated with active HHV-6 infection, identified by
immunohistochemical techniques [Knox 1995b]. HHV-6 infected cells were seen at the
edges of areas of demyelinisation and not elsewhere, implying an ongoing active destructive
process. A similar pattern of demyelinisation has also been described in a patient
immunosuppressed after a bone marrow transplant [Drobyski 1994],
HHV-6 associated clinical syndromes described in adults
Several cases of infectious mononucleosis like illness in adults have been described in
association with HHV-6 infection. In a number of these cases activity of other herpesviruses
such as EBV and CMV was also found, so it is hard to be certain whether the symptoms were
due to one or more of these herpesviruses [Niederman 1988; Kirchesch 1988; Steeper
1989 ; Bertram 1991; Akashi 1993 #136]. In the majority the only evidence presented of
HHV-6 activity was serological and not molecular. Since reactivation of HHV-6 is a well known
phenomenon and cross reactive antibodies are also known to occur the clinical significance
of these cases for an infection like HHV-6, known to occur ubiquitously in infancy, is
uncertain.
Chronic fatigue syndrome is a common condition, occurring in adults and older children. The
onset of this condition is often heralded by a viral type prodrome with fever, malaise and 'flu
like" symptoms. Many viral aetiologies have been sought and in some cases it may be
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possible that HHV-6 has a role to play. A number of studies have examined HHV-6 activity in
these patients, evidence of active serological responses to HHV-6, increased culture of the
virus from lymphocytes and an increased proportion of HHV-6 sub type A have all been
found [Krueger 1987a; Wakefield 1988; Josephs 1991b; Marshall 1991; Buchwaid 1992; Di-
Luca 1995b; Patnaik 1995; Sairenji 1995], However, it has not been possible to identify
HHV-6 as a single aetiological factor.
It has been suggested that HHV-6 may have a role to play in a number of connective tissue
disorders. Since HHV-6 is known to remain latent within the salivary glands its relationship to
Sjogrens syndrome has been examined [Biberfeld 1988]. In the most comprehensive study
however, no evidence of any difference from controls in serological response to HHV-6, nor
presence of HHV-6 in PBMC's or salivary glands was found [Ranger Rogez 1995],
HHV-6 is commonly found in lymph node tissue and whether it is pathogenic or not in
Kikuchi's disease (Histiocytic Necrotising Lymphadenitis) is not certain, but the virus has
been found in lymph nodes undergoing this process [Eizuru 1989; Hoffman 1991;
Sumiyoshi 1993a; Hollingsworth 1994], In patients with Systemic Lupus Erythematosis
(SLE) raised titres of antibody to HHV-6, as well as an increased ability to culture HHV-6 from
PBMC's has been shown [Krueger 1991], However, from the study reported it is impossible
to ascertain whether this is causal or secondary to more general immunosuppression in these
patients.
In all of the clinical situations mentioned in this section it is possible that HHV-6 activity may be
occurring, perhaps as a result of an abnormal or diminished host immune response, whether
innate or iatrogenic. However, in most cases it has not been possible to prove any prime
aetiological role for this virus.
Patients with abnormal immunity and HHV-6
Patients with lymphoproliferative malignancy
As certain herpesvirus infections are well known to be problematic from some
immunosuppressed patients, and as HHV-6 was first isolated from such patients, the
serological response to HHV-6 has been examined in these groups.
Early serological studies using the I FA test reported increased seroprevalence and increased
titre of IgG antibody to HHV-6 in patients with Hodgkin's disease, acute myeloid leukaemia,
African Burkitt's lymphoma, and other non-Hodgkin's lymphomas [Abiashi 1988b; Biberfeld
1988; Clark 1990], However the control seroprevalence to HHV-6 in these studies was lower
than might be now expected (10-55%). A case controlled study of 50 patients with acute
lymphoblastic leukaemia (mean age 17 years, range 1 -52 years) where antibody levels were
assessed by IFA and ELISA demonstrated no difference in seroprevalence or titre of
antibody between patients and controls (94% were seropositive) [Levine 1992b], The
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authors of this study suggested that the previous differences found may have related more
to age differences in the populations tested than disease. This group also found no
difference in pre-treatment HHV-6 antibody seroprevalence or titre in patients with Hodgkins
disease, but in follow up where titres to HHV-6 increased over time the Hodgkin's disease
was more likely to relapse [Levine 1992c],Using monoclonal antibodies, an ELISA was
developed which distinguished antibody responses to immunodominant early and late HHV-
6 antigens, enabling a possible differentiation between active and latent infection [Iyengar
1991]. In a control population, 56-96% were seropositive to the late antigen and 10-30% to
the early antigen. Patients with African Burkitt's lymphoma and Hodgkin's disease had a
similar response to the late antigen but a greatly increased response to the early antigen in
terms of seroprevalence and titre (63-97% were positive). This was considered to represent
possible increased viral replication or immune activation in such patients. In a serological
study of 121 German children with leukaemia, with age and gender matched controls, there
was no difference in seroprevalence or titres of antibody to HHV-6 [Schlehofer 1996 ].
However, antibodies to EBV were found more frequently in children with leukaemia who
were less than six years of age. Serological studies cannot be expected to demonstrate
aetiological links between HHV-6 and lymphoid malignancies, however it does appear that in
some patients the serological response to HHV-6 may be more active and this could be due
to increased viral activity or immune dysregulation. In a study of patients with various
myelodysplastic syndromes, elevation of titres of antibody to EBV, HHV-6 and CMV was
associated with expression of viral antigens in the bone marrow, implying active viral
replication [Krueger 1994a]. The authors suggested that the cytokine milieu created by the
presence of these viruses could contribute to development of dysregulation of host cellular
controls.
Herpes viruses in addition to being active in patients with malignancy may also play a part in
the oncogenic process leading to the development of malignancy, as is well known for
Epstein- Barr virus (EBV) [Gledhill 1991; Levine 1992d], The potential for HHV-6 to be an
oncogenic virus has also been explored, in-vitro HHV-6 DNA can neoplastically transform
cells of murine and human origin which will then go on to form murine tumours [Razzaque
1990; Puri 1991; Razzaque 1993], Sequences of HHV-6 DNA known to cause
transformation in vitro have also been identified in some human lymphomas. HHV-6 DNA can
be present without production of viral antigen, implying that expression of all viral proteins is
not required for transformation [Razzaque 1996], Recently, a possible HHV-6 oncogene has
been identified. An HHV-6 derived ORF-1 protein has been shown to bind to the human
tumour suppressor protein p53 at the specific DNA binding domain, and functionally
inactivates it. Interestingly, analysis of several human tumours, by PCR has shown ORF-1
DNA sequences in some angioimmunoblastic lymphadenopathies, Hodgkins and non-
Hodgkins lymphomas and glioblastomas [Kashanchi 1997],
Tissue from many human lymphoproliferative and other malignancies has been examined for
evidence of HHV-6 genome and the results remain controversial. Early studies using
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Southern blotting and HHV-6 DNA probes identified HHV-6 DNA in a small proportion of
tissues examined: 4/30, 7/50, 2/177 respectively [Ablashi 1988b; Josephs 1988a ; Jarrett
1988], Where the more sensitive technique of PCR has been used HHV-6 positive
specimens have been detected frequently in both malignant and reactive lymphoid tissues
[Borisch 1991; Shiroky 1992; Sumiyoshi 1993b], However, in other studies the number of
HHV-6 positive samples remains much lower (<10%) [Torelli 1991; Di Luca 1994],
A possible connection with Hodgkin's disease (HD) was identified where 29% (13/45) of
samples were PCR positive for HHV-6, 38% of samples were also positive for EBV, but there
was no correlation between presence of the two viruses[Di Luca 1994]. Where lymph nodes
and PBMCs have been examined a small number of patients (2 /64 with non-Hodgkin's
lymphoma (NHL), and 3/55 with HD) as well as having detectable HHV-6 in the lymph nodes
also had a higher copy number of HHV-6 in circulating cells. In half the cases this was
complete viral genome and in the rest fragmented [Torelli 1995], In all these cases the
complete viral genome was found to be attached to human chromosome 17 at the same site
(near the P53 gene). The authors suggest that these patients may demonstrate an unusual
type of HHV-6 viral latency with more viral replication and more cells affected. In a larger study
of 73 HD, 15 NHL, and 19 reactive lymph nodes, over 2/3 of all the lymph node tissue was
positive for HHV-6 by PCR and in-situ hybridisation, although not by southern blotting,
implying low copy numbers of virus [Valente 1996], HHV-6 was only seen in lymphocytes and
not in Hodgkins or Reed-Sternberg cells, and there was no expression of viral antigens by
immunocytochemistry. There was no relationship between presence of HHV-6 DNA and
histological type of HD, clinical parameters, or outcome of disease and the authors concluded
that a specific pathogenic role for HHV-6 was unlikely. In a much larger study of 243 lymph
node and salivary gland biopsies, HHV-6 DNA was detected by PCR in 39% of NHL, 52% of
HD, 64% of non-neoplastic lymph nodes, 23% of tumour metastases, and 50% of salivary
glands. The presence of HHV-6 correlated only with the age of the patient and not with the
diagnosis, present in 54% of those under 60 years and 35% of those over 60 years [Hallas
1996]. In a very large case control study of herpesvirus serology in HD (n = 494), a sub
sample of nodular sclerosing cases was examined for antibody titres to EBV and HHV-6.
Increased titres to both viruses were found in patients compared with controls, the highest
HHV-6 titres were found in cases where the Reed-Sternberg cells were PCR negative for
EBV, the significance of this is unknown [Alexander 1995],
In contrast to most studies, Krueger et al, demonstrated the presence of HHV-6 antigens in
over 3/4 of HD tissues examined [Krueger 1994b], They also detected HHV-6 antigen
expression most frequently in Hodgkins Disease and Reed-Sternberg cells and less often in
lymphoid cells. They suggested that viral replication may affect cellular cytokine release in
such a way as to encourage dysregulation of host cell proliferation, rather than as a direct
oncogenic effect. Whether HHV-6 may have a particular role in childhood HD is not known,
but reactivation of HHV-6 in such patients has been shown [Maeda 1993; Trovato 1994].
HHV-6 preferentially infects T cells and one study of childhood T cell leukaemia
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demonstrated bone marrow from 14/16 cases to be PCR positive for HHV-6 [Luka 1991]. In
situ PCR was positive in 20-58% of cells, and 2-7% of cells were expressing HHV-6 early
antigen, but no late antigen. HHV-6 has also been associated with a rare adult form of T cell
leukaemia, being found only in the malignant cells [Hanson 1991; Braun 1995], A case of
angioimmunoblastic lymphadenopathy with dysproteinaemia (AILD) associated with active
HHV-6 infection has been reported in a patient who had been treated successfully for acute
myeloid leukaemia. The patient developed pericarditis, polyclonal gammaglobulinaemia, and
died of fulminant hepatitis. At autopsy, all the major organs were infiltrated with lymphoma and
HHV-6 DNA (sub type B) was present in involved tissue. The authors suggest that in some
way reactivation of HHV-6 may have triggered the development of AILD [Daibata 1997]. In an
earlier study, HHV-6 sequences were found in tissue from 7/12 patients with AILD, and a
causitive role for HHV-6 was also suggested [Luppi 1993c],
Tissue from certain carcinomas (oral, salivary gland, larynx, breast, and cervix) has also been
examined for presence of HHV-6 by in-situ hybridisation and PCR [Arivananthan 1997], Not
surprisingly HHV-6 was found in over 70% of salivary gland and oral tissue, but only 33% of
cervical and in no breast tissue. Again, a possible cofactor role in carcinogenesis was
suggested for the virus. In vitro HHV-6 infection of human papilloma virus (HPV) infected
cervical epithelial cell lines enhanced expression of the HPV RNA's coding for viral
oncoproteins [Chen 1994a]. In a study of human cervical carcinoma tissue HHV-6 was found
in a small number (6/72) and in association with HPV-16 in 4 cases. None of 30 normal
cervical tissues was positive for HHV-6 DNA. The authors suggested that HHV-6 could in
some cases act as a cofactor with HPV for development of cervical malignancy [Chen 1994b],
Transplant patients
Serological responses to infections are often difficult to interpret in patients undergoing
severe immunosuppression for transplantation. In these cases it is often more helpful to
examine for evidence of direct viral activity. Most groups of transplant patients have been
examined for HHV-6 activity. None of the cohorts studied have been of very large numbers
and some of the findings have been conflicting.
Bone marrow transplantation and HHV-6
The majority of bone marrow transplant (BMT) patients are seropositive for HHV-6 prior to
transplant, and HHV-6 activity after transplant can be demonstrated in 18-88% of patients by
culture of virus from PBMC's or bone marrow, by greater than fourfold rises in antibody titre,
and by amplification of virus from saliva and urine. In studies with multiple sampling over
longer periods of time the highest HHV-6 positive rates are seen [ Yoshikawa 1991; Drobyski
1993b; Carrigan 1994; Wilborn 1994c; Kadakia 1996], Early studies of children
demonstrated that some of those with positive cultures for HHV-6 and rises in neutralising
antibody titres also experienced fevers and rashes. In one child the rash was associated with
acute graft versus host disease (GVHD)[Asano 1991c; Yoshikawa 1991; Fugita 1996]. In
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some cohorts of patients an association between HHV-6 activity early after transplant and
acute GVHD has been demonstrated [Wilborn 1994c; Appleton 1995], but this has not been
found in others [Kadakia 1996].
One of the most important effects of HHV-6 in BMT patients is the finding that HHV-6 activity
can suppress the bone marrow. This correlates with the situation in natural primary infection
where leukopaenia can be seen. In vitro HHV-6 can suppress bone marrow culture colony
formation [Knox 1992; Burd 1993a; Isomura 1997]. HHV-6 can infect the marrow
monocytes, although cell free virus could not be found, so this may not be a very productive
infection. Severe inhibition of all the colony forming units and stromal growth was seen, and
this effect could be reversed by addition of a neutralising monoclonal antibody specific for
interferon -a [Knox 1992 ]. Further experiments demonstrated that the inhibitory effect on
marrow macrophages did not require the presence of infectious virus, and was produced by
some soluble mediator (s) [Burd 1993a], In another in vitro study marrow progenitor cells from
cord blood were directly infected with both variants of HHV-6 [Isomura 1997], Variant B HHV-
6 was shown to have a more suppressive effect on granulocyte / macrophage colony forming
units than variant A, but both had an equal suppressive effect on erythroid colony forming
units. The authors suggest that as HHV-6 was frequently amplified by PCR from single
colonies, the suppressive effect was related to presence of virus rather than indirect effects
via accessory cells of the marrow. Further investigation of these mechanisms is warranted.
Clinically, in BMT patients bone marrow suppression can also be found with activity of HHV-6,
[ Drobyski 1993b; Carrigan 1994; Wang 1996], In one study 16 adult patients were followed
for the first 100 days after BMT for evidence of HHV-6 activity [ Drobyski 1993b], In 5 /16
patients unexplained post-transplant marrow suppression was found, this was more frequent
in those who had concurrent HHV-6 viraemia (4 / 6) than in those from whom HHV-6 was not
isolated (1 /10, p < 0.05). HHV-6 was also isolated from the marrow of the 4 patients during
the period of suppression, and by in vitro colony forming assays was shown to be
suppressive for granulocyte / macrophage colony forming units and erythroid colony forming
units. All the HHV-6 isolates were variant B. In a further cohort of 15 adult patients similar
findings were obtained by the same group [Carrigan 1994],
The activity of HHV-6, HHV-7, EBV and CMV in a group of 37 allogeneic BMT recipients was
studied before and after transplant by PCR of PBMC's [ Wang 1996], Prior to BMT, HHV-6
DNA was detected in 8 (22%) patients and HHV-7, EBV, and CMV DNA were detected in 21
(57%), 10 (27%), and 1 (3%) patient, respectively. After BMT, HHV-6 DNA was detected in
26 (70%), HHV-7 in 21 (57%), EBV in 28 (76%), and CMV in 21 (57%) patients. Thirty-two
(87%) patients were positive with more than one virus. HHV-6, HHV-7, and EBV DNA were
found earlier than CMV DNA in most patients after BMT. The proportions of HHV-6 positive
samples during the first 3 months after BMT were higher in the patients with either delayed
granulocyte engraftment (P = .04) or delayed platelet engraftment (P = .001). The HHV-6
DNA in samples from the patients with delayed engraftment was variant B. The detection of
any lymphotrophic herpesvirus was not related to the development of acute GVHD. in this
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study, high-dose aciclovir prophylaxis significantly reduced the proportion of HHV-6 positive
samples and tended to lower HHV-6 DNA levels. The authors suggest that since HHV-6
variant B can inhibit marrow engraftment, high-dose aciclovir may be beneficial to engraftment
after BMT by preventing HHV-6 reactivation. No relation between the proportions of HHV-7-,
EBV-, and CMV-positive samples in the first 3 months and engraftment was found.
The great majority of strains (97%) of HHV-6 isolated from BMT patients have been type B
[Drobyski 1993a; Gompels 1993; Wilborn 1994c; Frenkel 1994; Kadakia 1996; Wang 1996],
A case of late graft failure after BMT has been reported where both variant A and B HHV-6
were found, and no other attributable cause, the authors suggested that the graft failure may
have been due to the presence of A variant HHV-6 [Rosenfeld 1995], Restriction enzyme
analysis of three HHV-6 variant B isolates obtained from a child, one prior to and two post
BMT, demonstrated that the strain isolated before transplant was identical to one of the
strains found after transplant. In this case there was reactivation of an autologous strain and
also the possibility of new infection either from the donor or else where [Yoshikawa 1992b],
Although it is possible that HHV-6 could be more pathogenic in children than adults, very few
studies of the activity of HHV-6 after BMT have been undertaken in paediatric cohorts. It
would seem prudent to observe BMT patients closely for all the herpesviruses as they can
have a wide range of deleterious effects. Although HHV-6 may be important for causing
marrow suppression, its role in GVHD and rejection remains uncertain.
Liver transplantation and HHV-6
In vitro, it has been demonstrated that HHV-6 can productively infect the hepatoma cell line,
hep G2 [Inagi 1996]. The presence of HHV-6 induced activation of the inflammatory
cytokine IL-8, but not IL-1 p. This effect was only seen with infectious particles of HHV-6, and
the authors suggest that as HHV-6 can directly infect liver and this could result in organ
dysfunction in vivo. Indeed, there are case reports of primary infection with HHV-6 in
previously normal hosts which have been associated with fulminant hepatitis [Asano 1990b;
Tajiri 1990; Sobue 1991; Dubedat 1989], In one child, not only liver dysfunction but also
persistent anaemia and granulocytopaenia in association with persistent active HHV-6
infection was found [Takikawa 1992],
Small series of liver transplant recipients have been investigated for evidence of HHV-6
activity. The first case of primary infection after liver transplant was reported with associated
fever, convulsions and hepatic dysfunction [Ward 1989]. In a similar case post liver transplant,
with fever, hepatitis, cytopaenia, and encephalopathy, HHV-6 DNA was found in blood and
bone marrow at high copy number [Singh 1995]. This patient responded favourably to a
three week course of gancyclovir. A further 4 cases of HHV-6 infection in liver transplant
recipients were reported where liver dysfunction was associated with cytopaenia, and in one
case pneumonitis [Singh 1997]. In a prospective cohort of 46 patients, where all were HHV-6
seropositive, buffy coat samples were examined before and after liver transplant by PCR
[Schmidt 1996], Pre-transplant 9.5% were HHV-6 positive, comparable with 12.5% of blood
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donor controls, after transplant 28.3% were positive (but this did not achieve statistical
significance). All but one of the amplified strains were B type. No correlation was found
between the HHV-6 result and clinical problems and the authors of this study concluded that
HHV-6 did not reactivate and cause problems in their patients.
Serological studies of liver transplant recipients have often been difficult to interpret as
responses to HHV-6 and CMV are not easy to tease apart [Ward 1991; Ward 1993b;
Sutherland 1991; Chou 1990], In some cases it appears that dual responses occur and in
others cross reactive antibody may be produced, in most no strong correlations with
symptomatology have been shown. In a very large study of 247 liver transplant recipients,
HHV-6 seroconversion was identified as a significant risk factor for development of
symptomatic CMV infection in the first 90 days after transplant (P < 0.001) [Dockrell 1997], As
the authors point out the exact significance of this finding is difficult to explain and further
study of direct virus activity by molecular techniques is required. In another study which
examined 32 recipients of either liver or kidney transplants, HHV-6 infection or reactivation of
infection occurred in 31% [Herbein 1996], The findings of this study were that, severe clinical
disease only occurred in patients with concomitant HHV-6 and CMV activity. There was no
correlation between HHV-6 activity and graft rejection.
From the available evidence, it would appear that HHV-6 can occasionally cause hepatitic
problems in the host, whether immunocompetent or not. HHV-6 may also interact in some
way (s) with CMV to cause disease in the immunocompromised. There is not enough
evidence to say whether HHV-6 may participate in liver rejection.
Renal transplantation and HHV-6
HHV-6 has been found in renal tissue and HHV-6 DNA has been found more frequently in
the blood of post transplant patients than controls [Asano 1989c; Okuno 1990a; Wrzos
1990 ; Kikuta 1991; Hoshino 1995]. Several studies have indicated that HHV-6 can
reactivate and cause febrile illnesses after renal transplantation [Morris 1989; Gudnason
1991; Yoshikawa 1992c]. In a prospective examination of HHV-6 infection in 65 renal
transplant recipients all donors and recipients had neutralising antibody and virus could not
be isolated from PBMC's prior to transplant, but HHV-6 could be cultured from 3 transplanted
kidneys. [Yoshikawa 1992c], After transplant 14% of patients were viraemic, 2-4 weeks after
transplantation, and 41% had significant rises in antibody titre. There was no correlation with
organ rejection or clinical symptoms. The authors suggested that the kidney may act as a site
for latent HHV-6 infection, with reactivation after transplant, but they also point out that most
patients also received blood transfusions.
In a small study a strong association with HHV-6 reactivation and renal rejection was found
[Okuno 1990a], However, this may have had more to do with the level of
immunosuppression in rejecting recipients. A study of 37 paediatric transplant recipients was
undertaken to examine the role of herpesviruses in rejection, six of eight rejection episodes
were associated with herpesviruses ( HHV-6 - n = 6, EBV + HHV-6 - n =1) [Acott 1996], In this
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study treatment of rejection with immunosuppressives without anti viral therapy led to a poor
outcome, and the authors suggest that this implies that viral activity may be important in the
process of rejection. In a much larger study, renal tissue from 105 kidneys from 72 recipients
was examined for HHV-6 and any clinical effects on renal transplants [Hoshino 1995], HHV-6
antigen in the tubular epithelia was detected in 63 (61.2%) specimens, and a higher
incidence of the antigen was noted in specimens of accelerated rejection, acute rejection,
and cyclosporine nephropathy. The antigen was present and absent an almost equal number
of times in chronic rejection, intra-operative and routine protocol biopsies. These results
indicate that overall HHV-6 infection is common in renal allografts and might be reactivated in
acute rejection or cyclosporine nephropathy. The presence of HHV-6 antigen, however,
does not necessarily correlate with a poor prognosis for the renal graft.
Although it does appear that HHV-6 can reactivate post renal transplantation, it is still
uncertain whether it has a significant role in kidney rejection.
Heart transplantation and HHV-6
There is very little information about HHV-6 in heart transplantation. One case report of a 44
year old heart recipient has been described where the patient presented with
gastroduodenitis, pancreatitis, and hepatitis [Randhawa 1997]. HHV-6 variant A was amplified
from biopsies of multiple sites and the inflammatory infiltrate contained many giant cells.
The Lung and HHV-6
The first report of HHV-6 as a possible respiratory pathogen was from a severely ill previously
immunocompetent man with legionella infection [Russler 1991], HHV-6 was isolated from
PBMC,s and was found by immunohistochemstry in lung macrophages and lymphocytes on
lung biopsy. The patient did not improve with antibiotic therapy alone, but only when steroid
therapy was added. The authors suggest that HHV-6 may have contributed to lung
inflammation by induction of cytokines which could have been counteracted by the anti¬
inflammatory steroid therapy. It was demonstrated in vitro that culture of HHV-6 could be
inhibited in a dose dependent manner by addition of steroid. Further to this case, an
association of HHV-6 infection with pneumonitis was found in two BMT patients with isolation
of virus from the PBMC's and also within abnormal lung tissue [Carrigan 1991 ]. The HHV-6
infected cells were predominantly intra-alveolar macrophages present in large numbers, with
some lymphocytes also seen. There was no evidence of epithelial involvement with HHV-6,
suggesting more of an inflammatory than destructive process caused by HHV-6. Co-infection
with other respiratory pathogens could be exacerbated by HHV-6 induced inflammation.
These two patients also had evidence of poor function of their bone marrow, possibly also
related to HHV-6 activity [Knox 1994],
In a small postmortem study of the lung tissue of 8 immunocompromised patients who died of
pneumonitis, HHV-6 was found in the macrophages and pneumocytes of 6 / 8 [Pitalia 1993].
In 6 patients evidence of more than one virus was found ( HHV-6 / CMV / Adeno virus). This
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study was not able to address whether these viruses were pathogens or not. An
investigation of lung biopsies, by a quantitative PCR for HHV-6, from BMT patients with
pneumonitis and immunocompetent patients with other problems demonstrated all
seropositive patients to be PCR positive, however there was a group of BMT patients with
greatly elevated HHV-6 DNA levels (10 - 500 x) [Cone 1993b], This group of pneumonitis
patients with high levels of HHV-6 DNA had a decreased risk of mortality from pneumonitis, an
increased risk of GVHD, no other microbiological pathogens found in the lungs, and
frequently pneumonitis was associated with falling antibody levels to HHV-6. Although this
study suggests that idiopathic pneumonitis in BMT patients may be caused by HHV-6, and
may tend to have good outcome, further studies have yet to confirm this. Variant A and B
HHV-6 were found together in the majority of lung tissues from these patients, variant B
alone occurred not infrequently, and variant A alone rarely [Cone 1996]. In this study the
controls included patients undergoing lung resection for other reasons and victims of
accidental death, the HHV-6 variant findings were similar among controls and patients. In a
study of 33 children (aged 2 months -16 years) who died with pneumonitis, active HHV-6
infection was demonstrated by immunohistochemical staining in the post mortem lung
tissues of four: a BMT recipient with concomitant adeno virus infection; a patient with
hepatitis of unknown aetiology; a patient with congenital anomalies; and a patient with
congenital immunodeficiency [Hammerling 1996].
In summary, HHV-6 can definitely infect or reactivate in immunosuppressed transplant
patients, but the broader significance of its pathogenic role remains to be fully elucidated. It
appears that in many cases activation is not associated with obvious symptomatology, but in
others with more devastating organ failures. If HHV-6 can be shown in larger cohorts to
contribute to organ disease, GVHD or donated organ failure then treatment of reactivations
becomes an important issue. The study which showed that high dose aciclovir inhibited HHV-
6 activity is important in that respect even though HHV-6 does not appear to have a thymidine
kinase gene [ Wang 1996],
HIV infected patients
HHV-6 activity in HIV infected patients
Most serological studies of HHV-6 in HIV infected people have been of Caucasian, male,
homosexuals and there is very little information about children or heterosexually infected
adults. In the majority, no difference in seroprevalence or antibody titre to HHV-6 between
patients or controls has been shown [Brown 1988b; Enders 1990; Fox 1988; Soriano 1991].
Seroprevalence and titre of HHV-6 antibody may even decline with progression of immune
dysfunction to AIDS [Krueger 1988a; Spira 1990], In the only study of children almost all
were found to be HHV-6 IgG seropositive and 10/25 were IgM positive. The IgM positive
children had a higher prevalence of pneumonitis [Nigro 1995],
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HHV-6 in the blood of HIV infected patients
Where attempts have been made to correlate HHV-6 activity with progression of HIV disease
some interesting findings have emerged. A close correlation of HHV-6 genome equivalents
from PBMC's with CD4+ cell count in HIV infected men was demonstrated [Fairfax 1994]. All
patients with a CD4+ count > 400 x 106/l had detectable HHV-6 genome (median -800,
range 10-1500, genomes /106 cells), but only 58% of men with a CD4+ count< 400 x 106/l
had detectable HHV-6 genome (median -20, range 0-300, genomes /106 cells). There was
no correlation between HHV-6 PCR results and antibody titres or stage of disease. Dolcetti
et al also demonstrated a correlation between CD4+ count and amplification of HHV-6 by
PCR in PBMC's from HIV infected patients, 29% of healthy blood donors amplifed HHV-6
compared to 11% of asymptomatic HIV infected and 5% of AIDS patients [Dolcetti 1996]. A
similar positive correlation between presence of HHV-6 in PBMC's and high CD 4+ count was
found in another study, where a correlation between low CD4+ count and presence of CMV
was also seen [Fabio 1997], In this cohort however HHV-6 DNA was only detected in 6% (15 /
247) of patients, and the maximum median HHV-6 viral load was 400 genomes / ml of blood (
range 400 - 7,180,000). Conversely, in another cohort there was no relationship between
presence of HHV-6 and CD4+ count, and 21% of HIV infected and only 3.3% of controls
were HHV-6 positive in this group [Blazquez 1995],
HHV-6 in the saliva of HIV infected patients
Although Fairfax et al, found a positive correlation between HHV-6 in the blood and CD4+
count , HHV-6 DNA was found in 97% of their patients' saliva, and did not correlate with CD4+
count or stage of HIV disease [Fairfax 1994], In a study where saliva and urine from HIV
infected patients were examined, CMV (61%), HHV-6 (43%), and HHV-7 (63%) were
frequently detected in patients' saliva, and no correlation with CD4 count was found
[Gautheret-Dejean 1997], HHV-6 and HHV-7 were rarely found in urine and presence of CMV
in urine correlated with immune deficiency. In a study where salivary gland tissue was also
examined, HHV-6 was frequently amplified from the gland tissue (63%), but rarely found in
the saliva (3%), and no difference was found between healthy controls and HIV infected
patients [Di Luca 1995a].
HHV-6 in the lymph nodes of HIV infected patients
As HHV-6 and HIV are both CD4+ lymphotrophic viruses, it would seem important to examine
the role of HHV-6 in the lymph nodes as well as the blood. Corbellino et al, first detected
HHV-6 by PCR in the lymph nodes of the majority of patients with AIDS, compared to only half
their HIV uninfected controls [Corbellino 1993], Immunohistochemical examination of 9
patients who had died of AIDS infections also revealed evidence of HHV-6 activity in all their
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lymph nodes, compared to CMV activity in only 3 /9 [Knox 1994a], In 5 of these AIDS patients
without known active HHV-6 related disease at death, the lymph nodes contained 5 -122
HHV-6 infected cells / cm2 of tissues, compared with none in 4 healthy individuals and 1,823
HHV-6 infected cells / cm2 of tissues in a post BMT patient who died of HHV-6 pneumonitis
[Knox 1995c], In another quantitative PCR study of postmortem lymph nodes from AIDS
patients, all the samples from patients (5 / 5) and controls (5 / 5) contained HHV-6 DNA
[Secchiero 1995b], There was no difference in the number of HHV-6 copies per pg /DNA in
patients or controls (median value 230, range <10-1,150 genome copies / pg of DNA). In a
further postmortem quantitative PCR study of lymph nodes from AIDS patients, using a
slightly different technique, HHV-6 was amplified from the lymph nodes of 6/7 patients
(median value 170, range 5 - 1044 genome copies / pg of DNA) and 2/3 controls (range 5 -
165 genome copies / pg of DNA) [Clark 1996],
Examination of lymph node biopsies from HIV infected patients during life, may give more
information on the possible interactions of these lymphotrophic viruses during earlier stages
of disease. In an immunohistochemical study of lymph node biopsies from 10 HIV-infected
patients, with CD4 + counts > 200 / mm^, (8 with follicular hyperplasia, 1 with follicular
involution, and 1 with reactive lymphadenitis) all contained HHV-6 infected cells, but the virus
was seen in 0 /7 biopsies from HIV uninfected patients [Knox 1996], In this small cohort,
variant A was predominantly found, and in an in vitro experiment it was shown that variant A
can massively up regulate HIV replication from latency. The authors therefore suggest that
HHV-6 could catalyse the progression of HIV infection. In a PCR amplification study of lymph
nodes from HIV infected patients an association between presence of HHV-6 DNA and early
histological phases of lymphadenopathy syndrome (LAS) was noted, but no relationship with
malignancy [Dolcetti 1996], HHV-6 DNA was found in 65% (13/20) of LAS biopsies, and only
20% (2 /10) of HIV unrelated lymphadenopathies (p = 0.02). The presence of HHV-6
correlated closely with a histological pattern of follicular hyperplasia, 81% (13/16), although
HHV-6 prevalence was decreased in the PBMC's of LAS patients. In this group HHV-6 variant
B was the most prevalent sub-type. This study demonstrated HHV-6 more commonly in the
PBMC's of healthy controls and yet HHV-6 more commonly in the lymph nodes of patients, a
paradox not easily explained.
All the studies described are of very small numbers and none are longitudinal. There is
therefore very incomplete information on the activity of HHV-6 in the lymphoid tissue of HIV
infected patients. It would be an oversimplification to suggest that the presence of HHV-6
within populations of PBMC's is simply a proportional representation of activity within the
lymphoid system. Indeed the activity of both of these viruses may differ greatly in different
parts of the lymphoid system, such as the gut and respiratory associated lymphoid tissue.
Improved understanding of the activity of HHV-6 and HIV within the lymphoid system in vivo is
hampered by access to tissue, although fine needle aspiration techniques have greatly
improved. There is little or no data for children in this area.
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HHV-6 and clinical disease in HIV infected patients
In view of the possible associations of HHV-6 with diseases such as pneumonitis and bone
marrow suppression in the transplant patients and because HHV-6 and HIV preferentially
infect the same cells histopathological examination of tissue from HIV infected patients for
HHV-6 has been undertaken. In small studies of autopsy material from adults, an increased
prevalence of HHV-6 was found in all tissues from AIDS patients compared with
immunocompetent controls (brain, lymphoreticular system, bone marrow, gut, lung, skeletal
muscle, heart, liver, kidney, adrenal gland, pancreas and thyroid) [Corbellino 1993; Knox
1994a; Clark 1996], Using a sensitive quantitative PCR, the highest burden of HHV-6 in
controls and patients was found in the lungs, kidneys and lymphoreticular system [Clark
1996]. The median HHV-6 level in AIDS patients was 56 copies / pg DNA (range 0 - 43,321)
compared to 10 copies / pg DNA (range 0 - 423) in controls. Although an increased burden of
HHV-6 has been demonstrated here, no relationship to disease was sought in this small
group. In vivo, there is very little information about active HHV-6 infection and its effect on HIV
disease. One long term study of two patients demonstrated reactivation of HHV-6 to be
associated with a decline in the CD4+ count which persisted, this effect would need to be
confirmed in a much larger study [luliano 1997].
Respiratory problems are common in patients with HIV infection, but in a PCR study of
bronchioalveolar lavage in 34 adult patients, although CMV was commonly demonstrated, no
HHV-6 was amplified [Portolani 1996]. Retinitis, another common problem in patients with
advanced HIV disease, is most commonly caused by CMV. HHV-6 can also be found in the
retinal tissue of patients with HIV and even within areas of retinitis, but usually in association
with CMV [Qavi 1994; Fillet 1996], It seems unlikely that HHV-6 acts as a direct pathogen in
the eye, but it could be a predisposing factor to development of retinitis.
HHV-6 has also been demonstrated in the CNS of some patients with HIV, in a preliminary
study of 5 adult patients dying with AIDS, HHV-6 was demonstrated by PCR in different
areas of the brains of all patients but in no brain tissue from 2 patients with accidental deaths
[Corbellino 1993], CNS demylination associated with HHV-6 infection has also been reported
in adults with AIDS [Knox 1995c], This was associated with active HHV-6 infection, identified
by immunohistochemical techniques [Knox 1995c]. HHV-6 infected cells were seen at the
edges of areas of demyelinisation and not elsewhere, implying an ongoing active destructive
process. A similar pattern of demyelinisation has also been described in a patient
immunosuppressed after a bone marrow transplant [Drobyski 1994]. As CNS infection is not
uncommon in patients with HIV a large PCR study for virus associated diseases, including
HHV-6 was undertaken [Cinque 1996], Samples of CSF from 500 symptomatic adult HIV
infected patients were examined, and in 219 patients the CSF findings were compared with
histological examination. DNA of one or more viruses was detected in 36% of samples (HSV-
1 2%, HSV-2 1%, VZV 3%, CMV 16%, EBV 12%, HHV-6 2%, JC Virus 9%). HHV-6 was
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detected in 7 CSF samples (variant A 4, B 3) and in two patients the CSF was repeatedly
positive. HHV-6 was not found by immunocytochemistry in any patients, but could be
amplified from the frontal cortex of 1 / 7. In the majority of cases HHV-6 was found in
association with CMV and a possible interaction between the two viruses was suggested.
However, from this study of HIV infected adults there was no evidence that HHV-6 is a major
CNS pathogen. A case of fulminant HHV-6 encephalitis in an infant is the only specific
paediatric case reported of HHV-6 related CNS disease in HIV infected children [Knox
1995b]. In this case, immunohistochemstry demonstrated infection of all cell types and the
predominant variant was type A.
Thus, although there are reports of possible associations of HHV-6 with disease in different
systems in the HIV infected, the number of cases reported remains small and many studies
are poorly controlled. In particular there is very little information for children with HIV, who
might be expected to be more likely to have clinical problems with primary infection with HHV-
6 when they already have HIV on board.
HHV-6 and malignancy in HIV infected patients
The incidence of lymphoid malignancy is increased in patients with HIV, which may be related
to both the immunodeficiency and also the cell tropism of HIV. There is a well recognised
relationship between HIV associated lymphoid malignancy and presence of EBV. The
relationship of HHV-6 to malignancy in HIV infected patients has been examined in mainly
small studies and obtaining adequate controls is not easy. In the largest and best controlled
studies no obvious relationship between HHV-6 and development of lymphoid malignancy
has been demonstrated [ Di Luca 1994; Fillet 1995; Dolcetti 1996]. Using a nested PCR for
HHV-6, Fillet examined lymph node and malignant tissue from patients with non-Hodgkin's
lymphoma with or without HIV infection, as well as lymph nodes from patients with follicular
hyperplasia, with or without HIV infection. With this system PBMC's from 2% (2/95) of healthy
blood donors and 15% (3/20) of HIV infected patients amplified HHV-6. Around half of all the
tissues examined amplified HHV-6 and there was no significant difference in any of the
groups. Most commonly both types A and B were found. The authors note that the number
of DNA copies in each sample was low (< 1 copy / 750 cells) and therefore most tumour cells
did not carry HHV-6. The increased level of HHV-6 in lymph nodes compared to PBMC's
could implicate the nodes as a possible site of latency or persistent infection and further in
situ studies are required to examine this more closely. Dolcetti et al found no difference in
amplification of HHV-6 by PCR from lymphoid malignancies from patients with or without HIV,
around 30% of Hodgkin's lymphomas and 0-6% of non-Hodgkin's lymphomas were HHV-6
positive [Dolcetti 1996], Type B strain HHV-6 was amplified more frequently than type A. The
authors suggest that HHV- 6 is unlikely to be involved with development of malignancy in
these patients.
Malignancies are less common in children with HIV than adults, but any possible role for HHV-
6 in paediatric HIV associated lymphoproliferative disease has not so far been demonstrated.
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The herpesviruses and paediatric oncology patients
Background
In considering the role of HHV-6 as a possible pathogen in paediatric oncology patients, it is
useful to review the pathogenicity of the other human herpesviruses in this group of
patients. It is important to remember that the interaction between the virus and the host
depends not only on the activity of the virus but also on the level of immunity of the host. In
this respect paediatric oncology patients are not homogeneous, some children will be more
immunosuppressed than others, not only by therapy but also by their underlying condition.
As a result of more severely ablative and longer courses of chemotherapy which particularly
affect lymphocyte number and function, the pathogenicity of the herpesviruses in this
patient group has increased with time, although better anti-viral therapies are now available.
Susceptibility to infection with the herpesviruses depends on several factors. The younger
the child with a malignancy the less likely the child is to have met and become infected with
members of the herpesvirus family. Such a naive child will be at risk of primary infection during
a period of immunosuppression which may be severe. A child however, who has already
been infected with herpesviruses will harbour the persistent / latent virus and during
immunosuppression, will be susceptible to reactivation of this virus as well as new re¬
infections. This child, depending on the degree of immunosuppression, may also have some
persistent protective host immunity against the virus, so that the infection may conversely be
less severe.
Serological studies of children from different parts of the world demonstrate that in most
places acquisition of HHV-6 occurs within the first two years, but that acquisition of HSV,
VZV, CMV and EBV can occur at different rates. The acquisition may relate to different home
circumstances, child care practices, levels of crowding and breast feeding. In general, it
appears that acquisition of the herpesviruses occurs earlier in childhood in less developed
communities [Farr 1990; Shen 1992; Huang 1993; Kangro 1994], Local knowledge of the
patterns of acquisition of the herpesviruses is important in the monitoring of
immunosuppressed children, indeed at presentation, it is important to ascertain the antibody
status of each child.
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table 1: Herpesvirus seroprevalence in children of varying ages
in London and HongKong.
Taken from Kangro 1994. (593 samples tested ).
% seropositive at different ages
Cord 0.5 - 4yrs 4.1 - 12vrs
L HK L HK L HK
HSV 70 85 29 52 37 57
VZV 95 90 23 32 52 83
CMV 34 95 25 37 20 51
EBV 60 100 34 55 61 95
HHV-6 72 80 65 85 76 92
L = London HK = HongKong
Host responses against Herpesviruses
Control of human herpesvirus infections depends on the integrity of natural or innate
defence mechanisms as well as specific immunity, which may be cell mediated or via
antibody. In the host with an altered level of immunity as well as monitoring the immune
response it is also possible to monitor the activity of the virus. Evidence of persistent and
increased viral activity can be sought. This may be directly by examining for virus by culture,
antigen detection or genome detection, or indirectly by monitoring antibody levels. Where
the host is capable of mounting an antibody response rising or high titres of antibody may be
found, implying increased activity of persistent virus.
The host-virus interaction for some of the herpesviruses, including EBV, HHV-8 and possibly
HHV-6, is important not just for protection of the host from reactivation of the virus but also
from development of malignant transformation related to infection. Immune suppression
facilitates development of lymphoid and other malignancies in patients with EBV and HHV-8,
the role of HHV-6 remains controversial (see above).
The natural defence systems that are active against the herpesviruses are particularly
important for containment of primary infection and to moderate reactivation prior to the onset
of the specific immune responses. These defences are also often less effective in paediatric
oncology patients. An intact mucosa and skin is more protective than one which is breached
by mucositis, rashes or other lesions. Non specific killer cells are also known to be active
against virus infected cells, and these will also be diminished in number in those on
chemotherapy. Monocytes and macrophages will ingest and destroy antibody coated virus,
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natural killer (NK) cells also lyse virus infected and tumour cells, the activity of both these cells
is increased in the presence of the cytokines, interferon (INF) a, (3, and y. Other patients with
decreased numbers and activity of NK cells, such as premature and term infants, Wiskott-
Aldrich and Chediak Higashi immune-deficients, have increased susceptibility to herpesvirus
infections. Null cells are large granular lymphocytes which produce INF-a , in newborns and
patients with HIV these cells produce less of this important antiviral cytokine. INF-a and INF-p
are produced in response to virus infection and INF-y is produced by T cells when re-
exposed to known viral antigens [Lopez 1994].
Specific immunity to the herpesviruses is very important for clearance of primary infection as
well as containment of persistent virus. Cell mediated immunity (CMI) is the prime arm of the
immune system against the herpesviruses. In general, the antigens which activate the cycle
of CMI are viral surface glycoproteins, the very proteins which the virus uses for attachment
and entry to host cells. These antigens are taken up and processed by antigen presenting
cells and are then presented on the cell surface within the groove of the appropriate major
histocompatibility (MHC) molecules. From here they can interact with the appropriate T cells
to initiate the antiviral response. Against HSV the CMI response is more commonly a CD4+
cell response, and MHC class 2 restricted, against the others it is more commonly a CD8+ cell
response and MHC class 1 restricted. In healthy adults, between 1/4000 - 1/ 8000 circulating
CD4+ cells recognise and proliferate to HSV antigens, this high level of circulating memory
cells to HSV represents the host vigilance required to keep this virus from reactivating.
Persons with more frequent recurrences of HSV have less proliferative responses to HSV
antigens. Proliferation of the T cells is associated with production of cytokines, including
interleukin -2 (IL-2), and these are important for activation of macrophages and lymphocytes
[Lopez 1994] (figure 1).
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Figure 1: Diagram of cell mediated immune responses to HSV.
52
3) Herpesviruses & paed one patients EGH Lyall
Humoral immunity to the herpesviruses is complex. The first type of antibody to appear at
seroconversion is antibody to surface glycoproteins, against those used by the virus for
adhesion and penetration of cells. This antibody is recognised by cells which mediated
antibody dependent cell mediated cytotoxic responses (ADCC), such as macrophages and
killer cells. Neutralising antibody functions primarily against cell free virus, and is formed
against the surface glycoproteins and prevents viral adherence to and penetration of cells.
Early antibody responses tend to be of low avidity, where later antibody is of high avidity,
complement fixing antibody appears during convalescence. Anamnestic antibody
responses are very common and occur particularly for infections with viruses in the same
class, eg VZV and HSV, or CMV and HHV-6. These can be of different antibody classes
including IgG and IgM. High circulating antibody levels, are often associated with high
recurrence rates of infection where maintenance of latency has been poor [Lopez 1994].
Herpes Simplex 1 & 2
In a large study of over 1000 asymptomatic oral surgery patients, HSV DNA was detected in
saliva by PCR. Overall viral DNA was detected in 4.7% of patients, but more commonly in
those: under ten years and over sixty years; with inflammatory diseases; with malignancy; and
with trauma, implying that those with impaired immunity or damaged mucosal surface were
more likely to be shedding the virus [Tateishi 1994]. Other studies of secretion of HSV in the
immunocompromised have shown this to depend on the underlying disease as well as the
degree of immunity. In paediatric patients, HSV-2 is rarely a problem, where for adult patients,
especially those with HIV infection, this can be a major cause of genital symptoms.
Asymptomatic shedding in the immunocompromised can progress to local cutaneous
disease which may be atypical and extensive. In some patients oral mucositis may be as much
caused by HSV and other infections (eg Candida) as by the effects of chemotherapy and
obvious vesicular / ulcerated lesions are not necessarily seen [Carrega 1994]. Secondary
viraemia can also occur with dissemination and development of organ disease, in particular of
the central nervous system, respiratory tract, skin, and gut. In organ transplant patients,
those with the highest pre-transplant titres of antibody to HSV are at most risk of recurrence
[Schubert 1990], In most transplant programs patients are treated prophylactically with
aciclovirto suppress reactivating virus [Gluckman 1983],
Varicella Zoster virus
VZV infection can be lethal in patients with poor CMI, including the new born, those with
congenital immunodeficiency, acquired immunodeficiency, malignancy, on steroids or other
immunosuppressive therapy. Recovery from primary infection depends on making an
adequate T cell response, and this is more important than the antibody response. In the
normal host, VZV antibody can be detected on the first day of the rash. VZV surface
glycoproteins (pg 1, gp 111, p 170) stimulate the CD8+ T cell mediated immune response as
well as activation of CD4+ cells which help B cells to produce antibody. High titre antibody is
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well as activation of CD4+ cells which help B cells to produce antibody. High titre antibody is
not universally protective against infection and recurrence of infection as zoster can occur
with good antibody titres. A cytotoxic T cell response to VZV appears after 2-3 days of rash,
and this is necessary to terminate the cell associated viraemia. In the immune, VZV memory
cells are found to occur in 1 /10,000 - 1 / 30,000 circulating T cells. The number wains with
age, but is boosted in adults and children in contact with cases of VZV. A decrease in VZV
memory T cells is associated with an increased risk of reactivation and occurrence of herpes
zoster [Arvin 1996].
A very large follow up study of over a thousand paediatric patients treated with BMT between
1989 and 1994 identified 216 cases of VZV [Han 1994], The cases occurred from 4 days to
10.8 years after transplant, but 86% were within the first eighteen months after BMT. Most
were cases of dermatomal zoster (62%), but one third were complicated cases with CNS
infection, disseminated infection, and visceral infection. All the serious infections were within
7 months of BMT, but only 2 patients died of pneumonitis. The incidence of VZV was similar
in allogeneic and autologous BMT. Patients who were VZV seropositive prior to BMT had
more frequent, earlier, and often more complicated or disseminated infections. Age over 10
years and irradiation pre transplant were significant, independent risk factors for higher rates
of VZV infection. Using mathematical modelling the authors found that: VZV seropositive
patients aged over 10 years and irradiation pre transplant had a 44% incidence of infection by
3 years where, VZV seronegative patients aged under 10 years without irradiation pre
transplant had a 0% incidence of infection by 3 years. Aciclovir given for prophylaxis against
HSV or CMV did not affect the timing of VZV infection.
A paediatric study of 294 children with lymphoblastic leukaemia demonstrated 14% (41) to
have episodes of VZV [Rowland 1995 ]. Twenty patients (49%) had received prophylaxis
after their contact with varicella zoster immunoglobulin (VZIG) and all recognised to have VZV
were treated with aciclovir. The majority (70%) had only skin lesions and none of them died.
Visceral involvement occurred in 13 (30%) and 5 died. Risk factors for progressive infection
included age over 6 years, intensive immunosuppression at the time of presentation and
lymphopaenia. A very worrying symptom was severe abdominal and / or back pain, which
could occur up to several days before any rash, this was noted in 4 / 5 fatal VZV cases. Two of
the fatal cases had received VZIG. Disseminated intravascular coagulation and liver
dysfunction are commonly found in fatal cases of VZV [Chen 1994],
In a study of the regeneration of the immune response to VZV after autograft in 41 children,
the nadir of the T cell response even to T cell mitogens was at 3 months after transplant and
gradually improved over the next 6-12 months. In patients with previous VZV infection, a
proliferative T cell response to VZV was seen in 45% at 6 months and 67% at 12 months
[Takaue 1994]. NK cell activity and ADCC as well as cytotoxic activity against VZV have also
been shown to be decreased in children with leukaemia and this persisted for up to one year
after completion of therapy [lhara 1994], Although VZV immunisation could decrease the
frequent exogenous exposure of immunosuppressed children to this virus, this is not
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Epstein-Barr Virus
It is difficult to study the immune response to EBV in most natural infections in children as
these are usually asymptomatic. Infectious mononucleosis (IM), can be studied, but may
represent a particular type of host response to EBV which is not necessarily "normal". During
an acute episode of infectious mononucleosis around 10% of circulating B cells are infected
with EBV. The EBV epitopes presented on B cells which are recognised by CD8+ T cells
include: Epstein-Barr nuclear antigen (EBNA) 2; 3A; 3B; 3C; and latent membrane protein 2
(LMP 2). B cells which only express EBNA 1 are not recognised by the cytotoxic cells. Most
of the "atypical lymphocytes" seen in IM are NK cells or CD8+ T cells which are active against
the EBV infection and important to sustain long term immunity [Lopez 1994], However in IM,
the cytotoxic T cell response is not EBV specific, as there is polyclonal stimulation of multiple
MHC class 1 alloreactive CD8+ cytotoxic precursors. Lysis of allogeneic target cells occurs,
and this is what leads to the symptomatology of IM. In the normal host, ultimately the cytotoxic
response against the virus is effective and the EBV infection is brought under control, but
even in the immune individual 1 in 106 circulating B cells are latently infected with EBV.
Removal of an active CD8+ response will allow reactivation of EBV and polyclonal B cell
activation can occur. This activation can then proceed to become clonal and
lymphoproliferative malignancy can result. In conditions where the host has a low cytotoxic T
cell response, such as post transplant, during HIV infection, and in congenital
immunodeficiencies, increased numbers of EBV positive circulating B cells occur and there is
an increased risk of EBV associated lymphoproliferative diseases [Lopez 1994].
There is a recognised pattern of normal antibody response to EBV which evolves for several
months after primary infection. High titres of IgM and IgG antibody to viral capsid antigen
(VCA) are present during the acute illness and convalescence, after this IgM is lost and VCA
IgG persists at a lower titre life long. Heterophile antibody which gives the positive monospot
test (rarely present in young children), and antibody to early antigen (EA) persist for
approximately as long as VCA IgM. Titres of IgG antibody to EBNA 1 gradually increase during
convalescence to reach a steady level after recovery and as with IgG to VCA are maintained
life long [Epstein 1973; Henle 1987]. Persistence of high titres of antibody and the early
antibody responses can be found in those with altered immunity and increased virus
exposure.
lymphoproliferative diseases and Epstein-Barr Virus
This virus is associated with a number of different lymphoproliferative diseases. The first
human malignancy demonstrated to be associated with a virus infection was Burkitt's
lymphoma (BL) [Burkitt 1958], EBV can be isolated from more than 95% of BL cells grown in
culture, and most cells contain multiple copies. BL is common in equatorial Africa, particularly
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in areas holo-endemic for falciparum malaria infection. The majority of BL affects the jaw and
approximately half the abdominal viscera. There is a tight childhood age distribution, and it
has been demonstrated that children who go on to develop BL have been infected with EBV
for many months. Children who develop the tumour tend to have higher titres of IgG VCA
antibody to the virus than those who do not. It has been suggested that children who are
continuously reinfected with malaria have consequent polyclonal B cell proliferation, and this
leads to an expanded number of EBV infected B cells. The T cell immune response is
suppressed by a combination of infections, malnutrition and possible other host factors, thus
allowing further expansion of EBV positive B cells and consequently an increased risk of
development of cells with cytogenic abnormalities and malignant clonal potential [Liewbowitz
1994],
Development of malignant clones also depends on evading the cytotoxic T cell response.
The majority of BL are clonally identical with the chromosomal translocation t8:14. This
translocation leads to the placement of the c-myc oncogene sequence within the IgG heavy
chain constant region. C-myc expression is up-regulated by EBV which leads to proliferation
of cells with several growth advantages. EBNA 1 is the only EBV antigen expressed and this
epitope is not recognised by cytotoxic T cells. Presence of EBV latent membrane protein 1
(LMP1) upregulates Bel 2 expression which allows EBV infected cells to escape apoptotic
cell death as they traverse lymph node germinal centres. Eventually out of this dysregulated
proliferation a dominant malignant clone of cells will occur. BL grows extremely rapidly and is
highly sensitive to chemotherapy.
In patients who are immunosuppressed long term for iatrogenic reasons such as organ
transplantation, post transplant lymphoproliferative disease (PTLD) can occur [Wu 1996],
Loss of cytotoxic T cell responses leads to polyclonal B cell proliferation which can then
progress to malignant monoclonal lymphoma, however even the polyclonal disease itself can
also be very severe and symptomatic.
PTLD occurs in 2% of liver and kidney transplants and 5-13% of heart / heart-lung
transplants. The paediatric BMT patients with the greatest risk of infection are those who
have received T cell depleted grafts (14%) [Gerritsen 1996], PTLD is more common in
paediatric patients and the risk is greatest in those who are EBV seronegative and are
infected from a seropositive donor at a time of maximal immunosuppression [Ho 1988], It is
possible to monitor the load of EBV infected cells in patients post transplant to assess the
risk of PTLD [Kenagy 1995], A study of recovery of EBV cytotoxic T cell precursors in
patients post BMT demonstrated that after six months cytotoxic cells were recovered in 70%,
this time period correlates with the maximal susceptibility to PTLD [Lucas 1996], Various
treatments have been tried for PTLD, but the most effective is restoration of T cell immunity
to EBV. This can either be via reducing the host's level of total immunosuppression, or if this
is not possible, by transfer of donor T cell clones which are cytotoxic for EBV infected cells
[Lucas 1996],
Some types of Hodgkin's Disease (HD) lymphomas may be caused by EBV, the HD
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associated Reed-Sternberg cell is often EBV positive [Weiss 1989], EBV is strongly
associated with nasopharygeal carcinoma where all the tumour cells are infected with EBV.
This tumour is common in the Chinese of the Far East and many possible reasons for this
susceptibility have been suggested [Desgranges 1975]. Nasal T cell lymphoma, also
common in Asia, is also associated in some cases with EBV infection of malignant cells
[Tomita 1997].
Particularly in adult patients immunosuppressed by HIV and rarely in children, infection with
EBV causes a variety of different problems. There is an increased incidence of lymphoma in
these patients, especially in the central nervous system, where 80% contain EBV genome
[Levine 1990], Lymphomas in other sites are less frequently EBV positive. EBV is
associated with a condition known as oral hairy leukoplakia where the virus is infecting oral
epithelium and leads to ridged overgrowth of the epithelium often under the tongue, this can
respond to treatment with aciclovir [Niedobitek 1991 ]. EBV has also been associated with
leiomyosarcoma of the gut, a rare tumour which is more common in the HIV infected
[Timmons 1995], Finally, EBV may be associated with a condition known as lymphoid
interstitial pneumonitis, this is found in 30% of children with HIV and has been associated
with a better long term prognosis for survival [Katz 1987],
A rare congenital defect in the host response to EBV has been described which is usually x-
linked and affects boys [Seemayer 1995]. This is often known as Duncan's syndrome and a
number of affected kindreds are described, the genetic defect of the condition is close to
being defined and may give important general clues to the nature of the host response to
EBV. Boys affected by this condition cannot contain primary EBV infection and may die from
fatal primary infectious mononucleosis. If they survive the primary infection then they can go
on to develop: a more chronic lymphoproliferative state; immunodeficiency with
agammaglobulinaemia; and ultimately lymphoma.
Cytomegalovirus
As with EBV, it is also difficult to study the response to primary CMV infection in most
persons as the infection is usually asymptomatic. Some patients do suffer an IM type illness,
but again they may not have the "best" immune response to the virus and can take several
months to mount a T cell response to CMV antigens. Individuals vaccinated with the live
attenuated CMV vaccine take 2-4 weeks to produce a T cell proliferative response to CMV
and this persists long term. In immune adults, 1/4,000 -1 / 40,000 PBMC,s is a memory T cell
for CMV. Lack of an active T cell response to CMV leads to reactivation of infection and
development of CMV viraemia. After congenital infection the immunologically immature
foetus has a prolonged failure to develop T cell proliferation to CMV antigens [Lopez 1994],
In the immunocompromised the frequency and severity of CMV infection depends on the
nature and duration of the immunosuppression. In transplant patients the serostatus of the
donor and the type of transplant are also important. After BMT most CMV infections usually
happen within 1-4 months. The patient can develop a severe IM type illness, pneumonitis (
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which has up to 40% mortality) , chorioretinits, hepatitis, gut infection and CNS infections [
Arabia 1993; Enright 1993; Foot 1993; Mellon 1993; Einsele 1994; Ljungman 1994; Nagle
1994], In all cases the greatest risk of CMV disease occurring is where the host is
seronegative and the donor is positive, and a primary infection can occur during maximal
immunosuppression. The risk of symptomatic infection is also increased: where there has
been previous organ damage, eg to lungs or liver; where there is graft versus host disease;
where there is liver rejection; where there is use of non-CMV-screened blood products;
where T cell depleted BMT is administered; where there is prolonged lymphopaenia; and
where irradiation is used as part of the conditioning regimen [ Bostrom 1990; Miller 1991;
Einsele 1993; Atkinson 1995; Bacigalupo 1995; Cakaloglu 1995; Falagas 1996],
Delay in diagnosis of CMV activity in the immunocompromised host can lead to severe
symptomatic disease. Where culture and antigen detection techniques are used for
diagnosis, these are often only positive by the time the patient is symptomatic, so to
demonstrate evidence of viral activity earlier PCR is used. Earlier treatment of CMV before
development of symptomatic disease decreases the morbidity and mortality from this
infection. It also leads to use of shorter courses of gancyclovir, shorter episodes of
neutropaenia, and a decreased incidence of secondary non-viral infection [Link 1993;
Schmidt 1994; Einsele 1995; Boeckh 1996].
Prophylaxis against CMV infection in the immunocompromised includes use of CMV-
negative blood products [Winston 1993], Treatment with aciclovir is advocated by some and
considered ineffective by others [Nicol 1993]. Gancyclovir, a toxic antiviral drug, is usually
given for treatment but in some studies has been used prophylactically, although an
adequate dose is important [von-Bueltzingsloewen 1993; Enright 1993; Goodrich 1993].
CMV specific intravenous immunoglobulin has also been used, without proven success
[Boland 1993; Ljungman 1994],
Treatment of active CMV disease depends on gancyclovir and / or foscarnet. CMV disease is
associated with an increased risk of other secondary infections, including fungal sepsis, as
well as an increased risk of auto-reactivity [Ljungman 1992; Roberts 1993],
Monitoring of the host with PCR for CMV during immunosuppression and pre-emptive
treatment of any rise in blood viraemia with gancyclovir is currently the accepted practice to
control CMV disease in immunosuppressed patients.
Human Herpesvirus 7
This virus like HHV-6 also infects T cells but, unlike HHV-6 it uses the CD4+receptor to enter
cells [Lusso 1994a]. Although not so extensively studied as the other herpesviruses, there
is very little evidence that it causes problems for the immunosuppressed [Wang 1996; Fabio
1997] There is also no current evidence that it has any relationship to development of
malignancy in the host.
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Human Herpesvirus 8
The DNA of HHV-8, also known as Kaposi's sarcoma associated herpesvirus, was first
detected in lesions of Kaposi's sarcoma (KS) [Chang 1994], KS occurs endemically in Africa
and in certain Mediterranean populations, but since the arrival of HIV the incidence of this
tumour has increased in Africa, the USA and Europe [Beral 1991], Epidemiologically, KS in
HIV infected patients is most strongly associated with homo-sexually acquired HIV and is
uncommon in those who have acquired HIV via blood transfusion. KS has also been shown
to occur in other immunosuppressed patients [Beral 1991; Beral 1990], HHV-8 DNA has also
been demonstrated in association with lymphoproliferative conditions, including body-cavity-
based lymphomas and Castleman's disease [Cesarman 1995; Dupin 1995], Although KS is
rare in children with HIV in the USA and Europe its incidence has been rapidly increasing in
African children [Serraino 1996; Ziegler 1996],
Serological studies , have demonstrated that over 90% of HIV uninfected patients with
endemic KS are HHV-8 antibody positive, where 60-100% of HIV infected patients with KS
are antibody positive. Where adults with HIV but no clinical KS have been tested, between
20-50% have been found to have antibodies to HHV-8, the higher seroprevalence being in
Africans. Indeed among African adults with neither HIV nor KS, 6-43% have been found to
be HHV-8 antibody positive. Very low seroprevalence rates of 0-5%, have been found in
blood donor populations and haemophiliacs in Europe and the USA [Gao 1996a; Gao
1996b; Kedes 1996; Lennette 1996; Simpson 1996],
The largest group of children examined for antibodies to HHV-8 has been in the USA (n =
263), none had antibody to latent antigen and 3.8 % had antibody to the lytic antigen tested.
HHV-8 seropositivity was 0.9%(1 /115) in children aged from 1-5 years, 6.5% (7/108) those
aged 6-15 years, and 18% (7 /40) in young people aged 16-20 years (12). Seroprevalence to
HHV-8 was 0% in 24 UK children presenting with rash and fever (11). In a study of 51 HIV
infected children from the USA, median age 7 years (range 0.5-18), HHV-8 seroprevalence
was 0% [Blauvelt 1997],
Recent studies from Zambia and Japan have identified the possible clinical illness of HHV-8
seroconversion in children [Kasolo 1997, Kikuta 1997], In the Zambian study, 53 HIV
uninfected infants (median age 10 months, range 2-12) presenting to hospital with their first
fever had blood was examined by PCR for HHV-8. HHV-8 DNA was detected in 8%, with 300-
18,000 copies of HHV-8 per cell, consistent with primary infection. In two cases HHV-6 DNA
was also found in the blood. None of the mothers of these children were HIV infected. The
authors suggest that in the African setting of endemic KS and HIV, infection with HHV-8 may
be relatively common in childhood and that subsequent development of KS may have more
to do with decline in host immunity and increase in HHV-8 viral load, rather than denovo
sexual transmission. In the Japanese study peripheral blood lymphocytes from 56 children,
with acute febrile illness were examined for HHV-8 DNA by PCR. The children were aged 2
months to 6 years and none had HIV or KS. HHV-8 DNA was detected in 38% of those less
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than two years, in 87% of those over two years, and in 80% of healthy adult controls. These
results imply that infection with HHV-8 is widespread in Japan. A non-sexual mode of
infection is most likely in a population where there is a high rate of infection in childhood, eg
via saliva. There have been no studies to date of HHV-8 seroprevalence in paediatric
oncology patients.
Conclusions
This limited review demonstrates that the different herpesviruses have differing degrees of
pathogenicity for the immunosuppressed child. The nature of infections depends not only
on whether they are primary or recurrent, but also on viral escape from host immunity due to
immunosuppression, which is usually iatrogenic (figure 2).
The most severe problems are seen in the most severely T cell depleted patients. The cohort
of paediatric oncology patients in this study do not in the main reach such severe levels of T
cell depletion. However, many of the patients on treatment for leukaemia were intermittently
lymphopaenic for about two years.
figure 2: The balance of host immune function and herpesvirus activity,
see over page 62
60
3) Herpesviruses & paed one patients EGH Lyall
61
4) Immune responses of paed one patients EGH Lyall
The Immune response of paediatrio oncology patients
Prior to immunosuppressive therapy
Immunodeficiency or immunosuppression in paediatric oncology patients depends on a
variety of factors relating to the host and the underlying malignant condition. There may have
been defects in the host immune response which have allowed a malignancy to develop
which may also make the child more vulnerable to certain infections. These are most
noticeable in children with severe congenital immunodeficiencies such as Wiskott-Aldrich
syndrome, ataxia telangiectasia and common variable immunodeficiency where susceptibility
to severe infections is associated with a greatly increased risk of lymphoproliferative
malignancy [Kersey 1988; Rosen 1997], However, more subtle cellular control abnormalities
are likely to be involved in the development of most childhood leukaemias and lymphomas.
Genetic predisposition may play a part in the host's susceptibility to these changes, but
interestingly, the infections and responses to infections which the host has made may also
be important in moulding these responses. Children with solid tumours may or may not have
defects of cellular control which have allowed tumour development and could also increase
susceptibility to infections. Patients with malignancy, even after successful treatment for their
initial disease, have an increased risk of further malignancy. This partly relates to the cytotoxic
drug regimens administered but also to host response factors [Lowsky 1994],
Patients with leukaemias and lymphomas, in particular Hodgkins disease have abnormal T cell
responses at presentation with disease. Tests of T cell function demonstrate them often to
be anergic with poor proliferative responses, therefore increasing their risk for more severe
viral and intracellular infections (eg TB, Leishmania, salmonella etc). Children presenting with
malignancy may have more or less subtle defects in their immune responses which can
increase their susceptibility to infections even before commencing immunosuppressive
therapy. Unfortunately this area has been very difficult to investigate and more information in
many areas could be sought.
During and after immunosuppressive therapy
When immunosuppressive therapy has been commenced to treat a malignancy obvious
deficits in the host immunity develop. Treatment is aimed at fast dividing cells and affects
both normal and tumour tissues. Working from the simplest protective mechanisms to the
more complicated, treatment affects mucosal integrity and therefore increases the capacity
for organisms to penetrate the host, especially from the alimentary and respiratory tracts.
Total numbers of leukocytes are reduced which leads to deficiencies at varying levels. There
are greatly reduced phagocytes (neutrophils and monocytes) necessary to remove
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organisms. This makes the host especially susceptible to bacterial and fungal infections. The
cytokine milieu required to attract cells to a site of infection and amplify the host response is
also affected by the paucity of cells, thus local infections can quickly spread and become
systemic. The function of existing phagocytic cells is also affected by poor opsonisation and
complement activation.
Overwhelming bacterial infections are the acute risk of chemotherapy. The risk of more
severe viral infections in these patients increases with the length of the period of induced
lymphopaenia. Fatal varicella zoster or measles infections most often occur after 18 -24
months of treatment for leukaemia, when the course of chemotherapy is almost over, and
neutropaenia is rarely a risk but lymphopaenia has been prolonged. Lack of T and B cells is
the crux of this susceptibility. Deficiency of T cells which can recognise viral antigens
presented and then interact either to help B cells to proliferate to produce antibody or to
proliferate themselves to produce a cellular cytotoxic response, enables viruses to escape
immune control and progress, in some cases, to severe viraemia. The most lengthy periods
of immunosuppression and lymphopaenia are seen in the treatment of leukaemia and
lymphoma and are the price which has to be paid for eradication of malignant clones of cells.
This degree of immunodeficiency however, it not so severe as the bone marrow ablative
therapy which is required for transplantation. BMT patients are susceptible to bacterial /
fungal infections early on until phagocytic reconstitution occurs. Lymphopaenia and
lymphocyte dysregulation is more prolonged and severe. In all these patients, a degree of re¬
education of the cellular immune system has to occur and for as long as this persists the host
is more vulnerable to infection. This period is particularly protracted and severe in patients
who have received T cell depleted donor grafts to decrease the risk of graft versus host
disease in less well matched transplants. In certain circumstances T cell clones specific for
viral infections have been selected from the donor T cell pool to treat severely infected
recipients as well as recipients with PTLD [ llan 1994; Riddell 1994; Emanuel 1997].
Recovery of immune function after cessation of therapy
Analysis of recovery of immune function after therapy is important as this is required for return
of the host to a normal state of immunity. It also demonstrates the immune deficits which are
induced by chemotherapy. Studies have examined the cellular recovery as well as functional
recovery in terms of response to vaccination.
Lymphocyte numbers and function
Most of the data comes from patients recovering from BMT. After T cell depleted grafts, the
total lymphocyte count, total T cells and CD4+ cells can remain depressed for up to 2-3 years.
CD8+ cells normalise more quickly, within 18 months, giving an inverse CD4+: CD8+ ratio for
a year or so.The percentage or number of NK cells can be elevated early after BMT. B cells
can also be depressed for 12-18 months after the graft. Younger patients tend to have
higher total lymphocyte counts after transplant, but presence of graft versus host disease or
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CMV disease can delay the recovery [Milosevits 1995; Kook 1996], In vitro proliferative
responses to T cell mitogens normalise within 12 months of transplant and mixed lymphocyte
culture responses within 9 months. Again, presence of graft versus host disease or CMV
delay these responses. Recovery of proliferative immune function is correlated with a rise in
the total lymphocyte count, although the CD4+ : CD8+ ratio can still be abnormal [Kook
1997],
Delay in reconstitution of CD4+ cells renders longer term susceptibility, particularly to viral
infection , and the method of regeneration of CD4 cells is not well understood, it may be
thymus dependent or thymus independent. Naive CD4+ cells which express the surface
glycoprotein isoform CD45RA are likely to have been generated by a thymus dependent
pathway. In a study of 15 patients aged 1-24 years recovering from intensive chemotherapy,
expression of the CD4+ isoforms was serially measured [Mackall 1995]. Over the first six
months after BMT, the younger patients recovered the CD4+ T cell count most quickly, and
this correlated quantitatively with the presence of CD4+CD45RA+ cells in the blood. The
presence of CD4+CD45RA+ cells was also correlated with thymic enlargement after stopping
chemotherapy. In addition, patients with radiographic evidence of thymic rebound had
significantly higher ratios of circulating CD45RA : CD45RO, ie naive : memory cells. The
authors of this study concluded that rapid T cell regeneration requires residual thymic
function, which is more often present in young children.
The thymic influence does not seem to affect regeneration of the CD8+ cells [Koehne
1997]. It has been shown in adults that regenerating, non-thymus dependent
CD4+CD45RO+ cells have increased expression of HLA-DR, indicating activation of the
population. However this also renders them more prone to apoptosis, thus during recovery
this CD4+ cell population appears to be more vulnerable to cell death [Hakim 1997],
Gamma-delta (y5) T cells appear to regenerate quickly after BMT, and are often elevated in
patients with viral infections, so may be active in responding to infections when other cell
types are still depleted [Cela 1996]. Recovery of B cells appears to follow an ontogenic
pattern with deficiency of certain adhesion molecules as see on some cord blood B cells, the
significance of this requires further study [Parra 1996],
Recovery of B cells and immunoglobulin production after chemotherapy for acute leukaemia
in children has been studied in a small group of children [Alanko 1991], At the end of therapy
the blood lymphocyte counts of all children were reduced, the mean value being 60% of the
lower limit of normal. The reconstitution of lymphocytes was parallel to that of total leukocytes
and all but one child reach a normal level by one year. In 12/14 patients the number of B
cells was normal at cessation of therapy, however in terms of function, most children had low
levels of total IgG at cessation of therapy. In most, at cessation of therapy, the lgG1 lgG3 and
igG4 levels were normal but, in half lgG2 was decreased. In most children IgM and IgA levels
were in the low normal range at cessation of therapy. Recovery of antibody usually occurred
within the first year, but some children showed poor recovery, and they also had an
increased risk of relapse and infection.
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Specific antibody responses
In a small Dutch study of 49 children previously immunised to diphtheria, pertussis, tetanus
and polio and treated successfully for leukaemia with relatively mild therapy (only 2 or 3 drugs
in remission), antibody responses to the vaccines were measured [van der Does-van den
Berg 1981], At cessation of chemotherapy the antibody titres were generally lower than
those of healthy children, but in most, not below levels considered to be protective. One
year later, there was no spontaneous rise in antibody levels, but after revaccination,
responses equivalent to those of normal children were seen. In another study diphtheria-
pertussis-tetanus vaccine was administered to 27 children with various malignancies in
clinical remission on maintenance therapy (17 leukaemias, 5 lymphomas, 5 solid tumours)
[Kung 1984]. After 4 weeks only one child had no response to the two antigens tested
(diphtheria and tetanus). Two children did not respond to tetanus but did to diphtheria. Most
children made good antibody responses to both antigens regardless of the disease or
therapy. The study was too small to make comments about the reasons why three of the
children had poor responses.
A study of responses to Haemophilus influenzae type b (Hib) vaccine in Hib vaccine naive
older children, either during maintenance chemotherapy or after completing chemotherapy
was undertaken in a group of 27 children [Weisman 1987], Only 37% of children had a pre-
vaccine level of antibody considered protective. There was a generally good response to
vaccine in this group, and 85% of children had protective levels after this intervention. The
best response was in children with solid tumors who all achieved protective levels, compared
to only 81 % of children with leukaemia.
In a more recent study of 13 children treated for acute lymphoblastic leukaemia (ALL)
responses to measles, mumps, rubella, polio, Hib, and pneumococcus were examined 2-5
years after completing therapy [Smith 1995], More aggressive chemotherapy was given to
this group of children. Compared with age-matched control subjects, the long term survivors
of ALL had significantly lower baseline titres of protective antibody to measles and polio and
more than half had no protective antibody to one or more previously administered vaccines or
related prior childhood infections. Most produced protective responses of specific antibody
after re-immunisation Some were repeatedly unable to make protective antibodies or mount a
normal antibody response, despite natural infection and / or re-vaccination, demonstrating
persisting functional immune defects.
Examination of immune status in these 13 children demonstrated them all to have normal
absolute numbers of CD4+ and CD8+ T cells, although three had a reversed CD4+ : CD8+
cell ratio. Lymphocyte proliferation to the mitogen Phytohaemaglutinin (PHA) was normal in
all but one child and the delayed hypersensitivity response to varied antigens was normal in
all the children. Total haemolytic complement was normal in all cases and quantitative serum
immunoglobulins were normal for 8 children (2 had low lgG4 levels for age; 2 had increased
lgG4 levels for age; 1 had low lgG1; and 1 had low total IgG).
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Two children with poor responses to specific antibody after vaccination or true infection were
treated with IVIG for a year and 6 months later revaccinated, even after this they did not make
specific antibody responses to all vaccines. They appeared to represent a sub group of
children with persistently abnormal immunity after treatment. This study comprised a very
small group of children but demonstrated that recovery after therapy was variable over time,
these investigations need to be repeated in a larger group of patients.
A live attenuated vaccine against varicella zoster has been used to protect leukaemic patients
in remission and on maintenance therapy [Gershon 1989], The vaccine appeared to remain
effective even when detectable antibody levels wained, implying a persisting active T cell
response. With recovery of immune function reappearance of an anamnestic antibody to
VZV was often seen. In this study it appeared that immune function against this herpesvirus
was well maintained despite chemotherapy, however these studies were carried out at time
when chemotherapy regimes were less intense than currently.
Conclusions
Children presenting with malignancy may have more or less subtle defects in their immune
responses which have increased their susceptibility to infection as well as malignant escape
even before commencing immunosuppressive therapy. During treatment and for a variable
time after stopping treatment lymphopaenia and lymphocyte dysregulation are the most
important risk factors for severe viral infection, and T cell lymphopaenia carries the greatest
risk for the host for new or recurrent viral infections. The more protracted and severe the
duration of lymphopaenia the greater the risk. In all these patients for immune recovery, a
degree of ontogenic re-eduction of the cellular immune system has to occur and for as long
as this takes the host continues to be more vulnerable to viruses. Monitoring of immune
function during treatment and after cessation is important as when function is seen to return
then prophylactic therapies can be discontinued and re-immunisation schedules can be
initiated.
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Methods for the clinical detection of HHV-6
Detection of HHV-6 antibodies
Indirect immunofluoresence assay (IFA)
The first method used to test sera for an antibody response to HHV-6 was the indirect
immunofluorescence assay (IFA) [Salahuddin 1986; Downing 1987; Tedder 1987], This was
adapted from the assay first designed to study EBV infected cells [Henle 1966]. In this assay
a counted number of HHV-6 infected lymphocytes, either from cord blood or T cell
lymphoblastoid cell lines are spotted on to wells within slides and fixed. The cell layer is then
incubated with dilutions of human sera and after washing, with an appropriate dilution of
fluorescein conjugated anti-human IgG. After further washing and preparation, the slide can
then be visualised under ultraviolet light where reactive sera will show a recognised pattern of
immunofluorescence. Testing of different dilutions of sera can ascertain the titre of reactive
antibody. Sera can also be tested against uninfected cells as negative controls as some sera
show non specific reactions with the cells themselves. This system can also be adapted to
assay sera for IgM by first absorbing out IgG antibody and using a fluorescein conjugated,
anti-human IgM. Results of IFA for HHV-6 from different groups have not always been
concordant. This may be for a variety for different methodological reasons, as it is difficult to
standardise the nature of antigen presentation by infected cells. Thus the use of different
cell lines, different strains of virus and different ages of cells at harvest may affect results.
When HHV-6 infected cells are maintained for long periods in culture this can also decrease
the level of viral antigen expression [Yadav 1991], Prior to making slides it is therefore
important to assess HHV-6 replication and this can be done by examining for cytopathic
effect in cultures, or by use of monoclonal antibodies to stain for viral antigens.
Enzyme linked immunosorbent assay (ELISA)
Most early ELISA assays to detect antibodies to HHV-6 were noncompetitive and developed
by similar methods to those already existing for other herpesviruses, such as CMV [Chou
1988], HHV-6 was grown in cell culture to a maximal harvest, usually around 5-7 days. In the
majority of assays subtype A HHV-6 cultured in T lymphoblastoid cells has been used.
Preparation of viral antigen was either by separation of virus from cellular material by density
gradient centrifugation or more commonly, by preparation of a more crude infected cellular
lysate [Saxinger 1988; Asano 1990a; Chou 1990; Dahl 1990], Yield of viral antigen from the
cellular lysate is increased by glycine extraction of the infected cells followed by ultrasonic
disruption [Kettering 1977]. Soluble viral antigen can then be adsorbed to the wells of the
solid phase, and for protein antigens this should be at a concentration between 1 -10 pg / ml
[Wreghitt 1990], The antigen can be stored frozen until required. Control antigen from
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uninfected cells is also prepared in the same way.
Dilution of the serum applied to the antigen is required to reduce non-specific staining, and
the optimal incubation time has to be ascertained. Washing with buffer solution is critical to
ELISA between each stage to reduce nonspecific reactions and again for every ELISA the
optimal regimen has to be derived.
The detection phase of the ELISA depends on a further incubation with an enzyme labelled
anti-human IgG antibody, followed by application of the enzyme substrate which leads to the
development of a colour reaction. This reaction is stopped after a certain time by a change in
pH and the resulting colour density can be measured optically in a spectrophotometer. For
any ELISA all the optimal times of incubation, concentrations of reagents, temperatures etc,
have to be ascertained. Using well characterised control positive and negative sera, it is
necessary to demonstrate that the system can perform repeatedly within as tight as possible
a coefficient of variation, usually < 10%, to be considered robust enough for use with clinical
samples [Wreghitt 1990], Interpretation of the results obtained can be by a variety of
methods, and a cut off value for positive and negative results can be calculated, results can
also be expressed as a ratio (or index) when samples are tested against infected and
uninfected control antigen.
ELISA assays for HHV-6 IgG antibodies have been at least as sensitive, if not more so, than
I FA, they are also much easier to carry out when large numbers of samples are to be tested
[Asano 1990a; Chou 1990; Dahl 1990 ; Cermelli 1994]. A competitive ELISA for HHV-6 IgG (
using HHV-6 rabbit polyclonal antibodies and HHV-6 cellular antigen) has also been
developed and it appears to have greater sensitivity for antibody than IFA [Nielsen 1996], In a
competitive ELISA the antigen is adsorbed to the plate as before, but a comparison is then
made between a well to which sample and enzyme labelled antibody are added and a well to
which only enzyme labelled antibody is added. After addition of the substrate, the difference
in amount of product occurring between the two wells equates to the amount of antibody
present in the clinical sample [Wreghitt 1990], As well as increased sensitivity this technique
can also give a clearer distinction between positive and negative samples. Commercial ELISA
tests for antibodies to HHV-6 have now also been evaluated [Sloots 1996].
Earlier ELISA assays were not satisfactory to test for HHV-6 IgM antibodies, but an efficient
non-competative assay for this class of antibodies has now also been developed [Parker
1993],
Anticompliment immunofluorescence test (ACIF)
Slides with HHV-6 infected cells are prepared in the same way as for IFA. Diluted patient sera
are then incubated on the slides and subsequently washed with PBS. Diluted guinea pig
serum is then spotted on the slides as a source of complement and incubated for a similar
time, then subsequently washed. The slides are then mounted with fluorescein conjugated
goat anti-guinea pig C3 with a further similar incubation and wash. After mounting the slides
are examined for fluorescence under ultra violet illumination [Okuno 1989]. In a comparison
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of this technique with I FA , no difference in sensitivity was found, although the authors
suggested a more distinct pattern of immunofluoresence was seen with ACIF [Robert 1990],
However, as this technique is equally labour intensive to I FA , less sensitive than ELISA,
and cannot discriminate between classes of antibody it has not been widely adopted for
clinical purposes.
Radio-immunoassay (RIA) and Circular-immunoassay (CIA)
A competitive radio-immunoassay and a circular-immunoassay for HHV-6 were developed
and found to be more sensitive than IFA for anti-HHV-6 IgG [Coyle 1992], Crude viral
infected cellular antigen was used for both. RIA is obviously a less desirable test for clinical
use because of the requirement for radio-labelling. The CIA follows a similar protocol to
ELISA except that the antigen is fixed to Zetaprobe membrane rather than within wells of a
microtitre plate.
Tests for HHV-6 neutralising antibodies
Serial dilutions of test serum from infants with ES were added to cord blood cell cultures
inoculated with 10^-5 tissue culture infective doses 50/ 0.1 ml of cell free virus. After
incubation for 7 days the neutralising antibody titre was determined as the reciprocal of the
dilution of serum which completely prevented cytopathic effect and syncytium production
[Asano 1989a], Neutralising antibody is produced within 3-5 days of presentation with fever
and persisted for up to 6 months, the appearance of neutralising antibody is associated with
disappearance of virus from the blood [Asano 1989a], Neutralising antibody appears earlier
and to a higher titre than IgG antibody detected by IFA in children with ES although both
anti-HHV-6 IgG and IgM will be detected by this test [Suga 1990b; Suga 1992b], Sero-
epidemiological investigation for neutralising antibodies to HHV-6 in different age groups
give very similar results over all to those obtained by ELISA, implying that this may be a more
sensitive test than IFA [Yoshikawa 1990], Although a more refined monolayer culture
method has been developed to detect HHV-6 neutralising antibodies this remains a highly
labour intensive test and is not therefore applicable to routine clinical use [Asada 1989],
Detection of HHV-6 by virus culture
Due to the cellular tropism of HHV-6 for T lymphocytes, culture of this virus from clinical
samples depends on having either a ready source of cord blood lymphocytes, adult
peripheral blood mononuclear cells or T lymphoblastoid cell lines available. According to the
subtype of HHV-6, growth in certain cell types is preferential (see above). Culture is facilitated
by activation of the cells with IL-2, PHA, or anti-CD3. Detection of virus in the culture can
either be by evidence of the ballooned cells and / or syncitia of the cytopathic effect, by
electron microscopy or by using monoclonal antibodies to HHV-6 antigens. The culture
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method is expensive in terms of time and resources and although specific may not be as
sensitive as either molecular or antigen detection methods.
Detection of HHV-6 antigens
Recently an antigen capture assay method for detection of HHV-6 antigens (gp 116 / 64 / 54)
has been developed which can be used in the clinical setting as well as to monitor cell
cultures for virus isolation and quantification [Marsh 1996], A dot blot assay method for
detection of HHV-6 antigens has also been developed and used to evaluate efficacy of
antiviral drugs against this virus [Yoshida 1996],
Detection of HHV-6 Genome
Polymerase Chain Reaction (PCR)
The principles of amplification of genomic material by the polymerase chain reaction (PCR)
are briefly described. The technique was first used in 1985 for identification of genetic
variation in b-globin gene sequences associated with sickle cell anaemia and has been
continuously underdevelopment since [Saiki 1985], For the chain reaction amplification of a
DNA fragment certain conditions and substances are required: template DNA extracted from
the sample for analysis; a thermostable DNA polymerase; buffer solution; nucleotide bases;
primer oligonucleotides; and a thermal cycling heating block.
Extraction of DNA from samples requires digestion of proteins followed by precipitation of the
DNA and there are different methods for this process. The process of DNA extraction from
certain clinical samples is more difficult than others as substances which are inhibitory to PCR
can occur, eg in saliva. Where small amounts of viral DNA are sought within clinical samples
then great care maybe required at this stage not to loose the rare viral template during the
extraction process.
DNA polymerase from the organism Thermus aquaticus (Taq) is heat stable at a wide
temperature range. This enables the enzyme to continue assembling new genomic material
from the original template despite cycles in temperature which would inactivate most
enzymes after the first round of amplification. There are stringent requirements for optimal
enzyme activity in terms of buffer solution and magnesium concentration, and for any
particular reaction these need to be optimised. Nucleotide bases in appropriate
concentration must be added to allow the polymerase to build new copies of the template
and the oligonucleotide primers are crucial to the commencement of the amplification
process as they identify the area of attachment and amplification.
During the cycling process the template double DNA strand is first denatured at 94 - 98 °c for
up to a minute. This allows the primers to bind to the separated single DNA strands once the
temperature is lowered to an annealing temperature of around 50-60 °c for most reactions,
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again for up to a minute. The extension temperature is 72 °c when new nucleotide bases are
added to the primers along the template, again for up to a minute, but allowing enough time
for extension of the entire sequence. The timings of the different parts of the cycle should
always be optimised for any particular reaction. The number of cycles undertaken is often 30-
40 allowing exponential increase in the original number of template sequences.
The expected amplified genome product is usually detected after being run on an
electrophoretic gel. Detection methods include demonstration of the expected length of
amplimer under ultra violet light with ethidium bromide intercalation, or hybridisation with a
labelled oligonucleotide probe, or production of a specific restriction enzyme digest pattern.
The original 9000bp probe for HHV-6 developed from a fragment named pZVH 14 from a
Bam H1 restriction enzyme digest of the GS strain (subtype A) was demonstrated at that time
not to react with any other known herpesviruses [Josephs 1986] . This fragment contains the
open reading frame (ORF) for the large tegument protein gene [Josephs 1991a], Many
clinical investigations for HHV-6 genome have amplified sequences of genome from within
this region [Buchbinder 1988; Jarrett 1990; Collandre 1991; Aubin 1991; Aubin 1992a;
Torellil 991; Di Luca 1994 ]. Other subtype A, HHV-6 sequences have also been amplified
from conserved, specific regions identified within the U1102 strain of the virus [Downing
1987; Tedder 1987; Lawrence 1990; Sandhoff 1991; Sa'adu 1993; Cone 1993a; Cuende
1994; Wilborn 1994a], Different DNA sequences from subtype B HHV-6 strains have also
been amplified from clinical specimens [Kondo 1990; Kondo 1991; Collandre 1991;
Pruksananonda 1992; Cone 1993a],
Restriction enzyme digestion and HHV-6 strain variation
Variation between A and B strain HHV-6 have been demonstrated by different patterns of
digestion by restriction enzymes which recognise and cut specific short sequences of
nucleotide bases [Kikuta 1989a; Jarrett 1989; Pellet 1990; Ablashi 1991a; Aubin 1991;
Aubin 1992a; Aubin 1993; Gompels 1993]. It has been possible to use these differences to
differentiate between the two subtypes in clinical samples. For example, an 830 bp
sequence within the large tegument protein (LTP) gene amplified from the pZVH 14
fragment of HHV-6 genome [Collandre 1991] contains a Hind III restriction enzyme
digestion site at position 2945 of the LTP gene in "B" but not "A" strains (figure 1). This is
the result of a substitution of a thymidine nucleotide base for a cytosine at this position
[Aubin 1991; Aubin 1992a; Aubin 1993],This strain difference has been used in large clinical
studies to discriminate between the two subtypes of HHV-6 [Dewhurst 1992; Dewhurst
1993],
Further to the discovery of these genomic strain variations sequence specific
oligonucleotide probes have been devised to hybridise with the specific subtypes [Drobyski
1993a; Aubin 1994; Gautheret 1996], However, in one comparative study hybridisation was
found to be less sensitive and specific than subtype specific primers and PCR amplification
[Aubin 1994],
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Improvements in the technique for PCR
Many modifications to the basic method have led to great improvements in sensitivity and
specificity of this technique [Cone 1992], In particular, addition of a second round of
amplification using "nested " primers which anneal to sequences within the fragment
originally amplified will especially increase sensitivity. Use of various procedures such as a
"hot start" can also improve the specificity of the reaction [D'Aquila 1991; Hebert 1993]. One
of the greatest problems with PCR is the risk of contamination associated with such massive
amplification of genome, this has been addressed by strict adherence to procedures which
ensure separation of all pre-amplified and post-amplified products [Cone 1990], Liberal use
of negative control samples at all stages of the process is important to detect contamination.
Co-amplification of host "house keeping" genes is often undertaken to ensure that a
negative result is due to absence of viral template and not to inhibition of the PCR by
substances within the clinical sample.
HHV-6 DNA PCR has been continuously developed and methods to quantify HHV-6 viral
DNA in clinical samples now exist [Secchiero 1995b], Multiplex PCR systems for detection of
more than one herpesvirus in a single clinical sample have also been developed [Tenorio
1993; McElhinney 1995]. Using this highly versatile technique it has been possible to detect
the presence of HHV-6 DNA in many tissues of the body during different clinical
circumstances.
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Legend to figure 1: Simplified restriction enzyme map of the HHV-6
genome, with parts of the HHV-6 genome sequenced at the time of
commencement of this study.
6 long boxes each representing the digest map obtained with a different restriction enzyme.
The names of the restriction enzymes are indicated on the left hand side of the diagram
(Sail, Sma1, Hind III, Kpn1, Eco R1, BamH1).
Segments of the genome which had been sequenced at the time are represented as fine
dotted boxes (A,B, D,E,F,G,H,I,J). The segment of genome selected for amplification and
restriction enzyme digestion in this study is represented by a lightly hatched box (C).
A [Efstathiou 1992]
B [Lawrence 1990; Littler 1990]
C Region chosen for amplification in this study
[Collandre 1991; Aubin 1993]




H [Teo 1991 ]
I [Chou 1992]
J [Gompels 1993]
Figure 1: Simplified restriction enzyme map of the HHV-6 genome
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Retrospective Serological Study
Aim of this study
As described, this retrospective study was designed to examine whether children
presenting with malignant disease had mounted an immune response to HHV-6, and if so
whether it reflected the same pattern as that of normal children. Sera from a cross-sectional
group of new oncology patients were compared with a group of control patients. The
response of these children to four other herpes viruses (Herpes Simplex virus (HSV),
Varicella Zoster virus (VZV), Cytomegalovirus (CMV), and Epstein Barr virus (EBV)) was also
examined. Sera from a further group of patients were followed longitudinally to assess the
effect of chemotherapy on the HHV-6 antibody response.
Patients and Samples
The approval of the local paediatric ethical committee was obtained for this study. Samples
from paediatric oncology patients seen at the Royal Hospital for Sick Children are routinely
sent for viral serology at presentation before administration of blood products, and at regular
intervals during treatment. These samples are tested at the Regional Virus Laboratory (RVL),
City Hospital, Edinburgh, and any surplus serum is stored long term at -20°C.
Cohort of new children presenting with malignancy & controls
Computer search was used to identify serum samples taken from oncology patients at
presentation, from January 1987 to December 1991. In some cases samples had not been
taken at presentation or were exhausted (table 1). Sixty six sera were identified ( 31 from
acute leukaemics (AL) and 35 from patients with solid tumours (ST)). These samples were
age and season matched to 66 stored sera from patients who presented to the hospital in
the same year with minor illnesses (e.g. upper respiratory tract infection, pyrexia, or viral
infection). The age range of patients was 1 month to 13 years with a bimodal distribution with
peaks at 3 and 10 years of age, representing the typical age distribution of children
presenting with malignancy (figure 1 ). These sera were tested for anti-HHV-6 IgG by IFA and
ELISA, and for anti-HHV-6 IgM by IFA.
All the sera from presenting patients and controls, were also tested for anti-VZV IgG and anti-
CMV IgG by commercial ELISA kits following the manufacturers instructions (SIGMA).
Previous results were available from some patients for EBV and HSV antibody responses.
Anti-EBV IgG was tested by IFA on infected EB3 cells and antibodies to HSV were titrated by
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the complement fixation test (RVL standard methods, unpublished).
EGH Lyall
Cohort of patients followed sequentially whilst on chemotherapy
Sequential sera from 45 patients (26 acute leukaemics and 19 with solid tumours) on
continuing chemotherapy who presented between January 1989 and December 1991 were
examined for anti-HHV-6 IgG by ELISA. Three to thirty three samples were tested per patient
depending on the length of therapy. These samples were obtained approximately monthly
and there were more from the leukaemics who underwent longer courses of therapy. In 13 of
these patients where the sample taken at presentation was exhausted (9 acute
leukaemics and 4 with solid tumours), samples were available from within the first month of
treatment, usually but not always, before administration of blood products. The age range of
the patients was the same as for the presenting group with a similar bimodal distribution (data
not shown). Sequential sera from seven cases were selected and tested for anti-HHV-6 IgM
by IFA. (Two asymptomatic seroconversions to CMV, four cases of primary varicella or
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Ages of children included in the cohort
at presentation with malignancy
■ Control children
■ Patients with malignancy
<1 1 2 3 4 5 6 7 8 910111213+
Age in years
Figure 1: Age distribution of cases and controls in the presenting cohort.
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Methods
Culture of HHV-6 in JJhan Cells
Cells of the lymphoblastoid cell line JJhan were grown in culture medium (RPMI with Hepes
buffer, foetal calf serum (10%),glutamine (2 mM), and penicillin (100 iu /ml) and streptomycin
(100 pg /ml)). The cells were activated with phytohaemaglutinin (5 pg / ml) and then infected
with the AJ strain (sub type A) of HHV-6 from an infected aliquot of cells (a gift from Prof R
Tedder) [Tedder 1987], At the time of infection the maximal ratio of uninfected to infected
cells was 10:1. After seven days, infection could be shown under light microscopy by the
presence of HHV-6 induced cellular changes, numerous large ballooned cells and syncitia
having formed (figure1a,b,c, from chapter 1). Successful infection of the culture was
confirmed with mouse anti-HHV-6 monoclonal antibodies to an HHV-6 early antigen (H 64
A5), Late antigen (H61 G11), and envelope antigen (H68 H3) ( kindly donated by Dr PA
Coyle, Regional Virus Laboratory, Belfast) (figurelc from chapter 1 demonstrated the
monoclonal H 64 A5 on infected cells ). The cultures were then harvested for the IFA and
ELISA tests.
Several batches of HHV-6 infected cells were cultured and it was apparent that some cultures
were more successful than others, with more cytopathic effect (CPE) and and a stronger
immunofluorescent response with the mouse anti-HHV-6 monoclonal antibodies. Electron
microscopy of some of the different batches also demonstrated very scanty virus in the less
successful. Slides made from the different batches were compared for the
immunofluorescent response with the anti-HHV-6 monoclonal antibodies and only those
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Indirect Immunofluorescent Antibody (IFA) Test for HHV-6
For this test between 104-105 JJhan cells from an HHV-6 infected culture were spotted onto
each well of a 12 well slide. After drying in air, slides were fixed in acetone for five minutes at
room temperature, and then stored at -20°C until required. On each slide well the ratio of
infected to uninfected cells was usually less than 50%.
Sera were tested for anti-HHV-6 IgG at a dilution of 1 in 10 in phosphate buffered saline
(PBS) pH 7.2, with 0.2% bovine serum albumin (BSA). A positive control serum and diluent
only control were always run on each slide along with ten clinical samples. Slides were
incubated in a moist chamber at 37°C for one hour, washed 3x with PBS and dried.
Fluorescein isothiocyanate(FITC)-conjugated, anti-human IgG (Scottish Antibody Production
Unit -SAPU) was applied to slides at a dilution of 1 in 80 and incubated for 30 mins at 37°C.
Slides were then washed 2x in PBS and 1x in phosphate buffer (PB) pH 8.4, dried and
mounted in glycerol / PBS (50:50) for examination under ultraviolet light. Large bright dots of
fluorescence, mostly intracytoplasmic but also intranuclear, particularly apparent in ballooned
cells and syncitia, were observed with anti-HHV-6 IgG positive sera (figures 2 ,3). The
representative photograph of HHV-6 fluorescent cells was kindly donated by Dr KN Ward,
University College, London.
Sera tested for anti-HHV-6 IgM were diluted 1 in 10 with IgG blocking agent (Incstar),
incubated for 15 minutes at room temperature and after pulse centrifugation, the
supernatant was applied to slides for 3 hours at 37°C. The slides were washed 3x with PBS,
dried and FITC-conjugated, anti-Human IgM (SAPU) diluted 1 in 32 was applied for 1hour at
37°c. Slides were then washed and mounted, as above, for examination under ultraviolet
light. The pattern of fluorescence with IgM positive sera was of finer cytoplasmic and surface
brightness, often most marked in the ballooned cells.
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figure2 : Image of the immunofluorecent pattern for IgG on HHV-6 infected
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figure3 : Immunofluorecent pattern for IgG on HHV-6 infected JJhan cells
with an IgG positive human serum (400 x magnification).
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Cross-over sero-absorption experiment to ascertain specificity
of IgM to HHV-6 and CMV
A cross over sero-absorption experiment was carried out with samples which were found to
be IgM positive for HHV-6 and CMV to ascertain whether antibody was cross reactive or
produced to both viruses. Nine samples from the two patients who seroconverted to CMV,
and two positive and one negative well characterised control samples were included in the
experiment. To absorb out HHV-6 antibodies from the serum 10pil of serum was incubated
overnight at 37°c with 10 pi of HHV-6 infected cell suspension. The cell suspension
contained approximately 2 x 105 cells per reaction tube. The next morning the suspension
was centrifuged and 10 pi of the supernatant was then incubated with IgG removing solution
(Incstar) for 15 mins, giving a final dilution of serum of 1/8. The method for IgM by IFA was
then followed as above, and serum was spotted onto slides with HHV-6 infected
lymphoblasts and CMV infected fibroblasts, also prepared in house. The same procedure
was followed for CMV absorption of sera except that the cell suspension contained
approximately 1.2 x 105 CMV infected cells per reaction tube.
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Enzyme Linked Immunosorbent Assay for IgG to HHV-6
The method of Chou [Chou 1990] was adapted and used to detect anti-HHV-6 IgG with an
alkaline phosphatase detection system [Cubie 1993], Antigen was prepared by the same
method from infected and uninfected cells. Cells (3x107) were centrifuged at 1,200g,
suspended in 4ml of chilled glycine buffer (pH 9.5), and sonicated on ice for 30 seconds (see
page 93 for buffer recipes). The sonicate was centrifuged at 5,000g for 20 minutes and the
supernatant stored at -70°C.
Antigen was diluted in glycine coating buffer (pH 9.5) and a series of different dilutions were
used in the ELISA to ascertain the optimal working dilution. This was found to be a 1 in 160
dilution of the lysate with a protein content of 5 pg/ml (kindly measured by Dr Jean Kirk
Biochemistry, RHSC, using the Lawrie method). Alternating 8 well rows of a ninety-six well
microtitre plate (Nunc) were coated with either 100 pi of infected or uninfected antigen at this
dilution and incubated overnight at 4°C. The plate was washed 3x with PBST washing buffer
(Phosphate buffered saline pH 7.2, with Tween (0.05%), and BSA (0.1%)). Remaining
binding sites were blocked with 200 pi of PBST (with 5% BSA) at 37°C for 1 hour and the
plate was then washed 3x. Coated and blocked plates could be stored at 4°C for at least one
week before use. An automated ELISA plate washer was used for all washes.
100 pi of sera diluted 1 in 100 in PBST (with 1% BSA) was applied to pairs of wells and
incubated for two hours at 37°C. After three washes, 100 pi of diluted (1 in 1000) anti-human
IgG conjugated with alkaline phosphatase (Sigma) was added to each well for one hour at
37°C. After five washes, 100 pi of the substrate para-nitrophenyl phosphate (1mg/ml in
freshly made diethanolamine buffer, pH 9.8), was added to each well and incubated at room
temperature, in the dark, for 30 minutes. The reaction was stopped with 50 pi of 3 M sodium
hydroxide and the absorbance read at 405 nm.
At the outset a series of experiments were carried out to obtain the optimal dilutions of ELISA
antigen, patient serum, and antihuman IgG-alkaline phosphatase conjugate concentrations
(figures 4,5,6,7,8). The ELISA antigen concentration chosen was 1/160 which
corresponded with an appropriate protein content (see above) and was also most economical
of antigen. The patient serum concentration selected was 1/100 as this showed adequate
discrimination between positive and negative samples. The concentration of antihuman IgG-
alkaline phosphatase selected was 1 /1000 for simplicity of ditution, and because it gave the
most discrimination between positive and negative sera (figures 7,8).
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Dilutions of ELISA antigen with a weak positive (HL)
and a strong positive (1254) serum.
A-HHV-6 infected JJ cells and HL serum
B-HHV-6 infected JJ cells and 1254 serum
C-uninfected JJ cells and HL serum




Dilution of ELISA antigen
1/800
Figure 4 : Varying dilutions of ELISA antigen with serum dilutions of 1 /100
and antihuman IgG-alkaline phosphatase conjugate of 1/800. The sera
tested were a known strongly positive serum (1254) and a known low
positive serum (HL).
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Positive serum at a dilution of 1/100
on antigen at a dilution of 1/80.
A-uninfected JJhan cells
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Figure 5: Varying dilutions of antihuman IgG-alkaline phosphatase
conjugate with serum dilution of 1 /100 and antigen of 1/80
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Positive serum at a dilution of 1/200
on antigen at a dilution of 1/80.
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Dilution of antihuman IgG-alkaline phosphatase conjugate
Figure 6: Varying dilutions of antihuman IgG-alkaline phosphatase
conjugate with serum dilution of 1 /200 and antigen of 1/80
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Negative and positive sera at a dilution of 1/100
900 1000 1100 1200 1300 1400 1500 1600 1700 1800
Dilution of antihuman IgG-alkaline phosphatase conjugate
Figure 7: Varying dilutions of antihuman IgG-alkaline phosphatase
conjugate with serum dilution of 1 /100 and antigen of 1/80. The sera
tested were a known strongly positive serum (1254) and a known negative
control serum.
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Negative and positive sera at a dilution of 1/100
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Figure 8: Varying dilutions of antihuman IgG-alkaline phosphatase
conjugate with serum dilution of 1 /100 and antigen of 1/160. The sera
tested were a known strongly positive serum (1254) and a known negative
control serum.
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The ELISA Index
As the antigen was a crude cell lysate, it was necessary to test each serum sample on both
infected and uninfected antigen. Some sera had a stronger background reaction with the
uninfected antigen than others and this was compensated for by using the difference
between the two absorbances to calculate the ELISA Index:
ELISA Index = Absorbance Infected cells - Absorbance Uninfected cells
Negative Cut Off
The negative cut off for the test was the mean difference in absorbance of the three negative
controls plus 3 standard deviations, but if this figure was less than 0.1 then 0.1 was used.
The ELISA index was considered to be positive if greater than 1.1, negative if less than 0.9
and equivocal between 0.9 and 1.1.
The following control sera were included on each microtitre plate: a strong positive; a low
positive; and three negatives. Positive and negative control sera were initially tested by IFA.
Sera from infants presenting with minor illnesses (upper respiratory tract infection, pyrexia, or
viral infection) were screened to obtain negative control samples. A well characterised strong
positive control sample (1254) was obtained from Dr M Ogilvie (Medical Microbiology,
University of Edinburgh), a low positive control sample was provided by HL. The plate was
blanked on a well incubated with diluent only.
Statistical Methods
The results from the ELISA of the presenting cohort of patients were converted to positive,
negative or equivocal for comparison with the IFA results. The data was analysed by the Chi-
squared test or Fisher's exact test, for groups of data with very small numbers. A repeated
measures model which allows correlation between the repeated values from the same
patient, was applied to the sequential data from patients on treatment so the effects of time,
age at presentation and diagnosis on the trends in the ELISA values could be analysed
[Jennrich 1986]. The statistical package used was SAS (PROC MIXED). Dr Helen Brown,
Department of Medical Statistics, University of Edinburgh, undertook the statistical analysis
using the repeated measures model.
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Recipes for Buffers
Glycine Coating Buffer pH 9.8
0.1 M NaCI
0.1 M glycine
Na OH (5M) to achieve pH 9.8.
PBS




2.4g KH2Po4 to 800ml of distilled H2O.
Adjust the pH to 7.2 with HCI. Make up to 1L with H2O.
Dispense and sterilise.
PBST
Dilute 10 x PBS (pH 7.2) to 1 x PBS
Add Tween 20 to final concentration of 0.05%
Add BSA to a final concentration of 0.1%
Add 0.2g NaN3
PBST + 1% BSA - for serum and conjugate dilution
Add 1 g of BSA to 100 ml PBST. Dispense as 20ml aliquots and store at -20°c.
PBST + 5% BSA - for blocking
Add 5g of BSA to 100 ml PBST. Dispense as 10ml aliquots and store at -20°c.
Diethanolamine Buffer pH 9.8
Diethanolamine (store in hot room)
Distilled water
1MHCI
Make up immediately prior to use.
970pl
8ml
approx 1.1.5 ml to correct pH.
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Retrospective Serological Study
Results
Comparison of IFA and ELISA for Anti-HHV-6 IgG
There was no significant difference in the results obtained by these two tests in the
presenting cohort of patients, although there were more equivocal and negative sera by IFA
(table 3 ). The high degree of concordance between the tests is demonstrated graphically
(figure9). In particular all of the sera which tested negative by ELISA also did so by iFA.
Haemolysis of these small paediatric samples did not significantly alter the pattern of results in
either test (figures 10 & 11.) The ELISA performed consistently as the repeated values
obtained from the controls on different runs demonstrates (figure 12, table 4). For all ELISA
runs the control values fell within +/- 2 Standard Deviations (SD) of the mean control value
and for the majority of runs within +/- 1 SD of the mean control value. The variation in values
obtained appears wider for the negative controls, but this is a reflection of the sigmoidal
nature of the ELISA curve with a drop off of accuracy in readings at the top and bottom end of
the curve [Wreghitt 1990 ].
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figure 10: Effect of sample haemolysis on HHV-6 antibody result by ELISA
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Results of IFA for HHV-6 IgG in haemolysed
and non-haemolysed serum samples (p = 1).
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figure 11: Effect of sample haemolysis on HHV-6 antibody result by IFA
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A Reproducibility of Multiple runs of




Positive control sera negative control sera
figure 12: Reproducibility of ELISA with positive and negative control sera.
Each set of symbols represents a different ELISA run (i.e. red
closed circles, blue open circles, black closed squares, green
closed triangles). The same 7 samples ( 3 positive control sera
& 4 negative control sera) were tested on each run and gave
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Serological response to HHV-6
Presenting Samples from Oncology Patients and Controls
IgG antibodies to HHV-6 at presentation
Around 90% of patients and controls were anti-HHV-6 IgG positive by both tests and there
was no significant difference in seropositivity for anti-HHV-6 IgG between patients or controls
(table3). Solid tumour patients were as likely as leukaemics to have HHV-6 antibody. The
proportion of seropositive cases in children under one year was lower (50-60%), but there
was no significant difference between the patients or controls in this small group . By the
more sensitive ELISA, only five children had no antibody to HHV-6. Two were patients, a six
month old with neuroblastoma and a nine year old with acute leukaemia (see below). The
HHV-6 antibody negative control patients were infants aged, four, six, and seven months.
IgM Antibodies to HHV-6 at presentation
IgM antibodies to HHV-6 were found by I FA in two control patients. An eight year old with a
febrile illness and a thirteen month old with an upper respiratory tract infection. One
leukaemic patient was also positive for IgM at presentation (see below). All of these patients
also had IgG antibodies to HHV-6.
Antibodies to Five Herpesviruses at Presentation
There was no significant difference in antibody response to VZV or CMV between patients or
controls. Two thirds of patients and controls had IgG to VZV and one third of patients and
controls had IgG to CMV (table 5). The acquisition of antibodies to HHV-6, CMV and VZV
according to age for the whole group, including patients and controls, is demonstrated in
figures 13,14 & 15. The majority of children are seropositive for HHV-6 by one year of age,
where seropositivity to VZV increases progressively during childhood. In this group of
Scottish children seropositivity to CMV shows a much slower increase during childhood.
Evidence of past EBV infection was found in 33 (62%) of the 53 patients' samples available
for testing while HSV antibodies were detected in only 9 (15%) of 61 patients tested by
complement fixation. There was no significant difference in response between patients with
solid tumours or leukaemia.
In the patient group complete results of serological response to the five herpes viruses were
available for 79 %, and demonstrated an IgG response to an increasing number of
herpesviruses with increasing age. Where the child had antibody to one herpesvirus this was
usually HHV-6 (7/66). Those with IgG to only HHV-6 had a mean age of 3.7 years compared
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Acquisition of HHV-6 IgG with Age in years
(percentage seropositive at each year of age)
100% 100% 100%
age
Figure 13: Seropositivity to HHV-6 in the presenting cohort of patients and
controls, according to age.
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Acquisition of CMV IgG with age in years
(percentage seropositive at each year of age)
CMV pos
CMV neg
Figure14: Seropositivity to CMV in the presenting cohort cohort of patients
and controls, according to age.
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age
Figure15: Seropositivity toVZV in the presenting cohort of patients and
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Sequential Sera from Patients on Chemotherapy
Anti-HHV-6 IgG in sequential sera
676 sequential specimens from 45 patients were examined for anti-HHV-6 IgG by ELISA, and
the test performed consistently (table 7). Five hundred and forty-four samples were obtained
from the 26 leukaemia patients (9-33 samples per child) and 132 samples were tested from
the 19 patients with solid tumours (3-15 per child). The majority of samples were positive for
anti-HHV-6 IgG (figure 16). One nine year old leukaemic child had no antibody to HHV-6 in
the first sample tested, and 23 further samples from this child were tested, 3 had an ELISA
index of just over one, however each time this subsequently became negative and he
remained negative two years later when his leukaemia relapsed (figure 17). All sera from this
child were negative for anti-HHV-6 IgM. This group of children had a similar serological pattern
of response to the five herpes viruses tested as the other patients and controls (table 8).
A repeated measures model was fitted to all the data from these patients to analyse the
effects of time, age at presentation, and diagnosis (AL - acute leukaemia or ST - solid tumour)
on any trends in the ELISA Index values obtained. There was no overall significant difference
between AL or ST patients with both groups showing a decline in ELISA Index over time.
The slope of this decline was not significantly different between the two groups of patients
when compared over a one year time period. Most of the solid tumour patients were only
treated for one year or less, whereas many leukaemic patients were treated for at least twice
that time (figure 16). The relationship between age and ELISA Index was different between
the two groups of patients. In the ST patients there was little difference in ELISA Index values





























































































































































Sequential Measurements of Anti-HHV-6 IgG
in 26 Leukaemic Patients.
y = 3.2602 - 1.0458e-2x R/v2 = 0.007
v .
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J Sequential Measurements of Anti-HHV-6 IgG
! in 19 Solid Tumour Patients.
7.0371 e-2x R^2 = 0.055
Months of Treatment
Figures 16 a + b: Sequential sera tested for HHV-6 IgG, from leukaemia
patients above (16a), and solid tumour patients below (16b). The scatter-
grams represent the range of HHV-6 IgG concentrations obtained from all
the patients over time, see text for statistical interpretation. 108
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Sequetial sera from a leukaemic patient presenting at
9 years and persistently negative for HHV-6 IgG.
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Figure17: Sequential sera tested for HHV-6 IgG from a leukaemic patient
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Anti-HHV-6 IgM in sequential sera
With the resources available it was not possible to test all sequential sera for anti-HHV-6 IgM,
so sequential sera from six patients with changes in activity against other herpesviruses were
selected to be examined for anti-HHV-6 IgM. These included two children who sero-
converted to CMV asymptomatically during treatment. One produced a four fold rise in anti-
CMV IgG titre and was strongly positive for anti-CMV IgM at the time of seroconversion, and
again three months later, but in no other subsequent samples. None of the 29 samples from
this child had anti-HHV-6 IgM (figure 18). The other patient had a fourfold rise in anti-CMV
IgG titre two months after starting treatment and soon after was strongly positive for anti-CMV
IgM, three further samples were also positive for anti-CMV IgM. Anti-HHV-6 IgM was present
prior to the rise in CMV antibody, but insufficient sample remained to test for anti-CMV IgM.
Over the 24 months of therapy ten samples were positive for anti-HHV-6 IgM, three of these
were also anti-CMV IgM positive (figurel 9). None of the 4 clinical cases of varicella -zoster
infection which occurred during therapy were associated with production of IgM to HHV-6.
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Leukaemia patient (no 142) who seroconverted to CMV during treatment.
ELISA antibody levels of IgG to CMV, VZV, HHV-6, and samples CMV IgM posith
Months of treatment
Figure 18: A leukemia patient who seroconverted to CMV and produced
anti-CMV IgM but did not produced any change in antibodies to HHV-6.
Leukaemia patient (no 71) who seroconverted to CMV during treatment.
ELISA IgG antibody levels of IgG to CMV, VZV, HHV-6,
Months of treatment
Figure19: A leukemia patient who seroconverted to CMV and produced
anti-CMV IgM but also IgM antibodies to HHV-6. 115
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Cross over IgM sero-absorption
antibodies
EGH Lyall
experiment for HHV-6 & CMV
On nine selected samples from the two patients who seroconverted to CMV a cross over
sero-absorption experiment to test whether the IgM produced was specific or cross reactive
for HHV-6 or CMV was carried out. Using the method described, after over night incubation
of test sera with infected cells It was not possible to completely absorb out all the IgM
antibodies. For patient 142, it appeared that only IgM to CMV was produced. For patient 71,
the results of the experiment were not completely consistent, however for some of the
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Interpretation of the findings of the Retrospective Serological
Study of HHV-6 antibodies in paediatric oncology patients
Technical details of IFA & ELISA
More than 90% of the presenting patients and controls in this study had IgG to HHV-6 by
ELISA and slightly less by IFA (table 3). The interpretation of the fluorescent antibody test,
being visual, is more subjective and the differentiation of low positives from negatives can be
difficult. Although the ELISA used a crude cell lysate as antigen, lysates of both infected and
uninfected cells were used in parallel and the difference in absorbance was used to calculate
an HHV-6 specific ELISA index. The ELISA test results demonstrated a relatively clear
separation between positive and negative sera with very few equivocal results and all the
samples which were negative by ELISA were also negative by IFA (figure 9). The ELISA was
also robust and performed consistently for each batch of samples tested as demonstrated in
tables 4 & 7. However, the ELISA could only be considered to be a semi-quantitative
measure of HHV-6 antibody trends, and was not set up as a specifically quantifiable test.
For this study it was not possible to titrate out sera for the IFA to obtain information on the
concentration of antibody present in the samples, nor was it possible to examine the avidity
of the antibody which could have given usefull information on the age of the antibody
response and the possibility of cross reactivity of antibody response [Ward 1993a; Ward
1993b]
Although all the presenting sera were tested for anti-HHV-6 IgM by IFA , this was not possible
using this time consuming test for all the sequential sera. Ideally the ELISA protocol would
have been adapted for anti-HHV-6 IgM detection, but time was not available.
Cross reactive antibody responses
The absorption experiment carried out in this study, could not be repeated because of
scarcity of samples, but the inconsistency of the results also seem to point to the same
findings as others. Although in one child no HHV-6 IgM was produced with CMV
seroconversion, in the other cross reactive IgM probably was produced.
As described in "The Host and HHV-6" antigenic cross-reactivity with other herpesviruses,
especially CMV may affect the apparent response to HHV-6. This is not usually a problem for
primary HHV-6 infection, perhaps because HHV-6 may be this first herpesvirus infection
[Okuno 1989; Asano 1990a], Nor is it usually seen in the IgG responses of healthy donors
[Salahuddin 1986; Downing 1987; Tedder 1987; Briggs 1988; Lopez 1988; Saxinger 1988;
Buchbinder 1989; Fox 1990b], However in both immunocompetent and
immunosuppressed patients having primary CMV infection cross reactive antibodies
probably are produced, certainly to IgG and possible also to IgM [Irving 1988; Larcher 1988;
Linde 1988; Morris 1988; Chou 1990; Enders 1990; Fox 1990b; Irving 1990a; Irving
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1990b; Sutherland 1991; Ward 1991; Adler 1993], Divergent results have been obtained
using selective absorption of sera with cells infected with CMV or HHV-6, some groups not
finding antibody cross reactivity [Irving 1990a; Ward 1991] and others demonstrating
depletion of cross reactive antibodies [Sutherland 1991; Adler 1993], These differences
may be due in part to the complexities of absorption studies, but also to the possibility that in
different circumstances different responses or combinations of antibody responses may be
occurring. Most studies have examined the possibility of cross reactive IgG responses and
there is very little information on IgM responses, as were studied in this experiment. In
retrospect, since this was a study of IgM antibody, a clearer result might have been obtained
if the IgG antibody had been removed prior to the cross-absorption. Unfortunately insufficient
sera remained to repeat the experiment. Elucidation of this relationship will require not only
further serological information on cross reactive epitopes, but also quantitative assessment
of HHV-6 and CMV viraemia during the infection.
Interpretation of patient results
Presenting Samples from Oncology Patients and Controls
The percentage of anti-HHV-6 IgG seropositivity in previous studies has varied according to
the tests used, the dilution of serum tested, and the age range of the subjects. In paediatric
populations studied beyond the age of one year, the anti-HHV-6 IgG seropositivity is up to
100%, with the highest seropositive rate obtained by ELISA and neutralising antibody tests
(see table 2, "The Host and HHV-6"). The results obtained in this study are therefore in
agreement with other studies.
This study confirms that most paediatric oncology patients have encountered HHV-6 at
presentation and appear to have a similar serological response to the virus as age matched
controls. The findings are in agreement with a study which examined sera from 50 patients
with acute lymphoblastic leukaemia (age range 1-52 years, mean age 17.6 years), in which
there was no significant difference in titres for anti-HHV-6 IgG between cases and controls, by
IFA or ELISA [Levine 1992b], Also with a recent serological study of 121 German children
with leukaemia, with age and gender matched controls, where again there was no difference
in seroprevalence or titres of antibody to HHV-6 [Schlehofer 1996]. In contrast, earlier IFA
test studies of adult patients with leukaemia and lymphoma had suggested the
seroprevalence and antibody titres to be greater in patients than controls [Ablashi 1988b;
Clark 1990],
Further investigation of the serological response of paediatric oncology patients could
include examination of the pattern of avidity of the IgG response to HHV-6 as well as the
response to different HHV-6 antigens. In a study by Iyengar most healthy control sera tested
positive for a late HHV-6 antigen and only one third for an early HHV-6 antigen. Seropositivity
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for the early antigen was increased in patients with lymphoproliferative disease, which could
indicate increased activity of the virus and possibly an altered immune response of the host
[Iyengar 1991 ]. This is similar to the altered patterns of serological responses to EBV seen in
immunocompromised patients. In a study of patients with various myelodysplastic
syndromes, elevation of titres of antibody to EBV, HHV-6 and CMV was associated with
expression of viral antigens in the bone marrow, implying active viral replication [Krueger
1994a],
Five presenting sera had neither IgG nor IgM to HHV-6 by ELISA or IFA, three were from
control patients and one from a solid tumour patient all under the age of one year. According
to their age the children under one year of age had most likely not yet had a primary HHV-6
infection. The fifth negative serum was from a nine year old leukaemic patient who was
seronegative at presentation but tested IgG positive in three samples out of twenty-three,
and who was negative at relapse two years later. No samples from this child were IgM positive
making it unlikely that he underwent primary seroconversion. It is much more likely that
these unsustained rises in IgG antibody were related to blood products received during
treatment. Althought at presentation this child did have IgG to a single herpesviruses (VZV), it
might be speculated that his lack of responses to the other herpesviruses could have been
related either to an immunological problem or lack of exposure . It could also be speculated
that such an immune response problem may in some way be related to his risk for leukaemia.
Of the two control patients with IgM to HHV-6, the infant was probably having a primary
infection, and the older child may have been having a primary infection or a reactivation. The
leukaemic patient positive for IgM at presentation was further investigated in the cross over
absorbance study and may have been having a cross reactive response to CMV or
reactivation of HHV-6, but without direct viral detection this cannot be elucidated further.
While the serological response to all five herpesviruses was examined for 52 (79%) of the
patients, data was only available for CMV and VZV for the control patients. However, in this
group of children aged from less than one to thirteen years the overall seropositivity for
patients and controls was similar for VZV (65% and 60% respectively) and CMV (27% and
33% respectively). This pattern is similar to that reported by others for children in the UK
[Kangro 1994], In the patient group the acquisition of herpesvirus infection increased with
time, and not surprisingly it appeared that when a child had antibodies to only one
herpesvirus this was usually HHV-6. Further examination of control and patient responses to
the other herpesviruses including EBV would have been a useful addition to the study as
differential responses to EBV have been shown in paediatric oncology patients [Schlehofer
1996],
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Sequential Sera from Patients on Chemotherapy
Anti-HHV-6 IgG in sequential sera
Examination of the sequential sera from patients on chemotherapy for anti-HHV-6 IgG
demonstrated no significant difference between solid tumour (ST) and acute leukaemic (AL)
patients when compared over the same time period. Although the trend in anti-HHV-6 IgG
was downward with time, there was little evidence of large fluctuations in IgG levels which
might be expected if reactivation of HHV-6 was occurring. In a longitudinal study of 37
patients with Hodgkin's disease (age range 5-72 years) I FA titres increased significantly in
patients who relapsed and decreased significantly overtime in those who did not [Levine
1992c], It was not possible to examine any relationship between changes in ELISA indices
and relapse of disease in the current study. The finding that older children had lower ELISA
Indexes for HHV-6 reflects that of other workers who have shown that the highest geometric
mean titres for HHV-6 IgG are found in young children under five years [Brown 1988a;
Yoshikawa 1990],
In addition to changing titres of IgG, IgM can also be produced in reactivation or reinfection
with HHV-6. It was not possible to test all the sera for anti-HHV-6 IgM and so sera from only 5
patients who had demonstrated laboratory and / or clinical evidence of herpesvirus activity
were selected. In this small group VZV primary and reactivated infection did not appear to
cause reactivation of HHV-6 with IgM or increased IgG production. However this situation was
different for the two children with primary CMV infection. One made no IgM to HHV-6 at all
and the ELISA index for anti-HHV-6 IgG remained unchanged over time. The other produced
anti-HHV-6 IgM on several occasions, but again the ELISA index for anti-HHV-6 IgG
remained steady with no significant change in relation to the rise of anti-CMV IgG (figures 18
& 19) (see above - "Cross reactive antibody responses").
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Summary
In summary, this serological study has demonstrated that paediatric oncology patients ,
whether solid tumour or leukaemic patients, have a similar response to HHV-6 as age
matched controls and that almost all have encountered the virus at the time of presentation
with disease. The seroprevalence for the two herpesviruses, VZV and CMV, is also similar
between controls and patients. Acquisition of a response to an increasing number of
herpesviruses increased with age in the patients and where there was only a response to
one virus it was usually HHV-6. Sequential samples from patients during immunosuppressive
treatment showed a gradual decline in ELISA index for IgG to HHV-6 with time but did not
give any helpful information as to whether reactivation of HHV-6 was occurring. IgM to HHV-6
was produced by one child with a primary CMV seroconversion but again this did not confirm
reactivation and the possibility of antibody cross reactivity could not be excluded.
Assessment of serological response in the immunocompromised will always give an
incomplete picture of the host response. To ascertain further whether this virus is
pathogenic in immunosuppressed children the next phase of the study examined for
evidence of viral activity in immunosuppressed paediatric patients.
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Prospective PCR study of HHV-6 in paediatric oncology patients
Aim of this study
HHV-6 can be a pathogenic virus for immunosuppressed patients including bone marrow
transplant patients, liver transplant patients and others, but whether it is pathogenic for
paediatric oncology patients on chemotherapy is not known. The majority of such children
have IgG for HHV-6 at presentation and levels of antibody wain with treatment, but detection
of IgG or IgM antibodies to HHV-6 is not a reliable indicator of current virus activity in these
patients.
The aim of this study was to develop a nested polymerase chain reaction (PCR) for
HHV-6 which could be used to examine the saliva of paediatric oncology patients and
controls for HHV-6 DNA, giving direct evidence of HHV-6 excretion. Saliva was chosen for
examination as a source for HHV-6 because it has frequently been shown by PCR to contain
HHV-6 DNA in adults, but to date has only been examined in a few children [Cone 1993a],
Saliva is also an acceptable secretion to obtain voluntarily from healthy children. The study
aimed to compare findings in the saliva of normal healthy children with sequential samples
from paediatric oncology patients. In addition, serum samples were collected from patients at
routine visits for chemotherapy and during febrile episodes, these were also examined by
PCR for HHV-6 DNA for evidence of any active viraemia.
Patients and Samples
Local ethical committee approval and consent of parents and children were obtained for this
study. All new patients old enough and willing who attended the oncology service of the
Royal Hospital for Sick Children between August 1992 and September 1993 were invited to
take part. The first patient saliva sample was obtained before starting chemotherapy and
thereafter samples were obtained when the patient attended for treatment or was febrile and
unwell. Healthy siblings and local volunteer children with no clinical oral disease acted as
normal controls. Only children over 3 years of age were able to give saliva samples .
Saliva samples were obtained after a fifteen second gargle with 5 mis of normal saline and
processed as soon as possible. After rota mixing the saliva was centrifuged at 1000 rpm for 8
mins and the supernatant separated from the cell pellet. Viral transport medium was added to
the pellets and foetal calf serum (1.5%) and ampicillin to the supernates. The samples were
stored at -70°C and were tested together in batches.
Serum from each patient, taken at presentation, was tested for anti-HHV-6 IgG by IFA .
Serum from a group of these children obtained at routine visits for chemotherapy and during
febrile episodes and stored at -70°c, was also tested for HHV-6 DNA by PCR.
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Methods
Preparation of Saliva and Serum for PCR - Extraction of DNA
Saliva, supernate or pellet were thawed, and 200pl diluted in an equivalent volume of double
strength lysis buffer (0.1 M TRIS, 0.02M EDTA, 1% Tween 20) with proteinase K (100pg/ml).
The samples were incubated on a heating block for 90 mins at 55°c and 10 mins at 95°c, this
enabled lysis of cellular material and digestion of protein with final inactivation of proteinase
K (PK) at 95°c.
DNA was then extracted from the sample using a phenol / chloroform method and
precipitated over night at -20°c in pure ethanol [Sambrook 1989], An equal volume of
commercially prepared Phenol:Chloroform:lsoamyl alcohol (P:C:I) (25:24:1) (Sigma) was
added to the lysis buffer containing the PK digested sample and mixed well to form an
emulsion. This was spun at 12,000g for 1 min at room temperature, and the aqueous phase
(top) carefully transferred to a fresh tube with an equal volume of P:C:I, leaving the white
proteinacious layer. The process was then repeated but after spinning the second aqueous
phase was added to an equal volume of chloroform and then spun again. To the third
aqueous phase sodium acetate was added to a final concentration of 0.3M, and mixed well,
the salt being important to assist the precipitation of the DNA from solution. Two volumes of
ice-cold ethanol (100%), were added to the solution and the mixture stored over night at
-20°c.
DNA was recovered by centrifugation at room temperature at 12,OOOg for 10 mins.
Sometimes a whitish pellet was visible on the shoulder of the tube at this stage, the
supernate was removed very carefully and the tube half filled with ice cold ethanol (70%) and
centrifugation repeated at 12,OOOg for 2 mins. After the supernate was removed the tubes
were left open in an isolation hood until the last traces of ethanol had evaporated. The pellet,
which was sometimes invisible, was dissolved in 10Opil of warm (37°c), sterile, distilled water.
The extracted DNA was either stored at -20°c until required or 1Opl of this solution was used
directly for the first round PCR.
The same procedure of digestion with proteinase K and DNA extraction was also followed for
serum samples except that 1OOpI of serum was added to 1OOpI of sterile water and the
diluted serum added to the lysis buffer.
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Sequence of HHV-6 genome chosen for amplification
The original 9000bp probe for HHV-6 developed from a fragment named pZVH 14 from a
Bam H1 digest of the GS strain has been shown not to react with any other herpesviruses
[Josephs 1986], This fragment contains the open reading frame (ORF) for the large
tegument protein gene (LTP gene) [Josephs 1991a]. An 830 bp sequence from this part of
the genome was later amplified [Collandre 1991] and strain variations were demonstrated by
restriction enzyme digestion in this area [Aubin 1991; Aubin 1992; Aubin 1993], A Hind III
digestion site at position 2945 of the LTP gene, present in "B" but not "A" subtype strains of
HHV-6 has been used in paediatric studies to discriminate between the two types of HHV-6
[Dewhurst 1992; Dewhurst 1993],
To increase sensitivity and specificity a nested PCR was designed to amplify a 287bp outer
segment and 163bp inner segment across the Hindi 11 restriction enzyme site (position 2817-
3103) (figure 1). Details of the primers chosen including: position on the LTP gene; base
pair composition; length; optical density; molecular weight; melting temperature; and
amplimer lengths are given on table 1. Primers were made by Oswel, Department of
Chemistry, King's Buildings, University of Edinburgh.
Legend to figure 1: Sequence of HHV-6 genome chosen for amplification




Large tegument protein gene




Products of Hind 111 digestion Type "A" HHV-6 163 base pairs
Type "B" HHV-6 66 & 97 base pairs
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Figure 1: Sequence of HHV-6 genome chosen for amplification
HHV-6 Genome
1°KbP








287 bp Outer PCR Product
163 bp Inner PCR Product
I Hind III digestion
B" type HHV-6 two fragments
66bp 97bp
















































































































































































7) PCR study of HHV-6 EGH Lyall
Development and optimisation of the PCR
A series of experiments were undertaken to optimise the nested PCR for the detection of
low copy numbers of HHV-6 genome (table 2). A hot start (80°C) was used for the first round
PCR to minimise nonspecific priming and increase sensitivity. In the first and second rounds
of amplification 30 cycles were used. The first denaturation was for 5 minutes at 94°C and all
subsequent denaturations for 1 minute, annealing was for 1 minute at 60°C, and extension
for 1 minute at 60°C, except for the last cycle where extension was for 8 minutes. The first
round reaction volume was 1OOpI and the second round 50pl, and the same reaction mix was
used in each round. Two units of Taq polymerase (Perkin Elmer) with the manufacturer's
buffer, 1pM of primers, 0.2mM of all four d-Nucleoside triphosphates (dNTP's), and 1.5mM of
magnesium chloride were used per reaction. 10pil of extracted sample were added to the first
round PCR and 2pl of the subsequent product were then added to the second round. All
samples were amplified twice.
Sensitivity and Specificity of the Nested PCR for HHV-6
During the development of the HHV-6 nested PCR, sensitivity was assessed by using a
dilution series of measured HHV-6 DNA. Initially dilution series of extracted DNA from the
supernatant of cultured HHV-6 were used to obtain a rough estimate of the sensitivity of the
PCR and ultimately this was confirmed by using a pure dilution series of HHV-6 amplimers.
Dilution series of extracted HHV-6 DNA
The sensitivity of the nested PCR was assessed making a dilution series of freshly extracted
DNA from the supernatant of cultures of AJ strain HHV-6 (figure 2a). The virus culture
supernatant samples were ultracentrifuged to concentrate viral particles and subjected to PK
digestion and DNA extraction as described above. It was assumed therefore, that the majority
of DNA extracted would be of viral origin and the DNA content of the samples was measured
by spectrophotometry. The first sample V1, contained 12.75 pg DNA / ml and the second
sample V3, contained 16 pg DNA /ml. Tenfold dilutions of these samples were made in
sterile water down to 0.1 fg per sample of DNA and then the dilution series were amplified
according to the initial nested protocol. Figure 2a demonstrates that for supernatant V1,
HHV-6 could be amplified down to an input of 1.28 pg of DNA and for supernatant V3, HHV-
6 could be amplified down to an input of160 fg of DNA. One HHV-6 genome is equivalent to
0.172 femtogram (fg) of DNA (assuming the mass of a nucleotide pair is 660 daltons, and
one dalton, is equal to 1.67 x 10~24 grams, [Sambrook 1989]). Thus, in the two dilution
series described V1 and V3, the lowest concentrations amplified contained 7440 and 930
HHV-6 genomes respectively. With use of an initial hot start and increased primer 126
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concentrations in both rounds of the PCR (see table 2) it was possible to improve the
sensitivity to give a positive band on agarose gel down to an input of 16 fg of DNA, equivalent
to 93 HHV-6 genomes. This is demonstrated in figure 2b which shows the result of an
experiment where the use of wax or mineral oil to cover the PCR reaction was compared. In
this experiment clearer bands were obtained with mineral oil as well as amplification to a lower
concentration, oil was therefore used for the patient samples. A PCR sensitive to the level of
around 100 HHV-6 copies per reaction was considered acceptable for this study.
Dilution series of HHV-6 amplimers
In addition a dilution series of measured DNA from first round HHV-6 amplimers was
subjected to the full nested PCR to assess the PCR sensitivity . A positive band on agarose
gel was seen consistently at 10-100ag of input DNA and sometimes at lag of input DNA
(figure 2c). One attogram of DNA is equivalent to 3 HHV-6 amplimers (assuming the mass of a
nucleotide pair is 660 daltons, and one dalton, is equal to 1.67 x 10*^4 grams, [Sambrook
1989]).
The specificity of the primer set for HHV-6 was demonstrated in an experiment where DNA
was extracted from all seven herpesviruses, known at the time, and subjected to the nested
PCR. Herpes simplex types 1 and 2, varicella zoster and cytomegalovirus were all obtained
from laboratory isolates confirmed by fluorescent monoclonal antibodies. Epstein-Barr virus
was cultured from the EB3 cell line. HHV-6 type "A" (AJ strain) was cultured from JJhan cells.
Extracted HHV-7 DNA (MK strain) was a kind gift from Dr Duncan Clark, Royal Free Hospital.
The input DNA was not measured for any of the laboratory isolates, but the HHV-7 DNA was
at a concentration of 200 ng / pi and 400ng were added to the first round reaction . Three
dilutions of HHV-6 amplimers equivalent to 3000, 300 and 30 amplimers were also amplified.
The products of the nested PCR were run on agarose gel and a positive band was only seen
in two lanes. One corresponding to the extract of cultured HHV-6 (lane H) and the other to a






























































































































































































































































































































































































































7) PCR study of HHV-6 EGH Lyall
figure 2a : Sensitivity of the nested PCR for HHV-6, dilution series of







Legend to figure 2a : Sensitivity of the nested PCR for cultured HHV-6.
Dilution series of DNA extracted from supernate of two different cultures AJ strain HHV-6, V1
and V3. Lanes positive for HHV-6 amplimers indicated in bold type.
Lane
Extract of V1 Extract of V3
1 DNA ladder 13 empty
2 empty 1 4 1.6 ng of DNA
3 1.28 ng of DNA 1 5 160 pg of DNA
4 128 pg of DNA 1 6 16 pg of DNA
5 12.8 pg of DNA 1 7 1.6 pg of DNA
6 1.28 pg of DNA 1 8 160 fg of DNA
7 128 fg of DNA 1 9 16 fg of DNA
8 12.8 fg of DNA 20 1.6fg of DNA
9 1.28 fg of DNA 21 0.16 fg of DNA
10 0.128 fg of DNA 22 water
11 water 23 empty
12 empty 24 DNA ladder
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figure 2b : Sensitivity of the nested PCR for HHV-6, dilution series of
DNA extracted from the supernate of cultured AJ strain HHV-6,
comparison of wax or oil to cover the PCR reaction.
Legend to figure 2b : Sensitivity of the nested PCR for cultured HHV-6.
Dilution series of DNA extracted from the supernate of culture V3 of AJ strain HHV-6. Left
hand lanes covered with wax and Right hand with oil. Lanes positive for HHV-6 amplimers
indicated in bold type.
Wax Overlay OIL Overlay
1 DNA ladder 12 empty
2 empty 1 3 16 ng of DNA
3 16 ng of DNA 1 4 1.6 ng of DNA
4 1.6 ng of DNA 1 5 16 pg of DNA
5 160 pg of DNA 1 6 160 pg of DNA
6 16 pg of DNA 1 7 16 pg of DNA
7 1.6 pg of DNA 1 8 1.6 pg of DNA
8 160 fg of DNA 1 9 160 fg of DNA
9 16 fg of DNA 20 16 fg of DNA
10 1.6 fg of DNA 21 1.6 fg of DNA
11 water 22 water
23 DNA ladder
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figure 2c : Sensitivity of the nested PCR for HHV-6, dilution series of
HHV-6 templates.
Ethidium Bromide stained Gel of HHV-6 Amplimers of
a Dilution series of HHV-6 DNA Template.
1 ag of DNA = 3 HHV-6 DNA templates
Legend to figure 2c : Sensitivity of the nested PCR for HHV-6 amplimers.
Dilution series of amplified HHV-6 templates on a left and right hand ethidium bromide
stained gel. 1 ag of HHV-6 DNA is equivalent to 3 HHV-6 DNA templates (see text for
calculation). Lanes positive for HHV-6 amplimers indicated in bold type.
Left Gel Right Gel
1 100pg of HHV-6 DNA Lane 1 10fg of HHV-6 DNA
2 10pg 2 ifg
3 1 pg 3 1 OOag
4 10Of g 4 10ag
5 1 Of g 5 lag
6 ifg 6 0.1ag
7 water 7 water
8 DNA KB ladder 8 DNA KB ladder
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figure 3: Specificity of the nested PCR for HHV-6
EGH Lyall
Legend to figure 3: Specificity of the nested PCR for HHV-6
Only two positive bands seen at the level equivalent to 163 bp: lane H from extracted HHV-6
from culture supernatant; lane L from stored, aliquoted, HHV-6 amplimers. Lanes positive for
HHV-6 amplimers indicated in bold type.
Lanes A DNA ladder (Phi x 174 RF DNA / Hae 111, fragments - 1353, 1078, 872,







H HHV-6 ( extracted supernatant from cultured AJ strain)
J HHV-7
K Water
L dilutions of HHV-6 amplimers - 3000
M dilutions of HHV-6 amplimers ~ 300
N dilutions of HHV-6 amplimers - 30
P Water
R empty
S DNA mass ladder (fragments - 2000, 1200, 800, 400, 200, 100)
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PCR Reaction Mix Components
All reaction mixes were prepared in a designated clean pre-PCR laboratory where gloves,
aprons and lab coats were worn at all times. Filter tips were used for all pipetting to avoid
contamination from pipette hubs. Reaction mixes for the first and second round PCR's were
prepared in a still air hood which had been illuminated with UV light for at least 30 mins, and
wiped down with 70% ethanol before and after use.
A "hot start" method was used for the first round PCR only. The first round reaction mixes
were made up as "top" and "bottom" batches with a total volume of 10Opil per reaction. In the
"bottom" of the eppendorf tube was placed PCR buffer (Perkin Elmer), magnesium chloride
(1.5mM)(supplied as part of buffer), first round primers for HHV-6, and Betaglobin primers,
this was overlayed with 75pl of paraffin oil. The sample of extracted DNA was added to this in
a different class II extraction hood. The tubes were then taken to the thermal cycler (Hybaid)
and heated up to 80°c. As the samples were heating up, Taq polymerase (Perkin Elmer) was
added to the "top" solution which contained PCR buffer, and dNTP's. This was then layered
on top of the hot oil at the thermal cycler and the cycles of amplification allowed to
commence. For the second round of PCR all the elements, except target, were added to the
tubes in the still air hood (PCR buffer, magnesium chloride (1.5mM) (supplied as part of
buffer), second round primers for HHV-6, dNTP's and Taq polymerase) to make a total
volume of 48pl per reaction. Two pi of first round product was added to the tube in another
room and the second round of amplification allowed to proceed.
Betaglobin Primers
Although the conditions for this nested PCR were optimised for HHV-6 nested primers
alone it was decided to include primers for genomic DNA (beta-globin) in the first round PCR
(table 1). The aim was to identify the presence of host DNA in the samples and ascertain
whether this bore any relation to the presence of HHV-6 DNA. This also acted as an internal
control for inhibition of the PCR. Figure 4 demonstrates the amplimers generated by the
betaglobin PCR on one of the first runs of saliva samples tested, where most pellet samples
amplified betaglobin. As a result of this betaglobin primers were added to the first round PCR
mix, but the clear results demonstrated in this run were rarely repeated when all the test
samples were run.
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figure 4: Betaglobin primers added to the first round of the HHV-6 nested
PCR.
Legend to figure 4: Betaglobin primers in the HHV-6 nested PCR.
This agarose gel demonstrates a series patient samples (supernatant -S, pellet -P) with HHV-
6 and betaglobin PCR. All but one of the pellet samples amplified betaglobin, indicated with
an asterisk* in round one and ** in round two. One supernatant and three pellets amplified
HHV-6, indicated in bold type.
First round PCR Second round PCR
1 DNA KB ladder 16 empty
2 empty 17 patient sample S
3 patient sample S 18 patient sample S
4 patient sample S 19 patient sample S
5 patient sample S 20 patient sample S
6 patient sample S 21 patient sample S
7 patient sample S 22 patient sample S
8 patient sample S 23 patient sample P**
9 patient sample P* 24 patient sample P**
10 patient sample P* 2 5 patient sample P
11 patient sample P* 26 patient sample P**(w)
12 patient sample P* 27 patient sample P**(w)
13 patient sample P* 28 patient sample P
14 patient sample P 29 empty
15 empty 30 DNA KB ladder
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PCR Negative Samples
Any samples repeatedly negative to HHV-6 nested amplification or beta-globin amplification
were spiked with 600 HHV-6 (AJ strain) first round amplimers and the PCR repeated for
evidence of inhibition of the PCR.
Samples included in each PCR amplification run
Samples were amplified in batches of 21 with three water controls, one uninfected
lymphoblastoid cell line negative control, and three positive controls containing 30, 300, and
3,000 HHV-6 amplified genome segments of type "A" from the AJ strain of the virus. The
products of the first and second round amplification were run concurrently on an ethidium
bromide stained gel (figure 5).
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MINI GEL TEMPLATE FOR NESTED HHV-6 PCR
WATER J CELLLYSATE g DNA LADDER
m 3,000, 300, 30 HHV-6 AMPLIMERS








figure 5: Template for PCR Gel Runs used for each batch of PCR amplified
samples.
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Detection of Amplified HHV-6 - Ethidium Bromide stained Gels
Agarose mini-gels (60 ml) were prepared with 3% agarose (2% Nuseive and 1% Seakem) and
0.5 x TBE buffer. After dissolving the gel and cooling to about 60°c, 2pl of ethidium bromide
was added to the gel which was then poured into the mould, edged with autoclave tape and
the comb added. The gel was cooled to room temperature and then to 4°c. The
electrophoresis tank was filled with 0.5 x TBE buffer of the same batch and the tape removed
from the gel before it was submerged in buffer to 2-3 mm. The comb was carefully removed
from the gel.
Two pi of loading buffer stained with bromophenol blue (0.25% in 40% sucrose) was added
to 14 pi of sample and, 12(il of the mixture was then carefully added to each well.
The DNA ladder used to compare with the length of amplified fragments visualised was "DNA
molecular weight marker noV" ( Boehringer Mannheim). This is a mixture of fragments from
cleavage of plasmid pBR322 DNA and contains 22 fragments from 587 to 8 bp in length
(587/ 504/ 458/ 434/ 267/ 234/ 213/ 192/ 184/ 124/ 123/ 104/ 89/ 80/ 64/ 57/ 51/21/ 18/
11/ 8). The ladder was diluted 1/15 in sterile water, to approximately 3 pg of DNA per well,
and run in at least two wells on each gel.
Electrophoresis of the gel was for about one hour over 14.8 cm; at 100 volts and 50 mAmps,
ie 6.75 volts / cm. When the dye had reached to within 1 cm of the end of the gel the current
was discontinued, the gel removed from the buffer, wrapped in "Saran" film and examined
under UV light on the transilluminator and either photographed or transcribed to the template
diagram (figure 5). Ethidium bromide stained gels were disposed of with autoclaved rubbish
and used buffer washed down the drain with copious running water.
HHV-6 PCR Positive samples and Hind III digestion
Any sample which amplified HHV-6 DNA and gave a band at 163bp after the second round of
PCR was subjected to Hind III digestion to ascertain whether it was sub-type A or B HHV-6.
For this restriction enzyme (RE) digestion, 5pl of amplified product, 3pl of sterile water, and
1 pi of 10 X RE buffer B (the appropriate buffer for this enzyme,Boehringer Mannheim) were
added to a microcentrifuge tube. At -20°c the RE, Hind III, was diluted to 10 units per pi in
buffer B and 2 units added immediately to each reaction. The reaction tubes were incubated
for 1 hour in a water bath at 37°c and after this 2pl of 10OmM EDTA was added to each tube
to stop the reaction. As the products of this digestion gave small fragments (97 and 66 bp) a
3% "Metaphor" agarose gel (Flowgen) with 1 x TBE, stained with ethidium bromide was used
for better definition of fragments. The samples were tested in batches of up to 12 with an
HHV-6 type A positive control (which does not digest with Hind III) and the "DNA molecular
weight marker noV" ( Boehringer Mannheim) on each gel.
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Statistical Methods
Nonparametric tests were used to compare the small groups of patient samples including the
Chi-squared test and the Mann-Whitney-U test.
Recipes for Buffers
1M TRIS stock solution
121.1 g of TRIS dilute in 800ml distilled water
Adjust pH to 7.5 with HCI (5M)
Make to 11, aliquot and autoclave.
0.5 M EDTA stock solution
18.61g EDTA dilute in 80ml distilled water
Adjust pH to 8.0 with NAOH pellets (approx 2g)
(NB EDTA not go into solution without NaOH)
Make to 100ml, aliquot and autoclave.
TE Lysis buffer
To make 100ml
5ml stock solution 1M TRIS (final cone 50mM TRIS)
2ml stock solution 0.5M EDTA (final cone 10mM EDTA)
0.5ml Tween 20 (final cone 0.5%)
92.5 ml distilled water
Add proteinase K to a final cone of 100g/ml for protein digestion.
TBE electrophoresis buffer, 5 x stock solution
TRIS base 54g (89mM)
Boric acid 27.5g (89mM)
0.5M EDTA stock (pH 8.0) 20ml (2mM)
Make to 1L with distilled water, dispense as 50ml aliquots and autoclave.
(On long term storage TBE can precipitate, if so it should not be used).
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Prospective Saliva PCR Study
Results of PCR experiments
Patients and Controls
A total of 115 saliva samples, including pellets and supernates, were examined for HHV-6
DNA. Seventy seven saliva samples were obtained from 12 patients (2-13 per child), age
range 3-13 years. Thirty eight samples were obtained from 10 siblings (two from one sibling at
different times), and 27 healthy volunteer children, age range 4-16 years. Fifty one serum
samples were obtained from the 12 patients (1 - 9 per child), it was only possible to test an
initial 25 of these by PCR.
Performance of the HHV-6 PCR
No amplified HHV-6 DNA was ever found after PCR in any of the water or uninfected
lymphoblastoid cell controls. The lymphoblastoid cell control was only intermittently positive
for the betaglobin amplimer, which may have been related to lack of genomic DNA in some
samples , but may also have been related to the fact that the betaglobin primers were used in
a system which was not optimised specifically for them. All three concentrations of HHV-6
positive control were amplified on 65% of runs, however on 35% of runs only 3,000 and 300
HHV-6 amplimers were amplified. It appeared that the addition of the betaglobin primers to
the reaction mix could have affected the sensitivity of the HHV-6 nested PCR.
There were 36 completely PCR negative samples (both HHV-6 and betaglobin), and after
spiking these with 600 HHV-6 amplimers and reamplifiying them, only one saliva pellet and
two supernates were found to be inhibitory for the PCR.
Concordance of Results between two PCR runs
Over all for the HHV-6 PCR the positive concordance between the replicate PCR runs was
similar for both supernate (74%) and pellet (76%). The betaglobin PCR positive concordance
rate was much higher for supernate specimens (88%) than pellet specimens (67%), probably
because the majority of supernate specimens were, as expected, betaglobin PCR negative.
A similar pattern was seen when the results were divided into patient and control groups (
table 3).
These results demonstrate that some PCR runs were more sensitive than others. As there
was no obvious problem with contamination at any time, it was decided for interpretation of
the patient data, to consider a sample which had been PCR positive on at least one of the
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Prospective Saliva PCR Study
PCR Results for all samples
HHV-6 PCR
When the total number of samples obtained were considered and the results obtained for
the pellet and supernate were summed then 28/38 (74%) of healthy control saliva samples
and 45/77 (58%) patient saliva samples were PCR positive for HHV-6. When the supernate
and pellet results were considered separately then 23/38 (61 %) of healthy control supernate
samples and 30/77 (40%) patient supernate samples were PCR positive for HHV-6 and
21/38 (55%) of healthy control pellet samples and 31/77 (40%) patient pellet samples were
PCR positive for HHV-6 (table 4). The overall findings are represented diagrammatically on
bar charts (figure 6 -8). All the patients were seropositive for HHV-6 IgG by IFA.
Comparison of all the results obtained for the patient and control groups demonstrate that
HHV-6 DNA could be amplified from fewer patient supernate specimens than controls (Chi
squared test p = 0.04), but there was no significant difference for amplification of HHV-6 from
pellets or when.the results from pellets and supernates were summed. In the above
comparison a single specimen obtained from each control patient (except one sibling who
gave 2) was compared with a series of samples obtained from patients. When the results from
only the first patient sample obtained (n=12) were compared with those of the control group
(n=38), then the same pattern of results was demonstrated, but there was no significant
difference between patients or controls for supernatants, pellets or the combined results
(table 4).
Photographs of representative agarose gels of amplified HHV-6 DNA from salivary specimens
from patients and controls with a diagrammatic key are shown on figures 15-17.
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table 4: Results of HHV-6 PCR for Patients and Healthy Controls
HHV6 HHV6
Cases No Type of Samples Ever Positive Never Positive
First Patient sample 12 Supernate 2 (17%) CcTcr-coCO,o
Pellet 7 (58) 5 (42)
Both 7 (58) 5 (42)
All Patient samples 77 Supernate 30 (40) 47 (60)
Pellet 31 (40) 46 (60)
Both 45 (58) 32 (42)
All Sibs samples 11 Supernate 5 (45) 6 (55)
Pellet 6 (55) 5 (45)
Both 8 (73) 3 (27)
All Volunteer samples 27 Supernate 18 (67) 9 (33)
Pellet 15 (56) 12 (44)
Both 20 (74) 7 (26)
All Control samples 38 Supernate 23 (61) 15 (39)
Pellet 20 (53) 18 (47)
Both 26 (68) 12 (32)
table 4: Results of HHV-6 PCR for Patients and Healthy Controls
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figure 6: HHV-6 DNA in saliva supernatant samples from patients & controls
PCR for HHV-6 in Saliva Supernatants
□ HHV-6 DNA positive
■ HHV-6 DNA Negative
All controls Volunteers Siblings All Patients
figure 7: HHV-6 DNA in saliva pellet sample from patients & controls
PCR for HHV-6 DNA in Saliva Pellet
All Controls Volunteers Siblings All Patients
figure 8: Combined result of HHV-6 DNA in saliva pellet and supernatant
Combined Results of PCR for HHV-6 in
Supernate and Pellet
All Controls Volunteers Siblings All Patients
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Comparison of saliva results from Well and Febrile Patients
When the PCR results from the patients who were well were compared with those who were
unwell and febrile at the time of collection, fewer supernate samples from unwell children
amplified HHV-6 DNA (chi-squared test p=0.06), but there was no significant difference in
HHV-6 DNA in the pellet samples or when the results were summed for supernate and pellet
(figures 9-11, and table 5).
Comparison of saliva results according to Patients' White Blood
Count
Only one third of supernate samples from children with a total white blood count (WBC) less
than 1 x 10 9/l and absolute neutrophil count (ANC) less than 1 x 10 9/I amplified HHV-6 DNA
whereas in samples from children with counts greater than 1 x 10 9/l nearer half the samples
amplified HHV-6. However, these differences did not reach significance by the chi-square
test. Whether the absolute lymphocyte count was greater than or less than 1x10^/1 did not
affect the salivary HHV-6 DNA PCR result, (figures 12-14, and table 6).
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Figure 9: HHV-6 DNA in saliva supernatant from well & febrile patients
Figure 10: HHV-6 DNA in saliva pellet from well & febrile patients
PCR for HHV-6 DNA in Saliva Pellet
Well Patients Febrile Patients
Figure 11: Combined result of HHV-6 DNA in saliva pellet and supernatant
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table 5: HHV-6 DNA PCR results in well and febrile patients
HHV6 HHV6
Cases No Type of Samples Ever Positive Never Positive
All Patient samples 77 Supernate 30 (40%) 47 (60%)
Pellet 31 (40) 46 (60)
Both 45 (58) 32 (42)
Well patients 60 Supernate 28 (47) 32 (53)
Pellet 26 (43) 34 (57) ......
Both 35 (58) 25 (42)
Febrile patients 17 Supernate 3 (1.8). 14 (83)
Pellet 5 (29) 12 (71)
Both 8 (47) 9 (53)
table 5: HHV-6 DNA PCR results in well and febrile patients
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figure 12: HHV-6 DNA in saliva supernatants according to WBC
PCR for HHV-6 DNA in Saliva Supernate
WBC>1 WBC<1 ANC>1 ANC<1 ALC>1 ALC<1
figure 13: HHV-6 DNA in saliva pellets according to WBC
PCR for HHV-6 DNA in Saliva Pellets
WBC>1 WBC<1 ANC>1 ANC<1 ALC>1 ALC<1
149
7) PCR study of HHV-6 EGH Lyall












WBC>1 WBC<1 ANC>1 ANC<1 ALC>1 ALC<1
Legend to graphs 12 -14:
WBC> 1 Total white blood count greater than 1 x 10 9/l
WBC < 1 Total white blood count less than 1 x 10 9/l
ANC > 1 Absolute neutrophil count greater than 1 x 10 9/l
ANC < 1 Absolute neutrophil count less than 1 x 10 9/l
ALC > 1 Absolute lymphocyte count greater than 1 x 10 9/l
ALC < 1 Absolute lymphocyte count less than 1 x 10 9/l
□ HHV-6 DNA Positive
■ HHV-6 DNA Negative
PCR for HHV-6 DNA in Saliva
Supernate and Pellets
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Photographs of HHV-6 nested PCR Gel runs








Legend to figure 15: A series of patient samples amplied for HHV-6 DNA. All
the batches of samples were tested according to the template shown previously (figure 4).
Only the second round PCR products are shown, samples which amplfied HHV-6 are
indicated in bold (S - supernatant, P - pellet). Samples which were Betaglobin PCR positive
on the first round indicated by an asterisk *. The lymphoblastoid cell line did not amplifiy
betaglobin.
1 DNA KB ladder 1 6 patient sample P*
2 patient sample S 17 water
3 patient sample S 1 8 patient sample S
4 patient sample S 19 patient sample S
5 patient sample P 20 patient sample S
6 patient sample S 21 patient sample S*
7 patient sample S 2 2 patient sample P*
8 patient sample S 2 3 patient sample P
9 water 2 4 patient sample P
1 0 patient sample S 2 5 3000 HHV-6 amplimers
1 1 patient samples 2 6 300 HHV-6 amplimers
12 patient sample P 2 7 30 HHV-6 amplimers
13 patient sample P* 28 lymphoblastoid cell DNA
14 patient sample P* 29 water
1 5 patient sample P* 30 DNA KB ladder
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Photographs of HHV-6 nested PCR Gel runs




Legend to figure 16: A series of control samples amplied for HHV-6 DNA. All
the batches of samples were tested according to the template shown previously (figure 4).
The first and second round PCR products are shown, upper part of gel - first round, lower part
-second round. Samples which amplfied HHV-6 are indicated in bold (S - supernatant, P -
pellet). Samples which were Betaglobin PCR positive on the first round only are indicated by
an asterisk *, and those positive on the second round ** . The lymphoblastoid cell line did not
amplifiy betaglobin.
1 DNA KB ladder 1 6 Control sample P
2 Control sample S 17 water
3 Control sample S 18 Control sample P*, **
4 Control sample S 1 9 Control sample P
5 Control sample S**(+/-) 2 0 Control sample P*,**
6 Control sample S 2 1 Control sample P
7 Control sample S 22 Control sample P*, **
8 Control sample S** 2 3 Control sample P
9 water 24 Control sample P*, **
1 0 Control sample S 2 5 3000 HHV-6 amplimers
1 1 Control sample S 26 300 HHV-6 amplimers
12 Control sample S 27 30 HHV-6 amplimers
13 Control sample P 28 lymphoblastoid cell DNA
1 4 Control sample P 29 water
1 5 Control sample P 30 DNA KB ladder
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Photographs of HHV-6 nested PCR Gel runs




Legend to figure 17: A series of control samples amplied for HHV-6 DNA. All
the batches of samples were tested according to the template shown previously (figure 4).
The first and second round PCR products are shown, upper part of gel - first round, lower part
-second round. Samples which amplfied HHV-6 are indicated in bold (S - supernatant, P -
pellet). Samples which were Betaglobin PCR positive on the first round only are indicated by
an asterisk *, and those positive on the second round ** . The lymphoblastoid cell line did
amplifiy betaglobin.
Lane 1 DNA KB ladder 1 6 Control sample S
2 Control sample P 17 water
3 Control sample P 1 8 Control sample S
4 Control sample P 1 9 Control sample S
5 Control sample P 2 0 Control samples
6 Control sample P 21 Control sample S
7 Control sample P 22 Control sample S
8 Control sample P 2 3 Control sample S
9 water 24 Control sample S
10 Control sample P 2 5 3000 HHV-6 amplimers
11 Control sample P 2 6 300 HHV-6 amplimers
12 Control sample P 27 30 HHV-6 amplimers
1 3 Control sample S 28 lymphoblastoid cell DNA**
1 4 Control samples 29 water
15 Control samples 30 DNA KB ladder
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table 6: HHV-6 PCR results according to patient white blood count
WBC - total white blood cell count; ANC - absolute neutrophil count; ALC - absolute lymphocyte count.
HHV6 HHV6
Cases No Type of Samples Ever Positive Never Positive
All Patient samples 77 Supernate 30 (40%) 47 (60%)
Pellet 31 (40) 46 (60)
Both 45 (58) 32 (42)
WBC>1 59 Supernate 28 (47) 32 (53)
Pellet 26 (43) 34 (57)
Both 35 (58) 25 (42)
WBC<1 1 5 Supernate 25 (42) 34 (58)
Pellet 24 (41) 35 (59)
Both 34 (58) 25 (42)
ANC>1 45 Supernate 22 (49) 23 (51)
Pellet 17 (38) 28 (62)
Both 26 (58) 19 (42)
ANC<1 29 Supernate 8 (28) 21 (72)
Pellet 13 (45) 16 (55)
Both 16 (55) 13 (45)
ALC>1 41 Supernate 16 (39) 25 (61)
Pellet 14 (34) 27 (67)
Both 20 (49) 21 (51)
ALC<1 33 Supernate 14 (42) 19 (58)
Pellet 16 (48) 17 (52)
Both 22 (67) 11 (33)
table 6: HHV-6 PCR results according to patient white blood count
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Results of Hind III Restriction Enzyme Digestion
All the HHV-6 PCR positive saliva samples (53 supernatant extracts and 52 pellet extracts)
tested from patients and controls digested with Hind III to give two fragments and were
therefore "B" type HHV-6 (figure 18).
figure 18: A representative gel of the products of the Hind III restriction
enzyme digestion.
Lanes 1 2345678
Type of B B insuf B B B A KB
HHV-6 BB BBBBAKB
legend to figure 18: Agarose gel of Hind III digested products of PCR for HHV-6 DNA.
Upper and Lower rows lanes 1-6 patient samples, lane 7 positive control A type HHV-6. All
the patient samples digested to give two products of 97 and 66 bp, except top row lane 3
where there was insufficient sample in this run. The control A type HHV-6 did not digest
giving only one product of 163 bp. All the patient samples evaluable were therefore type B
HHV-6.
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Betaglobin PCR
When the total number of samples obtained were considered and the results obtained for
the pellet and supernate were summed then 26/38 (68%) of control saliva samples and
38/77 (49%) patient saliva samples were first round PCR positive for betaglobin. When the
supernate and pellet results were considered separately then 11/38 (29%) of control
supernate samples and 4/77 (5%) patient supernate samples were PCR positive for
betaglobin and 18/38 (47%) of control pellet samples and 34/77 (44%) patient pellet
samples were PCR positive for Betaglobin (table 7) (see figures 15,16,17 above).
Comparison of all the results obtained for the patient and control groups demonstrate that
betaglobin DNA could be amplified from significantly fewer patient supernate specimens
than controls (p< 0.001), but there was no significant difference for amplification of
betaglobin from pellets. When the results from pellets and supernates were summed this
difference remained significant (p = 0.03). There was no significant difference in betaglobin
amplification within patient groups compared. Saliva samples from which Betaglobin gene
sequence could be amplified, whether pellet or supernatant, were not any more likely to
amplify HHV-6 than those which did not.
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table 7: Betaglobin DNA PCR for Patients and Controls
Betaglobin Betaglobin
Cases No Type of Samples Ever Positive Never Positive
First Patient sample 1 2 Supernate 1 (8) 11 (92)
Pellet 6 (50) 6 (50)
Both 6 (50) 6 (50)
All Patient samples 77 Supernate 4 (5) 73 (95)
Pellet 34 (44) 43 (56)
Both 38 (49) 39 (51)
All Sibs samples 1 1 Supernate 4 (36) 7 (64)
Pellet 7 (64) 4 (36)
Both 10 (91) 1 (9)
All Volunteer samples 27 Supernate 7 (26) 20 (74)
Pellet 11 (41) 16 (59)
Both 16 (59) 11 (41) ...
All Control samples 38 Supernate 11 (29) 27 (71)
Pellet 18 (47) 20 (53)
Both 26 (68) 12 (32)
table 7: Betaglobin DNA PCR for Patients and Controls
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Sequential Salivary HHV-6 PCR Results from Individual Patients
A chronological series of samples was obtained from 12 patients, 7 with leukaemia and 5 with
solid tumours, and all these patients were seropositive for HHV-6. The samples were
obtained at regular intervals when the children were either well or febrile and unwell from the
time of diagnosis until the end of the collection period. The timing of sampling from these
children and results of the nested HHV-6 PCR are shown in figure 19.
Since the number of samples obtained per child varied from 2 to 13, to enable differences in
the sequential data to be considered between patients, for each child the ratios of the
summed, pellet & supernatant, results were compared (table 8 and figure 20). Comparison of
these ratios revealed two distinct groups of patients, those with mainly HHV-6 positive saliva
(group B) and those with mainly HHV-6 negative saliva (group A) (CHi-sq p<0.0001). There
was no difference between these two groups for, age, betaglobin PCR, total white blood
count, absolute lymphocyte count, or diagnosis (solid tumour / leukaemia). However, in the
mainly HHV-6 negative, group A, there were more febrile unwell children (10/30 group A
versus 7/47 group B, CHi-sq p=0.05) and they had lower absolute neutrophil counts (M- W -U
test p=0.02).
The results from unsummed supernates and pellets from the children were also expressed
as ratios and the results were very similar. For the supernates one child from group B had a
ratio of less than 0.5, for the pellets three children from group B had ratios of less than 0.5,
but they were all greater than the ratios from the patients in group A and none of the group A
children had higher ratios (data not shown).
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Week of chemotherapy when sample was obtained
figure 19: sequential series of HHV-6 saliva PCR results from 12 patients
HHV-6 saliva PCR results are presented for 12 patients as they were collected
chronologically over the weeks of chemotherapy. Samples from each patient are
represented by a different coloured symbol. Those patients who had mainly HHV-6 positive
samples are represented by circles and those with mainly HHV-6 negative samples are
represented by squares. In a week when a patient had an HHV-6 positive sample it appears
above the line and if it was an HHV-6 negative sample below the line.
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Individual patients' ratios of HHV-6 DNA
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figure 20: Ratios of HHV-6 positive / negative samples for each patient
Group A patients - mainly HHV-6 positive saliva (patients 3,6,7,8,9,11)
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PCR for HHV-6 and Betaglobin in Patient Serum Samples
An initial 25 / 51 serum samples from ten of the patients were examined for HHV-6 and
betaglobin DNA by PCR. These samples had been collected at routine visits as well as during
admissions when the patients were febrile and unwell. None of the samples amplified HHV-6
DNA or betaglobin DNA. When spiked with 600 HHV-6 amplimers all but one amplified.
There was insufficient time to amplify all 51 samples.
Anti-viral treatment and HHV-6 PCR results
During this sequential study, none of the 12 children were treated with ganciclovir, which is
known to interrupt HHV-6 excretion [Russler 1989], Three samples were obtained from
children whilst on aciclovir therapy, which has a much weaker negative effect on HHV-6
excretion [Russler 1989]. Two saliva samples from children on oral aciclovir were PCR
positive for HHV-6. One saliva sample from a child receiving intravenous aciclovir was HHV-6
PCR negative. Numbers are too small to assess whether aciclovir therapy had any effect on
results obtained for the HHV-6 PCR.
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Findings of the Prospective Study of HHV-6 DNA in the saliva of
paediatric oncology patients
Performance of the nested HHV-6 PCR
The sensitivity of a PCR will determine the number of positive results obtained and the
degree of positivity in any sample examined. In this study an indirect measure of the
sensitivity of the system could be gained from the dilution series of cultured virus and of first
round amplimers. However this does not necessarily relate directly to findings in saliva where
different biochemical conditions could alter the sensitivity of the system.
Only one saliva pellet and two supernatants, one pair being from the same child, were
inhibitory to the PCR and all the other repeatedly negative samples gave positive results
when spiked with 600 first round HHV-6 amplimers. Some of the PCR runs appeared more
sensitive than others, according to the dilutions of first round amplimer which could be
amplified, but with an end point dilution of 30 amplimers in the most dilute sample it is
possible that on occasions lack of amplimer in the dilution led to the negative result rather
than decreased sensitivity of the system. Indeed, although PCR is an extremely sensitive
technique it is also dependent on highly defined conditions and there are many variables
which can affect the performance of any particular run.
The decision to include Betaglobin primers as an internal control in the first round of the PCR
may also have affected the sensitivity of the HHV-6 PCR. Unfortunately the sensitivity
experiments for the HHV-6 PCR were undertaken prior to this and they were not repeated
with the Betaglobin primers in the mix. It is also the case that the PCR was optimised for the
HHV-6 primers and not the Betaglobin primers and they also may not have been amplifying at
maximal efficiency. In retrospect, it would have been preferable either to optimise the PCR for
both sets of primers or to have carried out separate PCRs for each primer set.
All samples were amplified at least twice, and it was decided to consider a sample positive
even if it amplified HHV-6 only once out of two tests. This was considered acceptable: 1)
because of the possibility of variable performance of the PCR; 2) because of the likelihood
that HHV-6 could been present very small numbers variable between replicates; and 3)
because of the fortunate lack of any contamination of water or uninfected cell extract
controls. Although the positive concordance between the two HHV-6 PCR runs was similar
for both supernate (74%) and pellet (76%), in a larger more definitive study more stringent
concordance between replicates would be required.
HHV-6 and HHV-7 are genetically closely related viruses [Frenkel 1990a; Frenkel 1991;
Schirmer 1991; Berneman 1992], and controversy over salivary findings for HHV-6 DNA
could be related to the specificity of the PCR used. Earlier studies did not necessarily test
primers for specificity to HHV-6 alone allowing the possibility for amplification of both viruses.
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The primers used in this study did not amplify HHV-7 DNA when tested. Therefore the
results obtained in this pilot study would appear to be specific for HHV-6 in the saliva. Of
note though, the sensitivity of the PCR in the specificity experiment was not as good as in
most of the patient runs as only the 3000 HHV-6 amplimer dilution was amplified where in
most of the patient runs 300 or even 30 amplimers were amplified. However this is balanced
against the fact that the concentration of HHV-7 DNA added to the sample was quite high
and therefore it might still be expected that any amplification would have been detected.
Interpretation of patient results
HHV-6 in Saliva
This preliminary examination of sequential saliva samples from paediatric oncology patients
for HHV-6 DNA demonstrated that "B" type HHV-6 DNA can frequently be found in the saliva
of healthy children (74%) and those with malignancy (58%). "B" type HHV-6 has been found
almost exclusively in children with primary infection and increasingly frequently in
immunosuppressed patients. Although there are only a small number of patients in this study
the finding that they could be clearly separated into two groups, one where the saliva was
frequently positive for HHV-6 DNA ( 81% of samples tested positive) and the other rarely
positive ( 20% of samples tested positive) is of interest. The former group appeared to most
closely resemble the healthy control children, not only in terms of HHV-6 positivity but also
they were generally well with fewer febrile episodes and less neutropaenia.
That HHV-6 is more frequently present in the saliva of more healthy children appears at first
surprising as latent herpes viruses are considered more often recurrent and more likely to
cause problems in immunosuppressed patients. A number of factors may be acting to
produce this seemingly paradoxical result in the "well" children. Immunosuppressed children
on chemotherapy could secrete less HHV-6 when they are unwell if the turnover of cells in
the salivary glands, a likely source of virus, is affected by the treatment. Chemotherapy also
tends to deplete the lymphocyte population which is a reservoir for HHV-6. Although in this
study, no relation between low blood lymphocyte counts and HHV-6 excretion was seen, it
is possible that the local lymphocyte situation in the mouth mucosa could be different. An
age effect might have meant that younger children more recently infected with HHV-6 would
be more likely to be secreting the virus. However there was no significant difference in age
between the groups. It could be that children who were less well were not so good at
producing saliva specimens and the findings are simply an artifact of technique. However
this did not appear to be the case when the specimens were collected. Further investigation
to confirm or refute this preliminary paradoxical finding would require: larger numbers; better
matching of patients and controls; sequential sampling of healthy controls as well as patients;
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and a fully quantitative HHV-6 PCR.
Saliva samples were divided into pellet and supernatant to examine for cell free HHV-6 DNA
in the supernatant. HHV-6 DNA was more often present in control sample supernates (23/38,
79%) than patient sample supernates (31/77, 40%). Strikingly, when the patients were
divided into the frequently HHV-6 positive and rarely HHV-6 positive groups, again the
frequently HHV-6 positive group most closely resembled the healthy children with a similar
percentage of supernate samples HHV-6 DNA positive (29/47, 61%), very few supernate
samples had HHV-6 DNA in the rarely HHV-6 positive group (2/30, 6%). That healthy children
and the patients who are well are more likely to be secreting HHV-6 into the saliva again
implies that in the others secretion is impaired for some reason. The factors which might
cause this were discussed above, and a chemotherapy effect on salivary glands or
mononuclear cells would seem a plausible explanation.
Pellet samples tested for HHV-6 DNA probably contained a mix of cellular material from the
mouth, including monocytes and lymphocytes, and HHV-6 detected in these samples could
have been latent or actively secreted. The percentage of samples positive for HHV-6 was
similar between the whole patient group and the healthy controls (31/77 (40%) v 21 / 38
(55%)). There was also no difference where patients were unwell or well, or according to the
blood white cell count. This would seem to imply that cell associated virus can be detected in
a constant proportion of patients, but that there may be a decrease of secretion of virus in the
less well children. Further examination of this would again require, larger numbers; better
matching of patients and controls; sequential sampling of healthy controls as well as patients;
and a quantitative HHV-6 PCR.
There are few published studies on secretion of HHV-6 in saliva of children. In a small study of
primary infection with HHV-6 and HHV-7, 41 cases with fever +/- convulsions and 7 control
patients were recruited [Clark 1997]. HHV-6 DNA was amplified from the saliva in 54% of
cases and 40% of controls and HHV-7 DNA was found in saliva in 34% of cases and 20% of
controls. These were all children who were seropositive and previously infected with HHV-6
or HHV-7. In this study the saliva was collected by rubbing the gums with a swab. The largest
study of primary HHV-6 infection and subsequent persistence of the virus has been carried
out in Rochester, USA, where over a number of years cases of primary HHV-6 infection have
been identified and subsequently followed for evidence of persistence of the virus in the
index case as well as other family members. Saliva, PBMC's and CSF specimens have all
been examined [Hall 1998], PCR analysis of 258 saliva samples, obtained from children 2-5
years after primary infection, demonstrated 52% to be HHV-6 positive. In family members,
after PCR for HHV-6, 24% of 204 saliva samples collected from adults, and 52% of 235
samples collected from children were found to be positive. In sequential samples of saliva
obtained from 199 children over a period of 6 months to 5 years after primary infection (
median 2.2 years), HHV-6 DNA was detected in: 70% after 6 months - 1 year; 33% after 2
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years; 67% after 3 years; and 50% after 4-6 years. Only 15 % of follow up adult specimens
were repeatedly HHV-6 positive. These sequential findings from impressive numbers of
children give similar percentage positivity to that observed in our small cross-sectional cohort
of children.
In the early adult studies, HHV-6 was frequently found in saliva by PCR (63 - 90% of samples
tested positive) [Gopal 1990; Jarrett 1990; Cone 1993a] and virus isolation (92 - 100% of
samples tested positive) [Pietroboni 1988a; Harnett 1990; Levy 1990a] . However, in a small
study where throat swabs from adults (n = 30) and children (n = 49) were examined for HHV-6
DNA , only 3% of adults and 12% of children had HHV-6 positive swabs [Kido 1990], In
another small Japanese study HHV-7 was isolated frequently from the saliva of
immunocompetent adults (13/16) and children over one year (7/10), and no HHV-6 was
isolated [Hidaka 1993]. Cone et al demonstrated HHV-6 DNA in the saliva of 18 out of 20
healthy individuals, including one child, and the copy number ranged from zero - 200,000
HHV-6 genome equivalents per ml of saliva [Cone 1993a], In 15 cases repeat samples were
obtained after several months and similar results were obtained.Yamanishi has also described
higher rates of HHV-6 DNA in throat swabs from children (age range 2-8 years, 78.6%
positive) (International Herpesvirus workshop, Vancouver, 1994).
In a more recent study, where salivary HHV-6 and HHV-7 secretion as well as presence of the
viruses in salivary gland biopsies were tested. DNA of each virus was found in 63% and 75%
of the biopsies ( n =8), respectively [Di Luca 1995a], HHV-7 was found more frequently in all
the saliva samples tested ( HHV-6 & HHV-7: healthy adults (n = 31), 3% & 55%; patients
with recurrent aphthous ulcers (n = 12), 17% & 66%; adults with upper respiratory infections
(n = 16), 0% & 56%). These results are very different from those obtained in the recent study
mentioned above where 24% of adult samples were HHV-6 DNA positive [Hall 1998],
Another recent study of saliva from 44 healthy young adults (aged 19 -38 years, median 23 )
demonstrated 95% HHV-6 DNA positive [Aberle 1996].
Difference in the frequency of amplification of HHV-6 and HHV-7 from saliva may be related
to technical problems, as at the time of the earlier studies HHV-7 had not yet been identified
and the specificity of primers for HHV-6 alone had not been tested. However recent primers
used are known to be specific for HHV-6, implying that frequent shedding of HHV-6 in saliva
is a true finding [Di Luca 1995a; Aberle 1996; Hall 1998], The volume of saliva tested may
also be important if the virus is secreted in relatively low concentration, Di Luca et al extracted
DNA from 150gl of saliva , where Cone et al used 400pl of saliva. Differences in isolation of
virus may also be due to differences of technique, and direct comparison of throat swabs and
saliva samples may not be appropriate.
Although there is some controversy about frequency of secretion of HHV-6 and HHV-7 in the
saliva of adults, it would appear that it is less frequently shed than in children. As the large
study of Hall et al has demonstrated, HHV-6 is frequently shed in the saliva of children, who
have relatively recently been infected with the virus [Hall 1998], It could be hypothesised
that secretion of HHV-6 in saliva may wain with increased age or other factors.
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Most studies where saliva has been examined for HHV-6 DNA in immunocompromised adults
have only small numbers and conflicting findings. In a study were only 2/25 healthy controls
were HHV-6 DNA positive in saliva, 2/8 patients with lymphoproliferative disease, 4 /25
patients with Sjogren's syndrome and 3/18 patients with nasopharygeal carcinoma were also
HHV-6 PCR positive [Saito 1991]. In this study the group with the highest positivity for HHV-
6 were 4/8 patients with infectious mononucleosis who were also all EBV DNA positive.
In the small studies where HHV-6 has been cultured from saliva, no difference in isolation rate
was found between HIV positive or negative individuals [Pietroboni 1988a; Harnett 1990 ;
Levy 1990a]. By PCR however, one study demonstrated that patients with symptomatic HIV
infection had a lower rate of HHV-6 positivity in saliva and PBMC than healthy adults [Gopal
1990], Another study of 26 HIV positive patients demonstrated none to have HHV-6 in the
saliva although this was found in only 3% of healthy controls, but significantly more HIV
patients (81%) had HHV-7 than healthy controls (55%) [Di Luca 1995a]. Nearly half of these
patients had AIDS and 77% were on AZT, implying that this was quite an immunosuppressed
group. In a cohort with less severely affected HIV patients a higher frequency and higher
copy numbers of HHV-6 DNA was demonstrated in the PBMC's of patients with high rather
than low CD4 counts, but no significant correlation was seen with the copy number of HHV-6
in the saliva and stage of HIV disease or CD4 count [Fairfax 1994],
In a larger study HHV-6, HHV-7 and CMV were amplified from saliva and urine of 125 HIV
positive adults and 29 controls [Gautheret-Dejean 1997], All the viruses were found
frequently in the saliva of patients and controls ( HHV-6 - 43%, HHV-7 - 63%, and CMV -
61%) . All three viruses together were detected in 28% of samples and none in 18%.
HHV-7 and CMV detection did not differ between HIV seropositive and negative individuals,
but the rate of HHV-6 detection was higher in saliva of seronegatives (HIV negative - HIV
positive, 62% - 38%) (p = 0.023). The rate of DNA detection in saliva in the HIV positive was
not affected by CD4 count for any of the three viruses. However, CMV was detected most
frequently in the urine and its presence was associated with immunodeficiency and lower
CD4 counts (HHV-6 - 2%, HHV-7 - 6.5%, and CMV - 37%).
Where quantitative PCR is used then more information can be gained as to the amount of
virus present in different situations. A semi-quantitative PCR based on a known dilution
series demonstrate a positive relationship of CD4 count to HHV-6 genome copies in PBMC's
in patients with HIV, but no such relationship was found in the saliva [Fairfax 1994]. Healthy
controls were not included in the study , so it was not possible to compare directly salivary
HHV-6 concentrations between HIV positives and negatives. However, the median
concentration of HHV-6 in saliva of the HIV patients was 20,000 genome equivalents / ml
(range 0-125,000), this compares with a median value of 5,000 genome equivalents / ml
(range 0 - 200,000) obtained in healthy adults in a previous study by the same group of
researchers using the same methods [Cone 1993a],
Two of the above four studies in HIV infected adults demonstrated less frequent HHV-6 DNA
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in the saliva of patients than controls [Gopal 1990; Gautheret-Dejean 1997]. This finding is
of interest as it appears to concur with the findings of the present investigation where HHV-6
was found most frequently in the healthy children and least frequently in the most unwell
patients, with the important proviso, that the immunodeficiencies of the different groups are
not necessarily the same. Large scale saliva studies of HHV-6 in immunocompetent and
immunosuppressed children have not been undertaken, the small number tested in this
study being amongst the largest group. Small studies of HHV-6 transmission have looked at
the DNA of salivary virus in mothers and infants for evidence of transmission with inconclusive
results [Suga 1995; van Loon 1995], There is no other published information about salivary
secretion of this virus in immunosuppressed children to date.
HHV-6 in Serum
It was only possible to test 49% of serum samples collected from patients in this study for
HHV-6 DNA and none of them amplified the virus. The implication being that none of these
children had an active HHV-6 viraemia at the time of sampling. However, this number is too
small to make any real assessment of whether any of these children who were know to be
seropositive for HHV-6 were having any reactivation, or re-infection with HHV-6 during their
treatment.
Since this study was undertaken a number of other studies have examined the presence of
HHV-6 DNA in plasma or serum by qualitative and quantitative PCR. Prior to this, it was
demonstrated during primary infection that the virus could be cultured from plasma in 26 %
(25 /98) of cases where the sample was obtained within 4 days of onset of the fever but in no
(0 /78) samples obtained after 5 days from onset of fever [Asano 1991a]. It also appeared that
the children with more severe symptoms had more infected cells in the blood as well as more
free virus in the plasma. A number of studies have confirmed that HHV-6 DNA can be
amplified from serum / plasma during the primary infection in 50 to 86% of samples tested
[Huang 1992a; Secchiero 1995a; Clark 1997], Plasma samples from healthy adult controls
have not amplified HHV-6 DNA [Huang 1992a; Cuende 1994; Secchiero 1995a], In a PCR
study which included children and adults plasma viral DNA was present: in nearly all children
(6/7) with primary infection; in 23% (3/13) of BMT recipients, where it was associated with
fever and respiratory infection;and in 22% (4/18) of HIV infected adult patients [Secchiero
1995a], This semiquantative PCR could detect down to less than 10 molecules of HHV-6
template. The children with ES had 6 x103 - 6 x 103 DNA copies / ml plasma, all the other
positive samples had 1.5 x 103 -1.5 x 103 DNA copies / ml plasma, except one of the BMT
samples which had 1.5 x 103 -1.5 x 104 DNA copies / ml plasma. It was not possible to
isolate virus from any of the PCR positive samples in this study. Immune dysfunction in the
BMT patients and the HIV infected patients was considered to have allowed either re¬
infection or reactivation of infection with HHV-6. None of the immunosuppressed patients
were children.
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Quantitative PCRs for HHV-6 and HHV-7 has been developed, and used to detect virus in
tissue samples,PBMCs and whole blood, but not plasma or serum [Secchiero 1995b; Clark
1996], In a very large, prospective, longitudinal study of HIV infected adults, DNA PCR was
carried out on whole blood samples for HHV-6, HHV-7 and CMV [Fabio 1997]. In total, 1001
samples were tested, a median of 3 samples from 247 patients. CMV was detected in 17% of
patients, HHV-6 in 6%, and HHV-7 in 3%. The maximal median viral load per patient of CMV
(10,300 genome copies / ml blood) was significantly higher than that of HHV-6 (400 genome
copies / ml blood)or HHV-7 (400 genome copies / ml blood). In this study, as in others
[Fairfax 1994; Gautheret 1995], a positive relationship between high CD4 count and
presence of HHV-6 was also found. The authors suggest that quantitatively testing whole
blood may give more sensitive longitudinal information about virus activity in the
immunocompromised than testing plasma alone, since HHV-6 is not always detectable in
serum or plasma even in primary infection [Clark 1997].
Multiplex PCR's have also been developed for the herpes viruses and can be useful to
detect the presence of these several of these viruses in the same clinical sample, but their
use has not yet been reported in immunocompromised children [Tenorio 1993; McElhinney
1995],
Subtype types of HHV-6 amplified
All the saliva samples which amplified HHV-6 in this study were found to be type B, the most
common subtype of HHV-6 found in the PBMC's of children with primary infection [Dewhurst
1993]. The largest study of saliva from children and adults also demonstrated that the majority
of samples were type B HHV-6 (97%) [Hall 1998], Similarly in the PBMC's of HHV-6 infected
children and their family members over 96% of nearly 3500 samples tested were type B [Hall
1998], Where type A was amplified it was often in association with type B, and where one
family member had type A it did not make it more likely that other family members would also
have this type. The most interesting finding of this study was that HHV-6 positive CSF
samples from children with primary infection demonstrated a significantly different pattern,
with 14 % of samples HHV-6 type A positive. In these cases where HHV-6 could be amplified
from PBMC's as well it was always type B. The significance of this is difficult to explain, type A
virus has more frequently been found in immunosuppressed patients, and it is still not known
whether it has a different pathogenicity from type B, but the authors here suggest that HHV-6
type A may be a more neurotropic strain of the virus. As it is not possible to differentiate
serological responses to the two types it is not possible to ascertain if infection with the
different types is happening simultaneously or at different times.
In a study of 44 healthy young adults, where 95% had HHV-6 in saliva, and in all cases this
was type B HHV-6. In 25 cases type B HHV-6 was found in saliva and PBMC's, in 17 only in
saliva, and in 1 only in the PBMC's. Seven of the individuals were infected with type A, but
this was only in PBMC's and in 5 cases there was a dual infection with both types. Di Luca et
al found all their HHV-6 positive samples (5/ 8 salivary gland biopsies and 3/85 salivas) to be
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subtype B on restriction enzyme digestion [Di Luca 1995a]. In 71 HHV-6 DNA positive
samples (most saliva and a few urine) from HIV infected patients and controls, all but one
were type B, and the single type A was from the saliva of a healthy control [Gautheret-
Dejean 1997].
Although none of the serum samples from paediatric oncology patients in this study
amplified HHV-6 DNA, examination of the subtype of virus amplified from serum in other
studies has demonstrated both subtypes A and B. In the plasma study of Secchiero et al, all
the HHV-6 DNA from children with primary infection was type B, three HIV infected patients
had type A and one type B, and all three BMT patients had type A HHV-6 [Secchiero
1995a], implying that both types can cause an active viraemia, and although again in this
study the type A was more prevalent in the immunocompromised the pathogenic
significance of this remains uncertain.
Summary
This study has demonstrated firstly, that HHV-6 DNA (type "B") occurs commonly in the
mouths of normal healthy children without any obvious pathology and secondly, that children
immunosuppressed on chemotherapy also frequently appear to secrete HHV-6 without
evidence of ill health. Furthermore those who are febrile, neutropaenic and unwell less
frequently secrete the virus. Whether this might be a local effect of chemotherapy on salivary
production of HHV-6 was considered. HHV-6 DNA was not found in any of serum samples
tested, suggesting no evidence of active HHV-6 viraemia was found in this small group.
The possible role of HHV-6 virus as a serious pathogen in immunosuppressed patients
remains to be fully elucidated, but in this limited study of a paediatric cohort of
immunosuppressed oncology patients no evidence of deleterious virus activity was found.
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Summing up of the Serological and PCR studies of Human
Herpesvirus 6 infection in immunocompromised children
Criticism of techniques and methods
Numbers
The number of patients included in the serological study, both the cross sectional study of
children (n =66 patients and 66 controls) presenting with malignancy and the longitudinal
study of children on therapy ( n = 45 patients, 3 -33 samples per patient) was considered
quite adequate to identify any significant differences or changes in the serological
responses of the patients. However, prospectively collected saliva samples were obtained
from only 12 new patients (2-13 samples per child) as the number of children presenting that
year with malignancy was fewer than the usual expected (30 -40 per year). Although 115
samples were obtained altogether from the children, and the patients did appear to fall in to
two groups, those frequently HHV-6 DNA positive like the healthy controls and those rarely
positive, this pilot study would need to be extended to a larger cohort for the findings to be
confirmed. This is also the case for the serum study of HHV-6 DNA of which only a proportion
of the samples were tested.
Techniques
Serological study
For the IFA test a well established technique was used, without problems. This required
culture of HHV-6 infected lymphoblastoid cells and some batches did have a better level of
viral infectivity than others, but it was possible to confirm this with the monoclonal antibodies (
a gift from Dr P Coyle, Belfast). IFA is a subjective technique and was demonstrated to be
more likely to miss low positive sera than the ELISA. It was not possible to titrate out sera for
the IFA in this study, but this would have been an interesting comparison with the ELISA
index. Testing for antibody avidity in the samples would also have been of interest to identify
whether infection was recent or distant and whether there was any difference in the pattern
in the oncology patients.
Several attempts were made during the study to culture Z29 strain , "B" type HHV-6 as well as
the AJ strain, "A" type HHV-6, with the aim of identifying any difference in the antibody
responses to the two virus strains. Unfortunately the cultures of this strain of the virus (carried
out in another laboratory) were not successful and it was not possible to pursue this.
The ELISA developed for this study was a relatively crude test using a whole HHV-6 infected
and comparison uninfected cellular lysate as the coating antigen. Although it performed
consistently there are now more refined and indeed commercial ELISA kits for HHV-6
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antibodies [Sloots 1996; Nielsen 1996], The ELISA was only used for HHV-6 IgG antibody
testing. Had there been time to make the developments required to adapt it for IgM antibody
testing, then it would have been possible to test many more of the sequential patient
samples for IgM. Instead as only the IFA test was used, it was necessary to restrict IgM testing
arbitrarily to the cases where activity of other herpesviruses had been demonstrated.
With the development of more refined antigens from HHV-6 it will be possible to identify the
pattern of evolution of the antibody response to this virus. The responses to early and late
antigens maybe different between different groups. In one study, more patients with
lymphoma and Hodgkin's disease than healthy controls had antibodies to an early HHV-6
antigen [Iyengar 1991], implying that these patients had evidence of viral activity leading to
this continued response to the early antigen, similar to the different responses seen in
patients with ongoing EBV activity. A study of the evolution of antibody responses to a
number of the herpesviruses in immunosuppressed children might be helpful to identify
differences associated with virus activity.
PCR Study
The PCR developed for this study was across a segment of genome known to have a
restriction site present in type "B" and not type "A" HHV-6 and it appeared to perform
relatively well. However, its sensitivity may have been affected by the addition of Betaglobin
primers to the first round and the sensitivity experiments were not repeated with the added
betaglobin primers. It might also have been useful to carry out the sensitivity experiments
with an HHV-6 DNA dilution series in saliva, but the difficulty arises of having a base line
definitely HHV-6 negative saliva sample.
Developments at all the stages from extraction of DNA to visualisation of amplification
products of PCR have been rapid over the last decade. More sensitive and refined PCRs for
HHV-6 are now available which can detect very low copy numbers of virus in different clinical
tissues and have the advantage of being quantitative [Secchiero 1995b; Clark 1996], These
more refined techniques enable quantitative comparison between presence of virus in
patients and controls in different settings. Quantitative PCR would have been useful in this
study to examine more closely the differences in saliva results between patients and
controls, as well as between frequently and rarely HHV-6 secreting patients. Quantitative
PCR would also enable comparisons between the load of virus in the saliva, the PBMC's and
the serum in individual patients.
One of the main aims of this study was to look for evidence of virus activity in the host, but in
retrospect too few sites in too few patients were examined. Saliva was initially selected as a
secretion easily obtainable from patients and controls for comparison. Other clinical samples
which could have been examined in the patients include: nasopharyngeal aspirates,
PBMC's, urine and CSF (lumbar punctures are regularly carried out on children with
leukaemia for administration of treatment).
The only technique developed here was PCR for HHV-6 DNA, but other techniques also
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give very useful information about virus activity. Presence of viral antigen or mRNA imply the
virus is replicating, important additional information when considering latent DNA viruses. A
number of HHV-6 antigen detection tests have now been developed and used on clinical
samples [Marsh 1996; Yoshida 1996], It had been hoped as part of this study, using the
monoclonal antibodies to HHV-6, to develop a fluorescent method of staining PBMC's for
HHV-6 antigens suitable for analysis by flow cytometry. Early experiments with infected
lymphoblastoid cells were promising but it was not possible to extend to clinical samples.
Since there has elapsed considerable time between the completion of this study and the
writing up, many new techniques have been developed which could examine more
sensitively the activity of HHV-6 in immunocompetent and immunocompromised children.
However, although some of these tests are commercially available, most clinical laboratories
are still not set up to regularly measure either antibody responses to HHV-6 or for evidence
of viral activity. Clinically available, rapid diagnostic techniques for HHV-6 would appear
useful. This common infection in infancy can be clinically impossible to differentiate from
other more sinister causes of fever, rash, or CNS disturbance. Acute identification of the
virus would enable clinicians to discontinue searching for other causes and would be
generally clinically reassuring. Delay in acute viral diagnosis remains a problem for
paediatricians.
Assessment of Findings of the Serological and PCR studies
Serological study
The findings of this study were as might have been expected, almost all children presenting
with malignancy had an antibody response to HHV-6, similar to controls. For the few who did
not, young age was the likely important factor. There was one 9 year old child who had
leukaemia who remained IgM antibody negative on all samples tested over 60 months, and
IgG antibody negative on almost all samples (those weakly positive, were after blood
products). This child later had a relapse of his leukaemia and died. It could be speculated that
he had some kind of immune deficiency leading to his development of leukaemia but also
potentially his lack of response to this very common virus.
The longitudinal decline in ELISA index for HHV-6 IgG is most likely to represent decreased
lymphocytic function with chemotherapy. The ability to look at this more closely with
responses to different HHV-6 antigens, e.g. early or late antigens, might have given more
useful information as to the activity of the virus or the nature of the remaining antibody
response. The finding that older children with leukaemia had lower ELISA indexes than the
solid tumour patients might also represent some defect / altered immune function in these
children with malignancy affecting the lymphocytic system. This would need to be
investigated further, in more cases, with more sensitive techniques, as discussed above.
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It would also be of interest to examine the cytotoxic T cellular immune responses to HHV-6 in
immunosuppressed children as judging by evidence from the other herpesviruses, this is
probably the most important host protective response.
PCR Study
This study and others would appear to concur that HHV-6 is frequently to be found in the
saliva of seropositive children. The most interesting finding in the saliva study was the
difference in secretion of HHV-6 in the supernatants as compared to the pellets, presumed
to contain the oral cellular material. It would appear that secretion of HHV-6 into the saliva is
common in healthy children as well as the majority of the oncology patients. However in a
minority of patients virus was rarely found in the supernatant. This could be due to: the
effects of chemotherapy on the salivary glands; different phenotypes of saliva e.g. pH etc; or
effects of other infections in the mouth. It remains a paradoxical finding, that evidence of an
active infection should be less common in the ill / immunosuppressed than the healthy. To
examine this further it would again be necessary to look for direct evidence of virus replicative
activity (e.g. antigen or mRNA) in addition to presence of DNA , which may still be due to
latent infection.
That others have found a similar paradoxical relationship in the PBMC's, although not saliva,
of patients with HIV tends to back up the possibility that this may be a real phenomenon
[Gopal 1990; Fairfax 1994; Fabio 1997], With HHV-6 DNA more easily identified in more
intact immune system. Further investigation of this would again require detection of viral
antigens / mRNA's.
Too few serum samples were examined to give a true impression of whether this virus is
active in the blood of these patients. A much larger cohort requires to be tested, and this
should include samples from children with primary HHV-6 infection as positive controls.
No cases of HHV-6 infection were identified in this small study which would have been likely
to benefit from anti-viral treatment.
Further studies
As this study only examined a small number of children who in current terms were only mildly
immunosuppressed, subsequent work could examine HHV-6 activity in other groups of more
severely immunosuppressed children. Although there are some small studies which include
children, the activity of this virus in children with congenital immunodeficiency as well as
those undergoing bone marrow transplantation could be further explored. In future studies it
would seem worthwhile to examine the activity of families of herpesviruses rather than
individual viruses as their interactions may be very important. The most sensitive techniques
should be used to examine for viral activation and differences relating to clinical symptoms,
including graft failure / delayed engraftment in BMT patients should be sought. As always
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with clinical studies a considerable problem will be one of sufficient numbers and such a
study should be multi-centre.
The activity of HHV-6 in HIV infected children has not been examined longitudinally over
time. This would appear to be important as some small adult studies have demonstrated that
this virus may disseminate in patients with advanced HIV disease. Clinical problems with
herpesviruses have not always been the same in children as adults, e.g. with EBV related
lymphoma and kaposi's sarcoma, both much less common in childhood. Theoretical
interactions between HHV-6 and HIV could lead to progression of HIV related disease and
this has not been pursued in children. The fact that most adults infected with HIV already
have HHV-6 on board and have previously mounted an immune response to it is quite
different from the situation in children where HHV-6 infection follows the vertical acquisition
of HIV. Studies of herpesvirus activity in children are now more difficult as most children are
on highly active anti-retroviral therapy which is likely to affect immune responses to the
herpesviruses as well as suppress HIV replication.
The findings of the Zambian study of primary HHV-6 and HHV-8 infection in infants should be
confirmed and extended [Kasolo 1997], This study demonstrates activity of more than one
herpesvirus simultaneously and also, unlike all other studies of primary HHV-6 infection type
A HHV-6 infection was found in 44%. This may be of significance to later development of
virus associated disease such as Kaposi's sarcoma. It is also notable that EBV associated
Burkitts lymphoma is prevalent in sub-Saharan Africa, a possible link with the increased
prevalence of HHV-6 sub type A in children and activation of EBV with subsequent
development of lymphoma should be examined. The interactions of these herpesviruses
with HIV in children in the African setting in also worthy of further study. Such studies which
require sensitive and complex virological techniques are not easy to establish in a
developing world setting.
The presence of HHV-6 in salivary glands, and the likelihood that this is a site of latency for
the virus suggests that examination of HHV-6 activity could be undertaken in conditions
associated with salivary gland dysfunction. No relationship has been found with HHV-6 and
Sjogren's syndrome [Ranger Rogez 1995], However, it is of interest that up to 20% of
children with HIV infection have quite marked salivary gland swelling, particularly affecting the
parotid glands, often in association with lymph node enlargement. A relationship between
this sometimes distressing symptom to herpesvirus activity has not been demonstrated.
Saliva from HIV infected children has not been examined for HHV-6 or other herpesviruses.
Parotid swelling in HIV infected children is also often found in association with the syndrome
of lymphoid interstitial pneumonitis. The aetiology of this syndrome also remains obscure,
whether it is related to a lymphocytic response to HIV itself or to other infections, such as the
herpesviruses, deserves further investigation.
CNS persistence of HHV-6 and other herpesviruses has been demonstrated in a number of
small studies and the possibility that this can lead to later problems in the immunosuppressed
has been suggested. However the numbers are small and larger scale studies with better
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controls are required. A nation wide study of HHV-6 and HHV-7 in childhood encephalitis in
the UK has started this Autumn (Dr K Ward and Prof E Ross, with the Surveillance unit of the
Royal College of Paediatrics and Child Health), long term follow up of these children could be
of interest in terms of the potential on going, or later activity of this virus in the CNS.
Lessons learnt
Most of what we currently understand about HHV-6 implies that as a herpesvirus, it is of
relatively low grade pathogenicity to humans, both immunocompetent and
immunocompromised. Perhaps this is because it has an ancient relationship with its host
leading to a useful level of mutual symbiosis. Never the less, there remain areas of activity of
this virus which do need further investigation, in particular its interactions with the other
herpesviruses within the host which could be detrimental.
The small studies described in this thesis, small because of the numbers, time constraints
and finances, have added only the tiniest pieces to the jigsaw of understanding of HHV-6.
They could not have been expected to deliver much more, but in personal terms they have
taught important lessons. The opportunity to work alongside scientists and learn the
patience required to develop methods and apply them was greatly appreciated. Clinicians
always desire interpretable results urgently. The scientist has knowledge of the
development and problems of a method and the gaining of results maybe of secondary
importance. This study has helped to me to understand better the dilemma of application of
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Serological Response of Paediatric Oncology Patients
to Human Herpesvirus-6
E.G. Hermione Lyall
Department of Haematology and Oncology, Royal Hospital for Sick Children, Regional Virus Laboratory, and
City Hospital, Department of Medical Microbiology, University of Edinburgh Medical School, Edinburgh,
United Kingdom
The serological response of paediatric oncology
patients to human herpesvirus-6 (HHV-6) was in¬
vestigated at presentation and during treatment.
Sera from 66 patients presenting with malig¬
nancy and 66 controls were examined for anti-
HHV-6 IgG by indirect immunofluorescence test
(IFA) and enzyme linked immunosorbent assay
(ELISA), and for anti-HHV-6 IgM by IFA. Serial
samples from 45 children on chemotherapy
were examined for anti-HHV-6 IgG by ELISA and
sera from selected patients on chemotherapy
were examined for IgM by IFA. The response of
these patients to four other herpesviruses was
also investigated.
Ninety percent of presenting patients and con¬
trols were IgG positive for HHV-6 by IFA and
E.LISA. Anti-HHV-6 IgG as measured by the
Hh'V-6 ELISA index declined overtime in patients
on chemotherapy. Two presenting controls and
one leukaemic child with a primary cytomegalo¬
virus seroconversion were anti-HHV-6 IgM posi¬
tive. In the patient group seropositivity to
herpesviruses (types 1-6) increased with age,
the mean age of those with IgG to HHV-6 alone
was 3.7 years compared to 6.8 years for those
with antibodies to all five viruses.
At the time of presentation paediatric oncol¬
ogy patients h&ve a similar serological response
to HHV-6 as agy-matched controls and this IgG
response wanes with treatment. Whether this is
significant in terms of viral pathogenicity is not
known and will require investigation of viral ac¬
tivity in these patients. © 1994 wiley-Liss, inc.
KEY WORDS: serology, children, malignancy
INTRODUCTION
Children with malignancy are immu.nosuppressed as
a result of their disease and therapy, and lymphopaenia
with altered cell mediated immunity and decreased
antibody production increase their susceptibility to vi¬
ral infection [Van Der Meer, 19891. They ar>e also well
known to be at risk from primary and reactivated infec¬
tion with herpesviruses [Hirsch, 1989]. In view of this
susceptibility to herpesvirus infection and the lack of
information concerning human herpesvirus-6 (HHV-6)
infection in this group of patients an investigation of
the possible pathogenic role ofHHV-6 was undertaken.
HHV-6 is a ubiquitous virus known to infect almost
all children, with more than 90% showing an IgG re¬
sponse to HHV-6 by 2 years of age [Asano et al., 1990,
Ward et al., 1993a]. Placental transfer of anti-HHV-6
IgG antibody occurs and as levels decline within the
first 6 months of life, the infant becomes susceptible to
primary infection [Yoshikawa et ah, 1989]. Following
primary infection latency is established probably in the
salivary glands or the peripheral blood mononuclear
cells [PBMC; Fox et al., 1990; Luppi et al., 1993].
HHV-6 was originally isolated from the PBMC of
immunosuppressed patients with lymphoproliferative
diseases and with acquired immunodeficiency syn¬
drome [AIDS; Salahuddin et al., 1986]. It appears that
in immunosuppressed patients HHV-6 can reactivate
more easily and that the patients may carry an in¬
creased load of viral DNA [Luppi et al., 1993]. HHV-6
can be pathogenic in the immunocompromised popula¬
tion, and primary and reactivated infections have been
described [Ward et al., 1989, 1993b; Yoshikawa et al.,
1992.] The virus has been responsible for causing pneu¬
monitis [Carrigan et al., 1991], hepatitis [Ward et al.,
1989], and bone marrow failure [Drobyski et al., 1993].
There is little information specifically relating to im¬
munocompromised children, although a study of 25
Japanese paediatric bone marrow transplant recipients
demonstrated reactivation ofHHV-6 [Yoshikawa et al.,
1991].
Several techniques have been used to examine the
serological response to HHV-6 including the indirect
fluorescent antibody test [IFA; Tedder et al., 1987], an-
ticomplement immunofluorescence test [Okuno et al.,
1989], neutralisation test (NT) [Yoshikawa et al.,
19901, enzyme linked immunosorbent assay [ELISA;
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Asano et al., 1990], radioimmunoprecipitation [Coyle
et al., 1992], and immunoblotting (IB) [Coyle et al.,
1992], Early reports of the serological response to
HHV-6 tended to underestimate the seroprevalence
and this was probably related to the dilutions of sera
examined. The more recent consensus is that the IgG
response to HHV-6 is positive in greater than 90% of
people. The slightly lower rates found in fluorescence
assays may relate to the more subjective nature of these
tests and the difficulty in establishing clear cut offs for
low-positive specimens. Young children have the high¬
est geometric mean titres of antibody to HHV-6 and
antibody levels wane with age [Brown et al., 1988].
This paper describes a retrospective serological in¬
vestigation of the IgG and IgM responses to HHV-6 in
paediatric oncology patients using ELISA and IFA
tests. Samples were tested from children at the time of
presentation with malignancy and compared with con¬
trols. During the period of treatment with chemother¬
apy sequential samples were also tested. The response
of these patients to the other four herpes viruses
(herpes simplex virus [HSV], varicella zoster virus
[VZV], cytomegalovirus [CMV], and Epstein Barr virus
[EBV]) was also examined.
MATERIALS AND METHODS
Patients and Samples
The approval of the local paediatric ethical commit¬
tee was obtained for this study. Samples from paediat¬
ric oncology patients seen at the Royal Hospital for Sick
Children are routinely sent for viral serology at presen¬
tation before administration of blood products, and at
regular intervals during treatment. These samples are
tested at the Regional Virus Laboratory (RVL), City
Hospital, Edinburgh, and any surplus serum is stored
long term at -20°C. Computer search was used to iden¬
tify serum samples taken from oncology patients at
presentation, from January 1987 to December 1991. In
some cases the samples taken at presentation were ex¬
hausted. Sixty-six sera were identified (31 from acute
leukaemics [AL] and 35 from patients with solid tu¬
mours [ST]). These samples were age and season
matched to 66 stored sera from patients who presented
to the hospital in the same year with minor illnesses
(upper respiratory tract infection, pyrexia, or viral in¬
fection). The age range of patients was 1 month-13
years with a bimodal distribution with peaks at 3 and
10 years of age, representing the age range of children
presenting with malignancy. These sera were tested for
anti-HHV-6 IgG by IFA and ELISA, and for anti-
HHV-6 IgM by IFA.
All the sera from patients and controls were tested
for anti-VZV IgG and anti-CMV IgG by commercial
ELISA kits (Sigma). Previous results were available
from some patients for EBV and HSV antibody re¬
sponses. Anti-EBV IgG was tested by IFA on infected
EB3 cells and antibodies to HSV were titrated by the
complement fixation test (RVL standard methods, un¬
published).
Sequential sera from 45 patients (26 AL and 19 with
ST) on continuing chemotherapy who presented be¬
tween January 1989 and December 1991 were exam¬
ined for anti-HHV-6 IgG by ELISA. Three to thirty-
three samples were tested per patient depending on the
length of therapy. These samples were obtained ap¬
proximately monthly and there were more from the
leukaemics who underwent a longer course of therapy.
In 13 of these patients where the sample taken at pre¬
sentation was exhausted (9 AL and 4 with ST), samples
were available from within the first month of treat¬
ment, usually but not always, before administration of
blood products. The age range of the patients was the
same as for the presenting group with a similar bimo¬
dal distribution. Sequential sera from eight cases were
selected and tested for anti-HHV-6 IgM by IFA (two
asymptomatic seroconversions to CMV, five cases of
primary varicella or shingles, and one case who re¬
mained IgG negative to HHV-6 throughout treatment.
Cell Culture
Cells of the lymphoblastoid cell line JJhan were
grown in culture medium (RPMI with Hepes buffer,
foetal calf serum [10%], glutamine [2 mM], and penicil¬
lin [100 IU/ml] and streptomycin [100 p-g/ml]). The cells
were activated with phytohaemagglutinin (5 p.g/ml)
and then infected with the AJ strain of HHV-6 from an
infected aliquot of cells (a gift from Prof. R. Tedder
[Tedder et al., 1987]). At the time of infection the maxi¬
mal ratio of uninfected to infected cells was 10:1. After
7 days, successful infection of the culture was confirmed
with mouse anti-HHV-6 monoclonal antibodies (kindly
donated by Dr PA Coyle) and the cultures were har¬
vested for the IFA and ELISA tests. For IFA cells were
spotted onto slides, air dried, fixed in acetone, and then
stored at -20°C until required. On each slide well the
ratio of infected to uninfected cells per well was always
less than 50%.
Serological Tests
Indirect immunofluorescent-antibody test. A
positive and diluent only control was run on each slide.
Sera were tested for anti-HHV-6 IgG at a dilution of 1
in 10 in phosphate buffered saline, (PBS), pH 7.2, with
0.2% bovine serum albumin (BS,A). Slides were incu¬
bated in a moist chamber at 3?°C for 1 hour, washed
three times with PBS, and dri'ed. Fluorescein isothiocy-
anate (FITC)-conjugated, anti-human IgG (Scottish
Antibody Production Unit-SAPU) was applied to slides
at a dilution of 1 in 80 and incubated for 30 minutes at
37°C. Slides were then washed twice in PBS and once in
phosphate buffer (PB), pH 8.4, dried, and mounted for
examination under ultraviolet light. Large bright dots
of fluorescence, mostly intracytoplasmic but also intra¬
nuclear, particularly apparent in ballooned cells and
syncytia, were observed with anti-HHV-6 IgG positive
sera.
Sera tested for anti-HHV-6 IgM were diluted 1 in 10
with IgG blocking agent (Incstar), incubated for 15
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TABLE I. Seroprevalence of HHV-6 IgG in Patients and Controls by ELISA and IFA
(Including All Patients and Controls and Those Under 1 Year)
Positive Negative Equivocal Not suitable
(%) (%) (%) (%) Total
ELISA patients (ALL) 64 (97) 2(3) 66
IFA patients (ALL) 61 (92.5) 4(6) 1 (1.5) 66
ELISA controls (ALL) 61 (92.5) 3 (4.5) 2(3) — 66
IFA controls (ALL) 58 (88) 4(6) 3 (4.5) 1 (1.5) 66
ELISA patients and controls 6(60) 4(40) — — 10
(<1 year)
IFA patients and controls 5(50) 5 (50) — — 10
(<1 year)
minutes at room temperature, and after pulse centrifu-
gation, the supernatant was applied to slides for 3
hours at 37°C. The slides were washed three times with
PBS, dried and FITC conjugated, and anti-human IgM
(SAPU) diluted 1 in 32 was applied for 1 hour at 37°C.
Slides were then washed and mounted, as above, for
examination under ultraviolet light. The pattern of flu¬
orescence with IgM positive sera was of finer cytoplas¬
mic and surface brightness, often most marked in the
ballooned cells.
ELISA. The method of Chou and Scott (1990] was
adapted and used to detect anti-HHV-6 IgG with an
alkaline phosphatase detection system [Cubie et ah,
1993]. Antigen was prepared by the same method from
infected and uninfected cells. Cells (3 x 107) were cen-
trifuged at 1,200#, suspended in 4 ml of chilled glycine
buffer (pH 9.5), and sonicated on ice for 30 seconds. The
sonicate was centrifuged at 5,000# for 20 minutes and
the supernatant stored at — 70°C.
Antigen was diluted in glycine coating buffer (pH
9.5) to give an optimal working dilution of 1 in 160
(protein content of 5 p.g/ml) and used to coat microtitre
plates. Alternating 8 well rows of a 96 well microtitre
plate (Nunc) were coated with either 100 p.1 of infected
or uninfected antigen and incubated overnight at 4°C.
The plate was washed three times with PBST washing
buffer (PBS, pH 7.2, with Tween [0.05%] and BSA
[0.1%]). Remaining binding sites were blocked with 200
p.1 of PBST (with 5% BSA) at 37°C for 1 hour and the
plate was then washed three times. Coated and blocked
plates could be stored at 4°C for at least 1 week before
use. An automated ELISA plate washer was used for all
washes.
One hundred microliters of sera diluted 1 in 100 in
PBST (with 1% BSA) was applied to pairs of wells and
incubated for 2 hours at 37°C. After three washes, 100
ixl of diluted (1 in 1,000) anti-human IgG conjugated
with alkaline phosphatase (Sigma) was added to each
well for 1 hour at 37°C. After five washes, 100 p.1 of the
substrate para-nitrophenyl phosphate (1 mg/ml in
freshly made diethanolamine buffer, pH 9.8) was added
to each well and incubated at room temperature, in the
dark, for 30 minutes. The reaction was stopped with 50
p.1 of 3 M sodium hydroxide and the absorbance read at
405 nm.
As the antigen was a crude cell lysate, it was neces¬
sary to test each serum sample on both infected and
uninfected antigen. Some sera had a stronger back¬
ground reaction with the uninfected antigen than oth¬
ers and this was compensated for by using the differ¬
ence between the two absorbances to calculate the
ELISA index: (absorbance infected cells — absorbance
uninfected cells)/(negative cut off).
The following control sera were included on each mi¬
crotitre plate: a strong positive; a low positive; and
three negatives. The plate was blanked on a well incu¬
bated with diluent only. The negative cut off for the test
was the mean difference in absorbance of the three
negative controls plus 3 standard deviations, but if this
figure was less than 0.1 then 0.1 was used. The ELISA
index was considered to be positive if greater than 1.1,
negative if less than 0.9, and equivocal between 0.9 and
1.1.
Statistical Methods
The results from the ELISA of the presenting cohort
of patients were converted to positive, negative, or
equivocal for comparison with the IFA results. The data
were analysed by the chi-squared test or Fisher's exact
test for groups of data with very small numbers. A
repeated measures model which allows correlation be¬
tween the repeated values from the same patient was
applied to the sequential data from patients on treat¬
ment so the effects of time, age at presentation, and
diagnosis on the trends in the ELISA values could be
analysed [Jennrich and Schlucher, 1986]. The statisti¬
cal package used was SAS (PROC MIXED).
RESULTS
Comparison of IFA and ELISA for Anti-HHV-6
IgG
There was no significant difference in the results ob¬
tained by these two tests in the presenting cohort of
patients, although there were more equivocal and neg¬
ative sera by IFA (Table I). The high degree of concor¬
dance between the tests is demonstrated in Figure 1. In
particular all of the sera which tested negative by
ELISA also did so by IFA. Haemolysis of these small
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Fig. 1. Comparison of ELISA index and IFA test results for HHV-6
IgG from all presenting sera, patients, and controls. The dotted line
represents the cut off between positive and negative ELISA results.
Presenting Samples From Oncology Patients
and Controls
Antibodies to HHV-6 at presentation. Around
90% of patients and controls were anti-HHV-6 IgG pos¬
itive by both tests and there was no significant differ¬
ence in seropositivity for anti-HHV-6 IgG between pa¬
tients or controls (Table I). ST patients were as likely as
leukaemics to develop antibody. The proportion of se¬
ropositive cases in children under 1 year was lower
(50—60%), but there was no significant difference be¬
tween the patients or controls in this small group. By
ELISA only five children had no antibody to HHV-6:
two were patients, a 6-month old with neuroblastoma
and a 9-year-old with AL (see below); all three controls
were infants aged 4, 6, and 7 months.
IgM antibodies to HHV-6 were found in two control
patients, an 8-year-old with a febrile illness and a 13-
month-old with an upper respiratory tract infection.
One leukaemic patient was also positive for IgM at
presentation (see below).
Antibodies to five herpesviruses at presentation.
There was no significant difference in response to VZV
or CMV between patients or controls. Two thirds of
patients and controls had IgG to VZV and one third of
patients and controls had IgG to CMV (Table II). Evi¬
dence ofpast EBV infection was found in 33 (62%) of the
53 patients' samples available for testing while HSV
antibodies were detected in only 9 (15%) of 61 patients
tested. Again there was no significant difference in re¬
sponse between patients with ST or leukaemia.
In the patient group complete results of serological
response to the five herpesviruses were available in 52
(79%) patients, and demonstrated an IgG response to an
increasing number of herpesviruses with increasing
age. Where the child only had antibody to one herpesvi¬
rus this was usually HHV-6. The mean age of children
who only had IgG to HHV-6 was 3.7 years compared to
6.6 years for the remainder who had antibodies to two
or more herpesviruses, including HHV-6.
Sequential Sera From Patients on
Chemotherapy
Anti-HHV-6 IgG in sequential sera. Six hundred
seventy-six sequential specimens from 45 patients were
examined for anti-HHV-6 IgG. Five hundred forty-four
samples were obtained from the 26 leukaemia patients
(9-33 samples per child). One hundred thirty-two sam¬
ples were tested from the 19 patients with ST (3-15 per
child). The majority of samples were positive for anti-
HHV-6 IgG. One 9-year-old leukaemic child had no
antibody to HHV-6 in the first sample tested, 23 further
samples from this child were tested, 3 had an ELISA
index of just over one, however each time this subse¬
quently became negative and he remained negative 2
years later when his leukaemia relapsed. All sera from
this child were negative for anti-HHV-6 IgM.
A repeated measures model was fitted to all the data
from these patients to analyse the effects of time, age at
presentation, and diagnosis (AL or ST) on any trends in
the ELISA Index values obtained. There was no overall
significant difference between AL or ST patients with
both groups showing a decline in ELISA index over
time. The slope of this decline was not significantly
different between the two groups ofpatients when com¬
pared over a 1-year time period. The relationship be¬
tween age and ELISA index was different between the
two groups, in the ST patients there was little differ¬
ence in ELISA Index values with age, but older AL
patients tended to have lower values (P = 0.039).
Anti-HHV-6 IgM in sequential sera. Sequential
sera from six patients with changes in activity against
other herpesviruses were examined for anti-HHV-6
IgM. There were two children who seroconverted to
CMV asymptomatically. One produced a fourfold rise
in anti-CMV IgG titre and was strongly positive for
anti-CMV IgM at the time of seroconversion, again 3
months later, but in no other later sample. None of the
29 samples from this child had anti-HHV-6 IgM. In
contrast the other patient had anti-HHV-6 IgM at pre¬
sentation, but insufficient sample remained to test for
anti-CMV IgM. Two months after starting treatment
he had a fourfold rise in anti-CMV IgG titre and was
strongly positive for anti-CMV IgM, at the same time
demonstrating IgM to HHV-6. Over the next 21 months
of therapy nine samples were positive for anti-HHV-6
IgM, five of these were also positive for anti-CMV IgM,
one was negative, and three could not be tested (Fig. 2).
None of the cases of varicella zoster infection were asso¬
ciated with production of IgM to HHV-6.
DISCUSSION
More than 90% of the presenting patients and con¬
trols in this study had IgG to HHV-6 by ELISA and
slightly less by IFA (Table I). The interpretation of the
fluorescent antibody test, being visual, is more subjec¬
tive and the differentiation of low positives from nega¬
tives is difficult. Although the ELISA used a crude cell
lysate as antigen, lysates of both infected and unin¬
fected cells were used in parallel and the difference in
absorbance was used to calculate an HHV-6-specific
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TABLE II. Seroprevalence for HHV-6, CMV, VZV, EBV, and HSV IgG in Presenting Patients and Controls
CMV VZV EBV HSV
Positive Negative Equivocal Positive Negative Equivocal Positive Negative Positive Negative
HHV-6
Positive patients" 18 39 7 41 22 1 32 19 9 50
Positive controls 21 38 4 40 20 3 NA NA NA NA
Negative patients — 2 — 2 — — 1 1 — 2
Negative controls 1 2 — — 2 1 NA NA NA NA
"Equivocal results added to positive results.
Months of Treatment
Fig. 2. Sequential serology for HHV-6 and CMV from a leukaemic patient who seroconverted to CMV.
IgG to HHV-6 (ELISA Index) and CMV (antibody units/ml) is recorded on the graph and IgM production
to HHV-6 and CMV is recorded in the table. NT, not tested; P, IgM positive; O, IgM negative.
ELISA index. The ELISA test results demonstrated a
relatively clear separation between positive and nega¬
tive sera with few equivocal results and all the samples
which were negative by ELISA were also negative by
IFA (Fig. 1). The percentage of anti-HHV-6 IgG sero-
positivity in previous studies has varied according to
the tests used, the dilution of serum tested, and the age
range of the subjects. In paediatric populations studied
beyond the age of 1 year, the anti-HHV-6 IgG seroposi-
tivity is up to 100%, with the highest seropositive rate
obtained by ELISA and NT [Asano et al., 1990;
Yoshikawa et al., 1990].
Antigenic cross-reactivity with other herpesviruses
might affect the apparent response to HHV-6, although
the work of several investigators would refute this. Ab¬
sorption of antibodies to other herpesviruses does not
reduce titres to HHV-6 by IFA or ELISA [Saxinger
et al., 1988; Buchbinder et al., 1989; Linde et al., 1990],
There is no correlation between antibody titres to dif¬
ferent herpesviruses and HHV-6 by IFA, ELISA, or IB
(Salahuddin et al., 1986, Saxinger et al., 1988, Asano
et al., 1990), and the majority of individuals seronega¬
tive for CMV and EBV are HHV-6 seropositive [Linde
et al., 1988].
This study confirms that most paediatric oncology
patients have encountered HHV-6 at presentation and
appear to have a similar response to the virus as age-
matched controls. The findings are in agreementwith a
recent study which examined sera from 50 patients
with acute lymphoblastic leukaemia (age range 1—52
years, mean age 17.6 years), in which there was no
significant difference in titres for anti-HHV-6 IgG be¬
tween cases and controls, by IFA or ELISA [Levine
et al., 1992a]. In contrast earlier IFA test studies of
adult patients with leukaemia and lymphoma had sug¬
gested the seroprevalence and antibody titres to be
greater in patients than controls [Ablashi et al., 1988;
Clark et al., 1990]. Further investigation of the serolog¬
ical response of paediatric oncology patients could in¬
clude examination of the pattern of avidity of the IgG
response to HHV-6 as well as the response to different
HHV-6 antigens. It has been shown that low avidity
IgG is produced in the first few months after primary
HHV-6 infection, followed by high avidity antibodies
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later [Ward et al., 1993a], In a study by Iyengar et al.
[1991] most normal sera tested positive for a late
HHV-6 antigen and only one third for an early HHV-6
antigen. Seropositivity for the early antigen was in¬
creased in patients with lymphoproliferative disease,
which could indicate increased activity of the virus and
possibly an altered immune response of the host.
Five presenting sera had neither IgG nor IgM to
HHV-6 by ELISA or IFA, three were from control pa¬
tients, and one from a ST patient all under the age of 1
year. The fifth serum was from a 9-year-old leukaemic
patient who was seronegative at presentation but
tested IgG positive in 3 samples out of 23, and who was
negative at relapse 2 years later. No samples from this
child were IgM positive making it unlikely that he un¬
derwent primary seroconversion. It is much more likely
that these unsustained rises in IgG antibody were re¬
lated to blood products received. At presentation there
was IgG to VZV but no other herpesviruses.
Examination of the sequential sera from patients on
chemotherapy for anti-HHV-6 IgG demonstrated no
significant difference between ST and AL patients
when compared over the same time period. Although
the trend in anti-HHV-6 IgG was downward with time,
there was little evidence of large fluctuations in IgG
levels which might be expected if reactivation of
HHV-6 had occurred. In a longitudinal study of 37 pa¬
tients with Hodgkin's disease (age range 5-72 years)
IFA titres increased significantly in patients who re¬
lapsed and decreased significantly over time in those
who did not [Levine et al., 1992b]. It was not possible to
examine any relationship between changes in ELISA
indices and relapse of disease in the current study. The
finding that older children had lower ELISA Indexes
for HHV-6 reflects that of other workers who have
shown that the highest geometric mean titres for
HHV-6 IgG are found in young children [Brown et al.,
1988; Yoshikawa et al., 1990].
It was not possible to test all the sera for anti-HHV-6
IgM and so sera from five patients who had demon¬
strated laboratory and/or clinical evidence of herpesvi¬
rus activity were selected. In this small group VZV
primary and reactivated infection did not appear to
cause reactivation ofHHV-6 with IgM production. Pri¬
mary CMV infection can be associated with rising titres
of IgG to HHV-6 and also IgM to HHV-6 [Chou and
Scott, et al., 1990; Irving et al., 1990; Ward et al., 1991 ].
One of the two children in this group with primary
CMV infection made no IgM to HHV-6 at all and the
ELISA index for anti-HHV-6 IgG remained unchanged.
The other child produced anti-HHV-6 IgM on several
occasions, including at presentation, but again the
ELISA index for anti-HHV-6 IgG remained steady with
no significant change in relation to the rise of anti-
CMV IgG (Fig. 2). HHV-6 and CMV are closely related
genetically with shared immunogenic surface glycopro¬
teins and yet there does not appear to be significant IgG
antibody cross-reactivity [Chou and Scott, 1990; Irving
et al., 1990]. Avidity studies have shown that immuno¬
competent and immunosuppressed patients with pri¬
mary CMV infection produce anti-CMV IgG of low
avidity and anti-HHV-6 IgG of high avidity, implying
reactivation of HHV-6 infection with a different anti¬
body response [Ward et al., 1993b]. IgM production
without changes in IgG antibody level to HHV-6 has
been demonstrated during reactivation [Enders et al.,
1990].
While the serological response to all five herpesvi¬
ruses was examined for 52 (79%) of the patients data
were only available for CMV and VZV for the control
patients. However, in this group of children aged from
less than 1—13 years the overall seropositivity for pa¬
tients and controls was similar for VZV (65% and 60%,
respectively) and CMV (27% and 33%, respectively). In
the patient group the acquisition of herpesvirus infec¬
tion increased with time even in this population, and
not surprisingly it appeared that when a child had anti¬
bodies to only one herpesvirus this was usually HHV-6.
This study has demonstrated that paediatric oncol¬
ogy patients, whether ST or leukaemic patients, have a
similar response to HHV-6 as age-matched controls and
that almost all have encountered the virus at the time
ofpresentation with disease. The seroprevalence for the
two herpesviruses, VZV and CMV, is also similar be¬
tween controls and patients. Sequential samples from
patients during immunosuppressive treatment showed
a gradual decline in ELISA index for IgG to HHV-6
with time but did not give any helpful information as to
whether reactivation of HHV-6 was occurring. IgM to
HHV-6 was produced by one child with a primary CMV
seroconversion but again this did not conform reactiva¬
tion and the possibly of antibody cross-reactivity could
not be excluded.
Assessment of serological response in the immuno¬
compromised will always give an incomplete picture of
the host response. To ascertain further whether this
virus is pathogenic in immunosuppressed children the
next phase of this study will examine for evidence of
viral activity in such patients.
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Human Herpesvirus-6 DNA in the Saliva of Paediatric
Oncology Patients and Controls
E.G.H. Lyall and H.A. Cubie
Royal Hospital for Sick Children (E.G.H.L.) and Regional Virus Laboratory (H.A.C.), City Hospital, Edinburgh,
United Kingdom
Children with malignancy are immunosup-
pressed and susceptible to serious infections
with herpesviruses. The majority of children on
chemotherapy for malignancy are seropositive
for human herpesvirus-6 (HHV-6), and although
HHV-6 has been demonstrated to be a pathogen
in severely immunocompromised patients,
whether this is the case for paediatric oncology
patients is unknown.
HHV-6 is secreted in saliva and in this study
samples were examined prospectively for HHV-6
DNA in healthy children and those with malig¬
nancy. In a nested polymerase chain reaction
(PCR), a 287 bp outer fragment and 163 inner
fragment of HHV-6 DNA were amplified. The re¬
sulting amplimer contained a Hind III restriction
site present only in "B" type HHV-6 and this was
used to identify the type of HHV-6 amplified. In
saliva from healthy control children, 74% (28/38)
of samples were HHV-6 DNA-positive in either
the supernate, pellet or both. In the patients, 58%
(45/77) of all samples were HHV-6 DNA-positive.
When sequential samples from twelve patients
were examined the children appeared to fall into
two groups: those who were frequently HHV-6
DNA-positive (60% of samples or more) and
those who were rarely HHV-6 DNA-positive (33%
of samples or less) (P < 0.0001). The only appar¬
ent difference between these two groups was
that the less frequently HHV-6-positive group
was more often febrile and unwell with neutro-
paenia. Hind III digestion demonstrated all the
positive samples to be "B" type HHV-6. Possible
explanations for this difference in HHV-6 secre¬
tion between the patient groups are discussed.
© 1995 Wiley-Liss, Inc.
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sananonda et al., 1992], The classical infectious syn¬
drome of exanthem subitum does not always occur and
many infections are sub-clinical. In common with the
other herpesviruses, once primary infection has oc¬
curred, latency is established in salivary glands and
blood mononuclear cells [Fox et al., 1990; Luppi et al.,
1993],
Children with malignancy are immunosuppressed as
a result of their disease and also their treatment and
are well known to be susceptible to herpetic infections
[Hirsch, 1989]. HHV-6 can be a pathogenic virus for
immunosuppressed patients including bone marrow
transplant patients, liver transplant patients and oth¬
ers [Drobyski et al., 1993, Ward et al., 1989].
Whether it is pathogenic for paediatric oncology pa¬
tients on chemotherapy is not known. The majority of
such children have IgG for HHV-6 at presentation and
levels ofantibody wain with treatment, but detection of
IgG or IgM antibodies to HHV-6 is not a reliable indica¬
tor of current virus activity in these patients [Lyall,
1994],
The aim of this study was to develop a nested poly¬
merase chain reaction (PCR) for HHV-6 which could be
used to examine the saliva of paediatric oncology pa¬
tients and controls for HHV-6 DNA, giving direct evi¬
dence that HHV-6 is present in the saliva. Saliva was
chosen for examination as a source for HHV-6 because
it has frequently been shown by PCR to contain HHV-6
DNA in adults, but to date has only been examined in a
few children [Cone et al., 1993]. Saliva is also an accept¬
able secretion to obtain voluntarily from healthy chil¬
dren. The study aimed to compare findings in the saliva
of normal healthy children with sequential samples
from paediatric oncology patients.
METHODS
Patients and Controls
Ethical committee approval and consent of parents
and children were obtained. Twelve new patients aged
3 to 13 years who attended the oncology service of the
INTRODUCTION
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Royal Hospital for Sick Children between August 1992
and September 1993 were enrolled. Seven had leu¬
kaemia and five, solid tumours. The first patient sam¬
ple was obtained before starting chemotherapy and
thereafter samples were obtained when the patients
attended for treatment or were febrile and unwell. Sev¬
enty-seven saliva samples were obtained from the 12
patients. Healthy siblings and local volunteer children
acted as normal controls. Thirty-eight control samples
were obtained from 27 healthy volunteer children and
10 siblings (two samples from one sibling), age range
4-16 years. The saliva supernate and cell pellet from
each sample was examined for HHV-6 DNA. At presen¬
tation, serum from each patient was tested for anti-
HHV-6 IgG by fluorescent antibody test [Lyall, 1994],
Preparation of Saliva for PCR
Saliva samples were obtained after a fifteen second
gargle with five ml of normal saline and processed as
soon as possible. After vortexing, the saliva was centri-
fuged at 1,000 rpm for 8 min and the supernatant sepa¬
rated from the cell pellet. Foetal calf serum (1.5%) and
ampicillin were added to the supernates and 0.5 ml of
viral transport medium was added to the pellets. The
samples were stored at — 70°C and were tested together
in batches. Two hundred pi of the samples were mixed
with an equal volume of double strength lysis buffer to
give a final concentration of 100 pg/ml proteinase K,
0.02 mM Tris HC1 pH 7.5, 0.01 mM EDTA and 1%
Tween 20. The samples were incubated for 90 min at
55°C and 10 min at 95°C. DNA was then extracted from
the sample using phenol chloroform and precipitated
over night at -20°C in pure ethanol [Sambrook et al.,
1989]. The DNA was resuspended in 100 p.1 of water
and 10 p.1 added to the first round PCR.
Sequence of Genome Chosen for Amplification
A sequence of the large tegument protein gene (LTP
gene) [Josephs et al., 1991] which contains HHV-6
strain variations demonstrated by restriction enzyme
digestion [Aubin et al., 1991, 1993] was chosen for am¬
plification. A Hind III digestion site at position 2945 of
the LTP gene was shown to be present in "B" but not
"A" type strains of HHV-6. This has been used to dis¬
criminate between the two types of HHV-6 [Dewhurst
et al., 1992, 1993], To increase sensitivity and specific¬
ity, a nested PCR was designed to amplify a 287 bp
outer segment and the 163 bp inner segment across the
Hind III restriction enzyme site (position 2817-3103).
The following primers were used: 1 outer, 2817-2840,
5'-agt cat cac gat egg cgt get atc-3'; 2 outer, 3103-
3081, 5'-tat eta gcg caa teg eta tgt cg-3'; 3 inner, 2879-
2902, 5'-tcg act etc acc eta ctg aac gag-3'; 4 inner, 3041-
3018, 5'-tga eta gag age gac aaa ttg gag-3'. Any samples
which amplified HHV-6 DNA were then digested with
Hind III and the product run on an agarose gel stained










287 bp Outer PCR Product
163 bp Inner PCR Product
i Hind III digestion
66bp 97bp
163 bp
"B" type HHV-6 two fragments
"A" type HHV-6 one fragment
Fig. 1. Diagram of the plan for nested PCR for HHV-6 and identifi¬
cation of any amplified products as either HHV-6 type "A" or "B"
according to the effect of Hind III digestion.
Nested PCR Method
A series of experiments was undertaken to optimise
the nested PCR for the detection of low copy numbers of
HHV-6 genome. A hot start (80°C) was used for the first
round PCR to minimise non-specific priming and in¬
crease sensitivity. In the first and second rounds of
amplification 30 cycles were used, the first denatur-
ation, was for 5 minutes at 94°C and all subsequent
denaturations for 1 minute, annealing was for 1 minute
at 60°C, and extension for 1 minute at 72°C, except for
the last cycle where extension was for 8 minutes. In the
first round reaction, 10 pi of extracted sample was
added to 90 p.1 ofmix and in the second round 2 pi of
first round product was added to 48 pi ofmix. The same
reaction mix was used for each round. Two units ofTaq
polymerase (Perkin Elmer, U.K.) with the manufactur¬
er's buffer, 1 pM of primers, 0.2 mM of d-Nucleoside
triphosphates, and 1.5 mM ofmagnesium chloride were
used per reaction. Great care was taken to avoid con¬
tamination at all stages of the PCR process.
All saliva supernate and pellet samples were sub¬
jected to nested PCR twice. Samples were amplified in
batches of 28: including three water controls; one unin¬
fected lymphoblastoid cell line negative control; and
three positive controls containing 30, 300, and 3,000
HHV-6 amplified genome segments of type "A" from
the AJ strain of the virus (a kind gift from Professor R.
Tedder). The products of the amplification were run on
a 3% agarose gel containing ethidium bromide. Positive
samples were digested with the restriction enzyme
Hind III for one hour at 37°C. Products of digestion
were run on a further ethidium bromide-stained gel.
Any sample which never amplified DNA on any occa¬
sion was checked for inhibition of PCR by "spiking" an
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Lanes 15 10 15 20 25 30
1 63bp
Fig. 2. Agarose gel of patient saliva samples for nested PCR for HHV-6 DNA. Lanes 1 and 30: DNA
molecular weight marker: lanes 9, 17, 29: water controls; lanes 25-27: HHV-6 amplimer controls; lane
28: uninfected lymphoblastoid cell line control; lanes 2, 3, 5, 8, 10, 11, 15, 16, 18, 20, 22-24: HHV-6-
positive samples; lanes 4, 6, 7, 12-14, 19, 21: HHV-6-negative samples.
aliquot with 600 HHV-6 amplimers as a template and
then repeating the nested PCR.
Statistics
Nonparametric tests were used to compare these
small groups of patient samples including the Chi-
squared test and the Mann-Whitney U-test.
RESULTS
Specificity and Sensitivity of the Nested PCR
for HHV-6
The sensitivity of the method was assessed by using a
dilution series of extracted DNA from Type "A" HHV-6
(AJ strain). Positive bands were observed on agarose
gel down to an input of 16 fg of DNA (equivalent to 93
copies of HHV-6 genome). Using DNA after a single
round of amplification as input, the nested PCR had a
detection limit of 1-10 ag on agarose gel, equivalent to
3 HHV-6 amplimers. The specificity of the primers cho¬
sen was demonstrated by lack of amplification of DNA
extracted from six other herpesviruses. HSV-1, HSV-2,
CMV and VZV were all obtained as laboratory isolates.
EBV was cultured from the EB3 cell line and HHV-7
DNA was a kind gift from Dr. D. Clark, Royal Free
Hospital, London (data not shown).
Performance of PCR
In 65% of runs, dilutions ofA type virus were positive
down to 30 genome copies, while in the remaining runs
the detection limit was 300 copies. No amplified HHV-6
DNA was even found after PCR in any of the water or
lymphoblastoid cell controls. Agreement in duplicate
PCR runs was obtained in 74% of supernate samples
and 76% of cell pellets, the discrepancy in results sug¬
gesting that some PCR runs were more sensitive than
others. Samples were interpreted as positive if they
were PCR-positive on at least one occasion. Spiking
experiments demonstrated only one saliva pellet and
two supernates were inhibitory for the PCR.
PCR Results for All Samples
When the total number of samples obtained was con¬
sidered and the results obtained for the pellet and su-
TABLE I. Results of HHV-6 PCR for All Samples Tested
Patients Controls Statistics
no. (%) no. (%) Chi-square
HHV-6 PCR
Supernate 30/77 (40) 23/38 (61) P < 0.05
Pellet 31/77 (40) 21/38 (55) NSa
Both 45/77 (58) 28/38 (74) NS
aNS, not significant.
pernate were summed, then 28/38 (74%) of control sa¬
liva samples and 45/77 (58%) patient saliva samples
were PCR-positive for HHV-6 DNA (Fig. 2). When the
supernate and pellet results were considered separately
then 23/38 (61%) of control supernate samples and
30/77 (40%) patient supernate samples were PCR-
positive for HHV-6, and 21/38 (55%) of control pellet
samples and 31/77 (40%) patient pellet samples were
PCR-positive for HHV-6 (Table I). All the PCR-positive
samples digested with Hind III and gave two fragments
on agarose gel confirming them as DNA from "B" type
HHV-6 (Fig. 3). No "A" type HHV-6 was identified in
this group ofpatients or controls.
PCR Results for Individual Patients
All the patients were seropositive for HHV-6 IgG at
presentation. The samples were obtained at regular in¬
tervals from the time of diagnosis until the end of the
collection period, when the children were either well or
febrile and unwell and the number of samples obtained
per child varied from 2 to 13 (Table II). The ratios of
positive/negative samples for each child were compared
and revealed two distinct groups of patients, those with
mainly HHV-6-positive saliva and those with mainly
HHV-6-negative saliva (Chi-squareP < 0.0001). There
was no difference between these two groups for age,
total white blood count or absolute lymphocyte count.
However, in the mainly HHV-6-negative group, there
were more febrile children (10/30 HHV-6 PCR-negative
versus 7/47 HHV-6 PCR-positive Chi-squareP = 0.05)
and they had lower absolute neutrophil counts (Mann-
Whitney U-test P = 0.02).
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TABLE II. Details of Patients' Sequential Saliva Samples and PCR for HHV-6
Patient Diagnosis Age Weeks HHV-6 PCRd HHV-6 PCR HHV-6 pos/ Febrile6 Well6
group and no.a ST/ALb yrs followed" positive negative total samples Pos Neg Pos Neg
A1 ST 3 9 4 0 __ 4
A2 AL 4 4 2 0 2
A4 AL 8 24 1 6 0.14 1 2 4
A5 ST 13 30 1 4 0.2 i 4
A10 AL 6 20 2 4 0.33 1 4 i
A12 AL 5 11 2 4 0.33 — — 2 4
B3 ST 7 47 4 1 0.8 4 1
B6 ST 5 59 10 3 0.77 1 10 2
B7 ST 10 32 6 2 0.75 2 — 4 2
B8 AL 8 36 12 1 0.92 3 9 1
B9 AL 12 6 3 2 0.6 — 1 3 1
Bll AL 4 5 3 — 1 — — 3 —
"Group A: Rarely HHV-6 DNA positive; group B: Frequently HHV-6 DNA positive.
bDiagnosis: ST, solid tumour; AL, acute leukaemia. Age at presentation, in years.
cWeeks followed: i.e., the number ofweeks over which samples were obtained from the patient.
dHHV-6 PCR: Number of positive or negative samples and the ratio of positive sample to the whole number.
' PCR results according to whether the patient was well or febrile at the time.
(29/47, 61%), very few supernate samples in the rarely
HHV-6-positive group contained HHV-6 DNA (2/30,
6%). This could imply that healthy children and paedi¬
atric oncology patients who are well are more likely to
secrete HHV-6 into the saliva.
Finding HHV-6 more frequently in the more healthy
children appears at first surprising, as latent herpes
viruses are more often recurrent and more likely to
cause problems in immunosuppressed patients. We con¬
sidered whether the children who were less well were
not so good at producing saliva specimens, but this was
not noted when specimens were collected. If the chil¬
dren who were less well had been receiving antiviral
therapy this might have affected secretion of HHV-6,
but only 3 samples were collected from children on acy¬
clovir and 2 of these were HHV-6 PCR-positive. We
suggest, therefore, that immunosuppressed and unwell
patients on chemotherapy secrete less HHV-6 due to
the effects of chemotherapy, with a depleted lympho¬
cyte population reducing the reservoir for HHV-6 and
affected salivary gland cells less able to support replica¬
tion ofHHV-6.
This small study has demonstrated firstly, that
HHV-6 DNA occurs commonly in the mouths of normal
healthy children without any obvious pathology and
secondly, that children immunosuppressed on chemo¬
therapy frequently secrete the virus without evidence
of ill health. Furthermore those who are febrile, neutro-
paenic and unwell less frequently secrete the virus.
HHV-6 latency is not completely understood and the
role of this virus as a serious pathogen in immunosup¬
pressed patients remains to be fully elucidated. Further
studies, including quantitative PCR, will be required to
confirm and extend this finding.
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Human herpesvirus 6: primary infection and
the central nervous system
E. G. HERMIONE LYALL, BSC HONS. MB CHB HONS, MRCP
HUMAN HERPESVIRUS 6 AND THE HISTORY OF
EXANTHEMA SUBITUM
The clinical syndrome of exanthema subitum (ES),
also known as roseola infantum, was first described in
1913 and in greater detail in the 1950s when an
association with an infectious pathogen was suggested
by the fact that the infection could be passed from one
infant to another.1"3 ES is a condition of infants in
whom several days of high fever and malaise were
followed by defervescence of the fever and appearance
of a rash. The rash was erythematous, maculopapular
and usually over the head and trunk and could last for
a few hours to several days. These observant clinicians
also documented that this condition was associated
with febrile convulsions.
In 1988 with elegant use of virologic techniques
Yamanishi et al.4 identified human herpesvirus 6
(HHV-6) as the cause of ES. In a series of infants with
primary infection he demonstrated: seroconversion
with production of antibody to HHV-6; culture of the
virus from peripheral blood lymphocytes (PBL); and
using PCR, amplification of the HHV-6 genome from
PBL. Further studies by others identified a relation¬
ship between the viral load of HHV-6 and the severity
of the infection in terms of days of fever and malaise.5
It is also possible to have primary HHV-6 infection
with fever without rash or rash without fever.6, 7 After
the discovery of HHV-6 as the cause of ES, seroepide-
miologic studies across the world soon confirmed that
an IgG response to HHV-6 was found in almost 100% of
children tested, and the peak period for seroconversion
occurred during the second half of the first year of
life.8, 9
Human herpesvirus 7 (HHV-7), which is genomically
closely related to HHV-6, was first isolated in 1990
from the PBL of a healthy adult.10 This virus, like
HHV-6, is secreted in the saliva. Most children also
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have a serologic response to HHV-7, although it devel¬
ops later than that to HHV-6. It has now been reported
that HHV-7 can also cause the classical syndrome of
ES.11 Whether it has other pathogenicity is not yet
known.
CHARACTERISTICS OF HHV-6
HHV-6 was first identified in cultures of PBL from
patients with malignancy and AIDS.12 This sixth mem¬
ber of the herpesvirus family and HHV-7 are most
closely related genetically to cytomegalovirus. These
three viruses belong to the beta subgroup of herpesvi¬
ruses, and the genomic similarity between HHV-6 and
cytomegalovirus is equivalent to that between the
alpha subgroup herpesviruses, herpes simplex virus
and varicella-zoster virus.13 There is cross-reactivity in
the host IgM response to HHV-6 and cytomegalovi¬
rus.14 HHV-6 is T cell-lymphotrophic in vivo and in
vitro and can coinfect cells that are infected with HIV,
although it does not use the CD4 surface protein to
enter these cells.15 In common with other herpesvi¬
ruses after primary infection latency is established and
HHV-6 genomic material can be found in PBL, salivary
glands and bronchial glands. Under certain conditions
HHV-6 infection can reactivate.16' 17 HHV-6 DNA is
frequently secreted in the saliva of healthy children.18
The two subtypes ofHHV-6, A and B, are very closely
related with >90% homogeneity in the areas of genome
examined.13 The two subtypes have different in vitro
cell tropism and can be identified by panels of mono¬
clonal antibodies.19 Type A, which grows more easily in
vitro, was the first HHV-6 subtype to be discovered, but
only a few isolates of this subtype have since been
identified. Most subtype A isolates have come from
immunosuppressed patients. Many more subtype B
strains have now been isolated from both immunocom¬
petent and immunosuppressed patients. Almost all the
isolates from children with primary infection have been
subtype B strains.20 Whether there are important
pathogenic differences between the two subtypes of
virus is unknown.
PRIMARY HHV-6: THE FIRST FEBRILE ILLNESS
The largest Japanese study of the clinical features of
primary HHV-6 infection, in which infection was diag¬
nosed in 176 of 688 children admitted to hospital with
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fever, rash or both, tended to confirm the classical
syndrome of ES.21 This study found that 94% of infants
were infected by 1 year of age, with a mean age of
infection of 7.3 months (range, 3 weeks to 18 months);
for the majority of infants this was the first febrile
illness. Virtually all children (98%) had high fever to a
maximum of 39.4°C, lasting for a mean of 4.1 days. A
maculopapular rash appeared on the face and trunk in
98% of cases, most commonly at the resolution of the
fever. The rash lasted for a mean of 3.8 days and there
was no desquamation. Mild diarrhea occurred in 68%
of cases and erythematous papules were seen in the
pharynx in 65%. Cervical lymphadenopathy was
present in 31% of cases and 50% had a cough. A bulging
anterior fontanel was present in 26% of the children
and convulsions occurred in 8%. The convulsions were
all of short duration and occurred before the rash
developed, during the febrile stage of the illness. The
mean age of infants having convulsions was 10.9
months (range, 5 to 17 months).
HHV-6: RARELY DIAGNOSED CLINICALLY
The most exhaustive studies of primary HHV-6 in
children have been performed in the US. The first of
two very large studies22 examined 243 children <2
years of age presenting consecutively to hospital with
fever (>38°C) for evidence of HHV-6 infection by cul¬
ture, PCR and antibody response. Primary HHV-6
infection was identified in 34 cases (14%), with a mean
age of 9.5 months. Features of this group included high
fever (mean, 39.7°C) and inflamed tympanic mem¬
branes. Three cases had a rash after the fever defer-
vesced and 3 had a rash with the fever. One child had
a febrile seizure. The mean white blood cell count on
presentation was 8.9 X 109/1 with 39% lymphocytes
and 51% neutrophils. All but one of the strains of
HHV-6 cultured were subtype B and the other culture
included subtypes A and B.20
A further study examined 2587 children <3 years of
age for adverse effects of HHV-6 primary infection.
There were 586 infants with acute nonfebrile illness
and 356 healthy controls; none of these control patients
had HHV-6 primary infection. Of 1653 infants with
acute febrile illness, 160 had HHV-6 primary infection
(9.7%). The mean age of this group was 9.4 months
(range, 2 weeks to 25 months). Considering only in¬
fants ages 6 to 12 months, 21% (75 of 365) of febrile
illnesses were caused by HHV-6.
In only 17% of the 160 cases was the correct clinical
diagnosis made; 30% were diagnosed as fever caused by
otitis media and 29% as fever of uncertain cause. The
incidence of infection did not vary with the seasons.
The majority had high fever(> 39°C) and 15% re¬
mained febrile for >6 days. Only 11% had a rash at
defervescence and 6% had a rash at presentation.
Seizures occurred in 13% (21 of 160), compared with a
9% seizure rate in the 1394 febrile children withe
HHV-6 infection (P = 0.18). HHV-6 primary infecti
accounted for one-third of first febrile seizures (medi
age, 14 months). Primary infection with HHV-6 occi
ring later, in the second year of life, was associat
with febrile seizures in 30% of cases. Some seizui
were prolonged or recurrent.
Cerebrospinal fluid (CSF) collected from 29 childr
with primary HHV-6 infection, including 7 with cc
vulsions, was examined. The cell count, protein a
glucose concentrations were normal in all specime
and no HHV-6 could be cultured. HHV-6 genome w
amplified from CSF by PCR in 7 cases, including 2 wi
convulsions.
In the UK there have been no large scale prospecti
studies of the role of HHV-6 as a pediatric pathoge
Ward and Gray24 examined a retrospective collection
sera from 248 children submitted for viral diagnosis i
anti-HHV-6 IgG antibody avidity. Low avidity antibo
implies recent infection. A group of 25 children h.
febrile seizures and in 1 case clinical ES was diagnos
at the time. Five of this group had low avidity an
HHV-6 IgG implying primary infection, whereas
were seronegative on acute phase serum and no com
lescent sample was obtained. The remaining 11 ch
dren had high avidity antibodies to HHV-6, almc
certainly excluding primary HHV-6 as a cause of ti
infection and seizures. This study might also suppc
the possibility that primary HHV-6 can be a cause f
febrile seizures. Again in the majority of cases prima
HHV-6 infection was not considered in the differenti
diagnosis.
DIAGNOSIS OF HHV-6 INFECTION
The diagnosis of primary ES is not straightforwar
Culture of HHV-6 from PBL is a specialized techniqi
available only as a research tool. A few laboratori
offer HHV-6 PCR of CSF and plasma as special test
Serology, although an indirect method of diagnosis,
more widely available and primary infection can 1
diagnosed in paired samples by seroconversion, pre
ence of IgM or low avidity early IgG antibodies. Paire
serum and CSF antibody titers could also be used
diagnose CNS infection.
As well as the technical limitations to diagnosis
HHV-6, it is clinically difficult to make the diagnosis
ES. Children with this infection are probably mo
often diagnosed as having otitis media or a "virus" wit
fever. They may or may not develop a rash, and if the
do it will most likely occur a few days after visiting ti
doctor. Indeed it is possible that many of these infan
are unnecessarily prescribed antibiotics and then if ti
rash appears are erroneously described as "allergic t
penicillin." Because the American study demonstrate
that 21% of infants ages 6 to 12 months presenting t
the "emergency room" with fever had primary HHV-
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infection, we could do better if we considered this viral
infection higher in the differential diagnosis of fever in
this group of our patients.
HHV-6 AND THE CENTRAL NERVOUS SYSTEM
4& (CNS)
Early clinical evidence described a relationship be¬
tween ES and febrile seizures, now confirmed by these
large studies. Although HHV-6 genome can be identi¬
fied in the CSF, the lack of inflammatory cellular
changes makes it difficult to understand the mecha¬
nism by which this virus affects the CNS. Since the
discovery of HHV-6 there have been several case re¬
ports of more serious CNS complications including
fatal encephalitis with primary HHV-6 infection.25-29
In only one of these cases was brain tissue examined
for evidence of HHV-6 infection, and in this case a
needle biopsy of brain was negative for HHV-6 anti¬
gens at a late stage, 21 days, after presentation.25
HHV-6 genome and antibodies to HHV-6 have been
found in the CSF; inflammatory changes have been
seen on computerized tomography and single photon
computerized tomography scans; and abnormal en¬
cephalograms have been reported. No adequate exam¬
ination of brain tissue by pathologic or in situ, virologic
techniques has been undertaken to ascertain the role of
HHV-6 as a possible acute CNS pathogen. Because
HHV-7 can cause ES with febrile convulsions, the role
of this virus in the CNS also needs to be considered.30
In an extension of the American study CSF and PBL
from children who had experienced primary HHV-6
infection were examined for persistence of HHV-6
DNA. HHV-6 was shown to persist in the CSF and PBL
after acute infection, and in some patients it was
detected only in CSF.31 In a small study of autopsy
brain specimens, HHV-6 DNA was found in frontal
cortex and/or basal ganglia of 11 of 13 immunocompe¬
tent adults.32 The authors suggest that the high fre¬
quency of HHV-6 DNA in the CNS implies that HHV-6
can invade the CNS and remain latent with the possi¬
bility of subsequent reactivation. Detailed virologic
investigation of the brains of children who die from
encephalitis and other causes for evidence of HHV-6
infection would help to ascertain whether this virus
does act as a CNS pathogen, or whether it persists as a
bystander.
Investigation of the brains of patients with multiple
sclerosis (MS) and controls for HHV-6 DNA has also
demonstrated that HHV-6 is frequently present in
patients and controls.33 Expression of HHV-6 virion
proteins in the nuclei of oligodendrocytes was demon¬
strated only in patients with MS. This usually occurred
in association with MS plaques, and it has been sug¬
gested that HHV-6 may have an etioiogic role in the
pathogenesis of MS. It is interesting to speculate
whether patients who later develop MS had a primary
HHV-6 infection with CNS manifestations such as
febrile seizures. More information on the CNS load of
HHV-6 and the immune response to the virus in the
CNS of these patients will help to elucidate any rela¬
tionship.
The immunocompromised patient could be consid¬
ered at particular risk; whether HHV-6 is a significant
CNS pathogen for children or adults immunosup-
pressed iatrogenically, congenitally or by infection is
unknown. In a preliminary study of five adult patients
dying with AIDS, HHV-6 was demonstrated by PCR in
different areas of the brains of all patients but in no
brain tissue from two patients with accidental
deaths.34 A case of fulminant HHV-6 encephalitis has
also been reported in an infant with HIV infection.35
CNS demyelination associated with HHV-6 infection
has also been reported in adults with AIDS.36
Because febrile convulsions are common and there is
evidence that HHV-6 and perhaps HHV-7 infection
may play an etioiogic role, clinicians must include
these viruses in the differential diagnosis of the cause
of the fever and attempt to make a virologic diagnosis.
Because there are long term sequelae of febrile convul¬
sions, including hippocampal sclerosis that can cause
subsequent epileptic problems, the role of these possi¬
ble neuropathogenic viruses should be considered in
the etiology of such complications. Where cases of
encephalitis have occurred, even a retrospective study
of necropsy brain tissue from children could give some
useful information about the CNS pathogenicity of
these herpesviruses. Diagnosis of infection could also
have treatment implications, for although HHV-6 is
relatively resistant to acyclovir, it is susceptible to
ganciclovir.13 Thus if HHV-6 was found to be a signif¬
icant CNS pathogen, antiviral therapy could be consid¬
ered in severe cases.
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